Medicare Part D: 5 Tier Closed Performance Formulary 2026

Por favor haga clic aquí.

Para Medicare Part D: Criterios de autorización previa

Por favor haga clic aquí.

Para Medicare Part D: Criterios de terapia escalonada

Por favor haga clic aquí.

Planes cubiertos en Pennsylvania

Community Blue Medicare HMO Distinct (HMO)
Community Blue Medicare HMO Signature (HMO)
Community Blue Medicare Plus PPO Signature (HMO)
Community Blue Medicare PPO Merit (PPO)
Community Blue Medicare PPO Signature (HMO)
Complete Blue HMO Distinct (HMO)
Complete Blue Plus PPO Distinct (PPO)
Complete Blue Plus PPO Merit (PPO)
Complete Blue PPO Distinct (PPO)
Complete Blue PPO Merit (PPO)
Complete Blue PPO Signature (PPO)
Freedom Blue PPO ValueRx (PPO)
Security Blue HMO-POS ValueRx (PPO)
Together Blue Medicare HMO Signature (HMO)

Para obtener información más reciente o hacer otras preguntas, comuníquese con:

Servicio de farmacia Freedom Blue PPO al 1-800-550-8722
Servicio de farmacia Security Blue HMO-POS al 1-800-935-2583
Servicio de farmacia Community Blue Medicare HMO al 1-888-234-5397
Servicio de farmacia Community Blue Medicare PPO al 1-888-757-2946
Servicio de farmacia Community Blue Medicare Plus PPO al 1-888-757-2946
Servicio de farmacia Complete Blue PPO al 1-833-227-9375
Servicio de farmacia Together Blue Medicare HMO al 1-888-328-5704

Los usuarios de TTY deben llamar al 711, los siete días de la semana, de 8 a. m. a 8 p. m.,
o visitar **medicare.highmark.com/formulary**.

ID del formulario: 26018 Versión: 21

Actualizado: 2026/11

Nota a los miembros actuales: Este formulario cambió desde el año pasado.
Revise este documento para asegurarse de que aún contenga los medicamentos que toma.

Cuando esta Lista de medicamentos (formulario) se refiere a “nosotros”, “nos” o “nuestro”, se refiere a Highmark Senior Health Company, Highmark Choice Company, o Highmark Health Insurance Company.

Cuando se hace referencia a “plan” o “nuestro plan”, se refiere a Community Blue Medicare HMO, Complete Blue HMO, Security Blue HMO-POS, Together Blue HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, Complete Blue PPO, Complete Blue Plus PPO, y Freedom Blue PPO.

Este documento incluye una Lista de medicamentos (formulario) para nuestro plan, que está en vigor al 1 de enero de 2026. Para obtener una lista de medicamentos actualizada (formulario), comuníquese con nosotros. Nuestra información de contacto, además de la fecha en que actualizamos por última vez la Lista de medicamentos (formulario), aparece en la portada y en la contraportada.

Generalmente, debe usar las farmacias de la red para recibir el beneficio de los medicamentos con receta. Los beneficios, el formulario, la red de farmacias o los copagos/coseguros pueden cambiar el 1 de enero de 2027 y de vez en cuando durante el año.

¿Qué es el formulario de Community Blue Medicare HMO, Complete Blue HMO, Security Blue HMO-POS, Together Blue HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, Complete Blue PPO, Complete Blue Plus PPO, y Freedom Blue PPO?

En este documento, usamos los términos Lista de medicamentos y formulario para que den a entender lo mismo. Un formulario es una lista de medicamentos cubiertos seleccionados por nuestro plan en consulta con un equipo de proveedores de atención médica, que representa las terapias con receta que se consideran una parte necesaria de un programa de tratamiento de calidad. Nuestro plan generalmente cubrirá la lista de medicamentos en nuestro formulario, siempre que el medicamento sea médicamente necesario, la receta se llene en una farmacia de la red de Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, Complete Blue PPO, Complete Blue Plus PPO o Together Blue Medicare HMO, y se sigan otras reglas del plan. Para obtener más información de cómo surtir sus recetas, consulte su Evidencia de Cobertura.

¿Puede cambiar el formulario?

La mayoría de los cambios en la cobertura de medicamentos ocurren el 1 de enero, pero podemos agregar o eliminar medicamentos del formulario durante el año, trasladarlos a diferentes niveles de costo compartido o agregar nuevas restricciones. Debemos seguir las reglas de Medicare cuando hacemos estos cambios. Las actualizaciones del formulario se publican mensualmente en nuestro sitio web aquí: **medicare.highmark.com/formulary**.

Cambios que pueden afectarlo este año: En los casos que se mencionan abajo, lo afectarán los cambios de cobertura durante el año:

- **Sustituciones inmediatas de ciertas versiones nuevas de medicamentos de marca y productos biológicos originales.** Podemos eliminar inmediatamente un medicamento de nuestro formulario si lo reemplazamos con una nueva versión determinada de ese medicamento que aparecerá en el mismo nivel de costo compartido o en uno más bajo y con las mismas restricciones o menos. Cuando agregamos una nueva versión de un medicamento a nuestro formulario, podemos decidir mantener el medicamento de marca o el producto biológico original en nuestro formulario, pero inmediatamente trasladarlo a un nivel de costo compartido diferente o agregar nuevas restricciones.

  Podemos hacer estos cambios inmediatos solo si estamos agregando una nueva versión genérica de un medicamento de marca, o agregando ciertas nuevas versiones biosimilares de un producto biológico original, que ya estaba en el formulario (por ejemplo, agregando un biosimilar intercambiable que puede sustituirse por un producto biológico original por una farmacia sin una nueva receta).

  Si actualmente está tomando el medicamento de marca o el producto biológico original, es posible que no se lo informemos con antelación antes de hacer un cambio inmediato, pero más adelante le daremos información sobre los cambios específicos que hemos hecho.

  Si hacemos dicho cambio, usted o su médico pueden solicitarnos que hagamos una excepción y continuemos cubriendo el medicamento que se está modificando. Para obtener más información, consulte la sección de abajo "¿Cómo solicito una excepción al formulario de Community Blue Medicare HMO, Complete Blue HMO, Security Blue HMO-POS, Together Blue HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, Complete Blue PPO, Complete Blue Plus PPO, y Freedom Blue PPO?"

  Algunos de estos tipos de medicamentos pueden ser nuevos para usted. Para obtener más información, consulte la sección de abajo titulada "¿Qué son los productos biológicos originales y cómo se relacionan con los biosimilares?"

- **Medicamentos sacados del mercado.** Si el fabricante retira un medicamento de la venta o la Administración de Alimentos y Medicamentos (FDA) determina que debe retirarse por razones de seguridad o eficacia, podemos eliminar inmediatamente el medicamento de nuestro formulario y luego informar a los miembros que toman el medicamento.

- **Otros cambios.** Es posible que hagamos otros cambios que afecten a los miembros que actualmente toman un medicamento. Por ejemplo, podemos eliminar un medicamento de marca del formulario cuando agregamos un equivalente genérico o eliminar un producto biológico original cuando agregamos un biosimilar. También podemos aplicar nuevas

restricciones al medicamento de marca o al producto biológico original, o trasladarlo a un nivel diferente de participación en los costos, o ambas cosas. Podemos hacer cambios según nuevas directrices clínicas. Si eliminamos medicamentos de nuestro formulario, agregamos autorización previa, límites de cantidad o restricciones de terapia gradual en un medicamento, o movemos un medicamento a un nivel de costo compartido más alto, debemos informar a los miembros afectados sobre el cambio al menos 30 días antes de que el cambio entre en vigor. Alternativamente, cuando un miembro solicita una resurtido del medicamento, puede recibir un suministro de 31 días del medicamento y una notificación del cambio.

Si hacemos estos otros cambios, usted o su médico pueden solicitarnos que hagamos una excepción para usted y continuemos cubriendo el medicamento que ha estado tomando. El aviso que le damos también incluirá información sobre cómo solicitar una excepción, y también puede encontrar información en la sección de abajo titulada "¿Cómo solicito una excepción al formulario de Community Blue Medicare HMO, Complete Blue HMO, Security Blue HMO-POS, Together Blue HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, Complete Blue PPO, Complete Blue Plus PPO, y Freedom Blue PPO?"

Cambios que no lo afectarán si actualmente está tomando el medicamento. Por lo general, si está tomando un medicamento de nuestra lista de medicamentos cubiertos de 2026 que estaba cubierto al inicio del año, no descontinuaremos ni reduciremos la cobertura del medicamento durante el año de cobertura del 2027, excepto como se describe arriba. Esto significa que estos medicamentos seguirán disponibles con el mismo costo compartido y sin nuevas restricciones para los miembros que los estén tomando durante el resto del año de cobertura. No recibirá un aviso directo este año sobre los cambios que no lo afecten. Sin embargo, el 1 de enero del próximo año, dichos cambios lo afectarán y es importante consultar el formulario para el nuevo año de beneficios para conocer si hay cambios en los medicamentos.

La lista de medicamentos cubiertos adjunta está actualizada al 01 de noviembre de 2026. Para recibir información actualizada sobre los medicamentos que cubre nuestro plan, comuníquese con nosotros. Nuestra información de contacto está en la portada y en la contraportada. En el caso de que haya cambios a medio año en la lista de medicamentos cubiertos, que no sean cambios de mantenimiento, se les avisará por correo a los miembros y los miembros potenciales recibirán una actualización de esta lista de medicamentos cubiertos. La Lista de medicamentos cubiertos más actualizada está disponible en nuestro sitio web: **medicare.highmark.com/formulary**.

¿Cómo uso la lista de medicamentos cubiertos?

Hay dos formas de buscar su medicamento en la lista de medicamentos cubiertos:

Condición médica

El formulario comienza en la página 9. Los medicamentos de esta lista de medicamentos cubiertos están agrupados en categorías según el tipo de condiciones para los que se usan. Por ejemplo, los medicamentos que se usan para tratar una condición cardíaca se mencionan en la categoría "Cardiovascular, hipertensión y lípidos". Si sabe para qué se usa su medicamento, busque el nombre de la categoría en la lista que comienza en la página 9. Luego, busque su medicamento abajo del nombre de la categoría.

Lista en orden alfabético

Si no está seguro en qué categoría buscar, debe buscar su medicamento en el Índice que comienza en la página 9. El Índice incluye una lista en orden alfabético de todos los medicamentos incluidos en este documento. Los medicamentos de marca y los genéricos se mencionan en el Índice. Consulte el Índice y busque su medicamento. Junto a su medicamento, verá el número de página donde puede encontrar información de la cobertura. Vaya a la página incluida en el Índice y busque el nombre de su medicamento en la primera columna de la lista.

¿Qué son los medicamentos genéricos?

Nuestro plan cubre medicamentos de marca y medicamentos genéricos. La FDA aprueba un medicamento genérico siempre que tenga el mismo ingrediente activo que el medicamento de marca. Generalmente, los medicamentos genéricos funcionan igual de bien y suelen costar menos que los de marca. Hay medicamentos genéricos sustitutos disponibles para muchos medicamentos de marca. Los medicamentos genéricos generalmente pueden sustituir al medicamento de marca en la farmacia sin necesidad de una nueva receta, según las leyes estatales.

¿Qué son los productos biológicos originales y cómo se relacionan con los biosimilares?

En el formulario, cuando nos referimos a medicamentos, esto podría significar un fármaco o un producto biológico. Los productos biológicos son medicamentos más complejos que los medicamentos típicos. Ya que los productos biológicos son más complejos que los medicamentos normales, en vez de tener una forma genérica, tienen alternativas llamadas biosimilares. Generalmente, los biosimilares funcionan tan bien como el producto biológico original y pueden costar menos. Hay alternativas biosimilares a algunos productos biológicos originales. Algunos biosimilares son intercambiables y, según las leyes estatales, pueden sustituir al producto biológico original en la farmacia sin necesidad de una nueva receta, al igual que los medicamentos genéricos pueden sustituir a los medicamentos de marca.

Para obtener información sobre los tipos de medicamentos, consulte la Evidencia de cobertura, Capítulo 3, Sección 3.1, “La ‘Lista de medicamentos’ indica qué medicamentos de la Parte D están cubiertos”.

¿Hay alguna restricción en mi cobertura?

Algunos medicamentos cubiertos pueden tener otros requisitos o límites de cobertura. Estos requisitos y límites pueden incluir:

- **Autorización previa:** Nuestro plan requiere que usted o su médico obtengan una autorización previa para ciertos medicamentos. Esto significa que necesitará la aprobación de nuestro plan antes de que se le surtan sus recetas médicas. Si no obtiene la aprobación, es posible que nuestro plan no cubra el medicamento.
- **Límites de cantidad:** Para ciertos medicamentos, nuestro plan limita la cantidad la medicamento que cubriremos. Por ejemplo, nuestro plan da 31 tabletas, cada 31 días, de 100 mg de Medicamento A. Esto puede ser además del suministro estándar para uno o tres meses.
- **Terapia gradual:** En algunos casos, nuestro plan requiere que primero pruebe con ciertos

medicamentos para tratar su estado médico antes de cubrir otro medicamento para dicha condición. Por ejemplo, si el Medicamento A y el Medicamento B están recomendados para su estado médico, es posible que nuestro plan no cubra el Medicamento B, a menos que pruebe primero el Medicamento A. Si el Medicamento A no funciona para usted, entonces nuestro plan cubrirá el Medicamento B.

Puede averiguar si su medicamento tiene más requisitos o límites consultando la lista de medicamentos cubiertos que comienza en la página 9. También puede obtener más información sobre las restricciones aplicadas a medicamentos cubiertos específicos visitando nuestro sitio web. Publicamos documentos en línea que explican nuestra autorización previa y las restricciones de la terapia gradual. También puede pedirnos que le enviemos una copia. Nuestra información de contacto, junto con la fecha de la última actualización de la lista de medicamentos cubiertos, aparece en la portada y en la contraportada.

Puede pedir a nuestro plan que hagamos una excepción a estas restricciones o límites, o para una lista de otros medicamentos similares que pudieran servir como tratamiento para su condición. Consulte la sección "¿Cómo solicito una excepción al formulario de Community Blue Medicare HMO, Complete Blue HMO, Security Blue HMO-POS, Together Blue HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, Complete Blue PPO, Complete Blue Plus PPO, y Freedom Blue PPO?" en la página 6 para obtener información sobre cómo solicitar una excepción.

¿Qué pasa si mi medicamento no está en la lista de medicamentos cubiertos?

Si su medicamento no está incluido en esta Lista de medicamentos cubiertos (formulario), primero debe comunicarse con Servicios de Farmacia y preguntar si su medicamento está cubierto.

Si usted se entera que de nuestro plan no cubre su medicamento, tiene dos opciones:

- Puede pedir a Servicios de Farmacia una lista de medicamentos similares que están cubiertos por nuestro plan. Cuando reciba la lista, preséntesela al médico y pídale que le recete algún medicamento similar que cubra nuestro plan.
- Puede solicitar a nuestro plan que haga una excepción y cubra su medicamento. Consulte más abajo para obtener información sobre cómo solicitar una excepción.

¿Cómo solicito una excepción al formulario de Community Blue Medicare HMO, Complete Blue HMO, Security Blue HMO-POS, Together Blue HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, Complete Blue PPO, Complete Blue Plus PPO, y Freedom Blue PPO?

Puede solicitar a nuestro plan que haga una excepción a nuestras reglas de cobertura. Hay varios tipos de excepciones que puede pedirnos.

- Puede pedirnos que cubramos un medicamento aunque no esté en nuestra Lista de medicamentos cubiertos. Si se aprueba, este medicamento estará cubierto a un nivel de costo compartido predeterminado, y no podrá pedirnos que le demos el medicamento a un nivel de costo compartido más bajo.

- Puede solicitarnos que eliminemos una restricción de cobertura, incluyendo la autorización previa, la terapia gradual o un límite de cantidad en su medicamento. Por ejemplo, para ciertos medicamentos, nuestro plan limita la cantidad del medicamento que cubriremos. Si su medicamento tiene un límite de cantidad, puede pedirnos que no apliquemos el límite y cubramos una cantidad mayor.
- Puede pedirnos que cubramos un medicamento de la Lista de medicamentos cubiertos a un menor nivel de costo compartido, a menos que el medicamento esté en el nivel de especialidad. Si se aprueba, esto reduciría la cantidad que debe pagar por el medicamento.

Generalmente, nuestro plan solo aprobará su solicitud de excepción si los medicamentos alternativos incluidos en el formulario del plan, el medicamento con menor costo compartido o la aplicación de la restricción no serían tan efectivos para usted o le causarían efectos adversos.

Usted o su médico deben comunicarse con nosotros para solicitar una excepción de nivel o de formulario, incluyendo una excepción a una restricción de cobertura. ***Cuando solicite una excepción, su médico deberá explicarle las razones médicas por las que necesita la excepción.*** Por lo general, debemos tomar nuestra decisión en un plazo de 72 horas después de recibir la declaración de respaldo de la persona que receta. Puede solicitar una decisión acelerada (rápida) si cree, y estamos de acuerdo, que su salud podría verse gravemente perjudicada si espera hasta 72 horas para recibir una decisión. Si estamos de acuerdo, o si su médico le solicita una decisión rápida, debemos darle una decisión a más tardar 24 horas después de que recibamos la declaración de respaldo de su médico.

¿Qué puedo hacer si mi medicamento no está en el formulario o tiene alguna restricción?

Como miembro nuevo o actual de nuestro plan, es posible que esté tomando medicamentos que no están en nuestra lista de medicamentos cubiertos. O es posible que esté tomando un medicamento que está en nuestro formulario pero tiene una restricción de cobertura, como una autorización previa. Debe hablar con su médico sobre cómo solicitar una decisión de cobertura para mostrar que cumple los criterios de aprobación, cambiar a un medicamento alternativo que cubramos o solicitar una excepción al formulario para que cubramos el medicamento que toma. Mientras usted y su médico determinan el curso de acción adecuado para usted, es posible que cubramos su medicamento en ciertos casos durante los primeros 90 días que sea miembro de nuestro plan.

Para cada uno de sus medicamentos que no esté en nuestro formulario o tenga una restricción de cobertura, cubriremos un suministro temporal para 31 días. Si su receta es para menos días, permitiremos resurtidos para que tenga un suministro máximo de medicamentos para 31 días. Si la cobertura no se aprueba después, de su primer suministro para 31 días, no pagaremos estos medicamentos, incluso si ha sido miembro del plan menos de 90 días.

Si usted es residente de un centro de atención de largo plazo y necesita un medicamento que no está en nuestra lista de medicamentos cubiertos o si su capacidad para obtener sus medicamentos es limitada, pero ya cumplió los primeros 90 días de membresía en nuestro plan, cubriremos un suministro de emergencia para 31 días de ese medicamento mientras pida una excepción a la lista de medicamentos cubiertos.

El proceso de transición de arriba se implementará para acomodarlo si tiene una necesidad inmediata de un medicamento que no está en el formulario o un medicamento que requiere autorización previa por un cambio en su nivel de atención mientras espera que se procese una solicitud de excepción.

Para obtener más información

Para obtener más información detallada sobre la cobertura de medicamentos con receta de su plan, revise su Evidencia de cobertura y otro material del plan.

Si tiene alguna pregunta sobre su plan, comuníquese con nosotros. Nuestra información de contacto, junto con la fecha de la última actualización de la lista de medicamentos cubiertos, aparece en la portada y en la contraportada.

Si tiene preguntas generales sobre la cobertura de medicamentos con receta de Medicare, llame a Medicare al 1-800-MEDICARE (1-800-633-4227), 24/7. Los usuarios de TTY deben llamar al 1-877-486-2048. O visite **http://www.medicare.gov**.

Formulario de Community Blue Medicare HMO, Complete Blue HMO, Security Blue HMO-POS, Together Blue HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, Complete Blue PPO, Complete Blue Plus PPO, y Freedom Blue PPO.

La Lista de medicamentos cubiertos que empieza en la siguiente página da información de cobertura sobre los medicamentos cubiertos por su plan. Si tiene problemas para buscar su medicamento en la lista, consulte el Índice que comienza en la página 9.

La primera columna de la tabla muestra el nombre del medicamento. Los medicamentos de marca están en mayúsculas (por ejemplo, ABELCET) y los medicamentos genéricos están en cursiva minúscula (por ejemplo, *abacavir*).

La información en la columna Requisitos/Límites le dice si su plan tiene algún requisito especial de cobertura de su medicamento.

El siguiente es solo un ejemplo del formato de la lista de medicamentos cubiertos:

Nombre del medicamento	Rendimiento de nivel del medicamento	Requisitos/ Límites
Antiinfecciosos		
MEDICAMENTO XYZ	NF	QL-28

Table of Contents

Anti-Infecciosos 3
Cardiovascular, Hipertensión / Lípidos 11
Dermatológicos/Terapia Tópica 17
Diagnósticos / Agentes Varios 21
Endocrino/Diabetes 22
Gastroenterología 27
Inmunología, Vacunas / Biotecnología 29
Medicamentos Antineoplásicos E Inmunosupresores 32
Medicamentos Autonómicos/Snc, Neurología/Psico 40
Medicamentos Para Oídos, Nariz Y Garganta 54
Musculoesquelético / Reumatología 55
Obstetricia / Ginecología 57
Oftalmología 60
Respiratorio Y Alergia 62
Suministros Variados 65
Urológicos 65
Vitaminas, Hematinicos / Electrolitos 66

	Nivel de medicamento **T1** = El Nivel 1 de costo compartido incluye medicamentos genéricos preferidos. Este es el nivel de costo compartido más bajo. **T2** = El Nivel 2 de costo compartido incluye medicamentos genéricos. **T3** = El Nivel 3 de costo compartido incluye medicamentos de marca preferidos y puede incluir algunos medicamentos de fuente única (aquellos medicamentos genéricos fabricados por un solo fabricante). **T4** = El Nivel 4 de costo compartido incluye medicamentos de marca no preferidos y puede incluir algunos medicamentos genéricos de una sola fuente (aquellos medicamentos genéricos fabricados por un solo fabricante). **T5** = El Nivel 5 de costo compartido incluye medicamentos especializados. Este es el nivel de costo compartido más alto.	**Requisitos/Límites** **LA** = Acceso limitado **PA** = Se requiere autorización previa **PA-BvD** = Este medicamento puede estar cubierto por la parte B o D de Medicare según las circunstancias. Es posible que sea necesario enviar información que describa el uso y la establecimiento del medicamento para tomar la determinación. **PA-NC** = Se requiere autorización previa solo para nuevos inicios **QL** = Se aplica límite de cantidad. El límite de cantidad se anota para cada medicamento. Por ejemplo, si el límite de cantidad es LC (90 c/u por 180 días), el límite de cantidad sería 90 unidades por suministro de 180 días. **ST** = Se aplica la terapia escalonada **ST-NC** = La terapia escalonada se aplica únicamente a los nuevos comienzos.
lowercase italics = Generic drugs **UPPERCASE BOLD** = Brand name drugs		

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
Anti-Infecciosos		
abacavir	T4	
abacavir-lamivudine	T4	
acyclovir oral capsule	T2	
acyclovir oral suspension 200 mg/5 ml	T4	
acyclovir oral tablet	T2	
acyclovir sodium intravenous solution	T4	PA-BvD
adefovir	T4	
albendazole	T4	
amantadine hcl oral capsule	T3	QL (124 EA per 31 days)
amantadine hcl oral solution	T3	
amantadine hcl oral tablet	T3	
amikacin injection solution 500 mg/2 ml	T4	
amoxicillin oral capsule	T1	
amoxicillin oral suspension for reconstitution	T1	
amoxicillin oral tablet	T2	
amoxicillin oral tablet,chewable 125 mg, 250 mg	T1	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
amoxicillin-pot clavulanate oral suspension for reconstitution	T2	
amoxicillin-pot clavulanate oral tablet	T2	
amoxicillin-pot clavulanate oral tablet,chewable	T2	
amphotericin b	T4	PA-BvD
amphotericin b liposome	T5	PA-BvD
ampicillin oral capsule 500 mg	T2	
ampicillin sodium injection recon soln 1 gram, 10 gram	T4	
ampicillin sodium injection recon soln 2 gram	T2	
ampicillin-sulbactam injection	T4	
APTIVUS	T5	
ARIKAYCE	T5	PA
atazanavir	T4	
atovaquone	T4	
atovaquone-proguanil	T3	
azithromycin intravenous	T2	
azithromycin oral tablet	T2	
aztreonam	T4	
BICILLIN C-R	T3	
BICILLIN L-A INTRAMUSCULAR SYRINGE 600,000 UNIT/ML	T3	
BIKTARVY	T5	QL (31 EA per 31 days)
BLUJEPA	T4	QL (20 EA per 5 days)
caspofungin	T4	
CAYSTON	T5	PA
cefaclor oral capsule 500 mg	T2	
cefadroxil oral capsule	T2	
cefadroxil oral suspension for reconstitution 250 mg/5 ml	T2	
cefadroxil oral suspension for reconstitution 500 mg/5 ml	T4	
cefadroxil oral tablet	T3	
cefazolin injection recon soln 1 gram, 500 mg	T2	
cefazolin intravenous recon soln 10 gram	T4	
cefdinir oral capsule	T2	
cefepime injection	T4	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
cefixime oral capsule	T2	
cefoxitin	T4	
cefpodoxime oral suspension for reconstitution 100 mg/5 ml	T4	
cefpodoxime oral suspension for reconstitution 50 mg/5 ml	T3	
cefpodoxime oral tablet	T3	
cefprozil	T2	
ceftaroline fosamil	T5	
ceftazidime	T4	
ceftriaxone injection recon soln 1 gram, 10 gram, 2 gram, 250 mg, 500 mg	T2	
cefuroxime axetil oral tablet	T2	
cefuroxime sodium injection recon soln 750 mg	T3	
cefuroxime sodium intravenous recon soln 1.5 gram	T3	
cephalexin oral capsule 250 mg, 500 mg	T2	
cephalexin oral suspension for reconstitution	T2	
chloroquine phosphate oral tablet 250 mg	T3	QL (50 EA per 30 days)
chloroquine phosphate oral tablet 500 mg	T3	QL (25 EA per 30 days)
CIMDUO	T5	QL (31 EA per 31 days)
ciprofloxacin hcl oral tablet 250 mg, 500 mg, 750 mg	T1	
ciprofloxacin in 5 % dextrose intravenous piggyback 200 mg/100 ml	T2	
clarithromycin oral suspension for reconstitution	T4	
clarithromycin oral tablet	T2	
clarithromycin oral tablet extended release 24 hr	T2	
clindamycin hcl	T2	
clindamycin in 5 % dextrose	T2	
CLINDAMYCIN PEDIATRIC	T4	
clindamycin phosphate injection	T2	
clotrimazole mucous membrane	T2	
COARTEM	T4	
colistin (colistimethate na)	T4	
CRESEMBA ORAL	T5	
dapsone oral	T3	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
daptomycin intravenous recon soln 350 mg	T4	
daptomycin intravenous recon soln 500 mg	T5	
darunavir oral tablet 600 mg	T4	
darunavir oral tablet 800 mg	T5	
DELSTRIGO	T5	QL (31 EA per 31 days)
DESCOVY	T5	QL (31 EA per 31 days)
dicloxacillin	T2	
DOVATO	T5	QL (31 EA per 31 days)
DOXY-100	T4	
doxycycline hyclate intravenous	T4	
doxycycline hyclate oral capsule 100 mg, 50 mg	T2	
doxycycline hyclate oral tablet 100 mg, 20 mg	T2	
doxycycline hyclate oral tablet,delayed release (dr/ec) 100 mg	T4	
doxycycline monohydrate oral capsule 100 mg, 50 mg	T2	
doxycycline monohydrate oral tablet 100 mg, 50 mg	T2	
EDURANT PED	T5	
efavirenz oral tablet	T4	
efavirenz-emtricitabin-tenofov	T5	
efavirenz-lamivu-tenofov disop	T5	QL (31 EA per 31 days)
emtricitabine	T4	
emtricitabine-tenofovir (tdf) oral tablet 100-150 mg, 167-250 mg, 200-300 mg	T4	
emtricitabine-tenofovir (tdf) oral tablet 133-200 mg	T5	
emtricita-rilpivirine-tenof df	T5	
EMTRIVA ORAL SOLUTION	T3	
entecavir	T4	
ertapenem	T4	
erythromycin oral tablet	T4	
ethambutol	T2	
etravirine	T5	
EVOTAZ	T5	
famciclovir	T3	
fidaxomicin	T5	QL (20 EA per 10 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
fluconazole in nacl (iso-osm) intravenous piggyback 200 mg/100 ml	T2	
fluconazole in nacl (iso-osm) intravenous piggyback 400 mg/200 ml	T3	
fluconazole oral suspension for reconstitution	T3	
fluconazole oral tablet	T2	
flucytosine	T5	
fosamprenavir	T5	
fosfomycin tromethamine	T4	
gentamicin in nacl (iso-osm) intravenous piggyback 100 mg/100 ml, 60 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml	T2	
gentamicin injection	T4	
GENVOYA	T5	
griseofulvin microsize	T4	
griseofulvin ultramicrosize oral tablet 125 mg, 250 mg	T4	
HEPCLUDEX	T5	PA; QL (31 EA per 31 days)
hydroxychloroquine oral tablet 200 mg	T2	QL (93 EA per 31 days)
IDVYNSO	T5	QL (31 EA per 31 days)
imipenem-cilastatin	T4	
INTELENCE ORAL TABLET 25 MG	T4	
ISENTRESS HD	T5	
ISENTRESS ORAL POWDER IN PACKET	T5	
ISENTRESS ORAL TABLET	T5	
ISENTRESS ORAL TABLET,CHEWABLE 100 MG	T5	
ISENTRESS ORAL TABLET,CHEWABLE 25 MG	T3	
isoniazid oral solution	T2	
isoniazid oral tablet	T1	
itraconazole oral capsule	T4	PA
ivermectin oral	T3	PA
JULUCA	T5	
ketoconazole oral	T2	
LAGEVRIO (EUA)	T3	
lamivudine oral solution	T2	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
lamivudine oral tablet 100 mg	T3	
lamivudine oral tablet 150 mg, 300 mg	T2	
lamivudine-zidovudine	T3	
levofloxacin in d5w intravenous piggyback 500 mg/100 ml, 750 mg/150 ml	T2	
levofloxacin oral solution	T4	
levofloxacin oral tablet	T2	
linezolid in dextrose 5%	T4	
linezolid oral tablet	T4	
LIVTENCITY	T5	PA; QL (372 EA per 31 days)
lopinavir-ritonavir oral tablet	T4	
maraviroc oral tablet 150 mg	T5	
maraviroc oral tablet 300 mg	T3	
MAVYRET ORAL PELLETS IN PACKET	T5	PA; QL (140 EA per 28 days)
MAVYRET ORAL TABLET	T5	PA; QL (84 EA per 28 days)
mefloquine	T2	
meropenem intravenous recon soln 1 gram, 500 mg	T3	
methenamine hippurate	T4	
metronidazole in nacl (iso-os)	T2	
metronidazole oral tablet 250 mg, 500 mg	T2	
micafungin	T4	
minocycline oral capsule	T2	
minocycline oral tablet	T2	
moxifloxacin oral	T3	
moxifloxacin-sod.chloride(iso)	T4	
nafcillin injection recon soln 1 gram, 2 gram	T4	
nafcillin injection recon soln 10 gram	T5	
neomycin	T2	
nevirapine oral suspension	T2	
nevirapine oral tablet	T2	
nevirapine oral tablet extended release 24 hr	T4	
nitazoxanide	T5	
nitrofurantoin macrocrystal oral capsule 100 mg	T2	QL (90 EA per 365 days)
nitrofurantoin macrocrystal oral capsule 50 mg	T2	QL (180 EA per 365 days)
nitrofurantoin monohyd/m-cryst	T2	QL (90 EA per 365 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
nystatin oral suspension	T2	
nystatin oral tablet	T2	
ODEFSEY	T5	QL (31 EA per 31 days)
ofloxacin oral tablet 400 mg	T2	
ORLYNVAH	T4	QL (10 EA per 5 days)
oseltamivir oral capsule 30 mg	T2	QL (170 EA per 365 days)
oseltamivir oral capsule 45 mg, 75 mg	T2	QL (90 EA per 365 days)
oseltamivir oral suspension for reconstitution	T3	QL (1080 ML per 365 days)
oxacillin injection recon soln 1 gram, 2 gram	T2	
PAXLOVID ORAL TABLETS,DOSE PACK 150 MG (10)- 100 MG (10)	T2	QL (180 EA per 365 days)
PAXLOVID ORAL TABLETS,DOSE PACK 150 MG (6)- 100 MG (5)	T2	QL (99 EA per 365 days)
PAXLOVID ORAL TABLETS,DOSE PACK 300 MG (150 MG X 2)-100 MG	T2	QL (270 EA per 365 days)
penicillin g pot in dextrose intravenous piggyback 2 million unit/50 ml, 3 million unit/50 ml	T4	
penicillin g potassium injection recon soln 20 million unit	T4	
penicillin v potassium oral tablet	T1	
pentamidine inhalation	T4	PA-BvD
pentamidine injection	T4	
PIFELTRO	T5	QL (62 EA per 31 days)
piperacillin-tazobactam intravenous recon soln 2.25 gram, 3.375 gram, 4.5 gram, 40.5 gram	T4	
posaconazole oral tablet,delayed release (dr/ec)	T5	PA
praziquantel	T4	
PREVYMIS ORAL PELLETS IN PACKET	T5	PA; QL (124 EA per 31 days)
PREVYMIS ORAL TABLET	T5	QL (31 EA per 31 days)
PREZCOBIX	T5	
PREZISTA ORAL SUSPENSION	T5	
PREZISTA ORAL TABLET 150 MG	T5	
PREZISTA ORAL TABLET 75 MG	T4	
primaquine	T3	
pyrazinamide	T4	
pyrimethamine	T5	PA
quinine sulfate	T4	PA; QL (42 EA per 28 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
RELENZA DISKHALER	T3	
REYATAZ ORAL POWDER IN PACKET	T5	
ribavirin oral capsule	T3	
ribavirin oral tablet 200 mg	T3	
rifabutin	T4	
rifampin	T4	
rifapentine	T3	
rilpivirine hcl	T5	
rimantadine	T4	
ritonavir	T3	
RUKOBIA	T5	QL (62 EA per 31 days)
SIRTURO	T5	PA
sofosbuvir-velpatasvir	T5	PA; QL (28 EA per 28 days)
streptomycin	T5	
STRIBILD	T5	
sulfadiazine	T4	
sulfamethoxazole-trimethoprim oral suspension	T2	
sulfamethoxazole-trimethoprim oral tablet	T1	
SUNLENCA	T5	
SYMTUZA	T5	QL (31 EA per 31 days)
tenofovir disoproxil fumarate	T3	
terbinafine hcl oral	T1	QL (90 EA per 180 days)
tetracycline oral capsule	T4	
tigecycline	T4	
tinidazole	T2	
TIVICAY ORAL TABLET 50 MG	T5	
TIVICAY PD	T5	
TOBI PODHALER	T5	PA; QL (224 EA per 56 days)
tobramycin in 0.225 % nacl	T5	PA
tobramycin inhalation	T5	PA
tobramycin sulfate injection solution	T4	
trimethoprim	T2	
TRIUMEQ	T5	
TRIUMEQ PD	T4	QL (186 EA per 31 days)
valacyclovir	T2	
valganciclovir oral recon soln	T4	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
valganciclovir oral tablet	T3	
vancomycin intravenous recon soln 1,000 mg, 10 gram, 500 mg, 750 mg	T4	
vancomycin oral capsule 125 mg	T4	QL (124 EA per 31 days)
vancomycin oral capsule 250 mg	T4	QL (248 EA per 31 days)
VEMLIDY	T5	QL (31 EA per 31 days)
VIRACEPT ORAL TABLET	T5	
VIREAD ORAL POWDER	T5	
VIREAD ORAL TABLET 150 MG, 200 MG, 250 MG	T5	
VIVJOA	T4	PA; QL (18 EA per 84 days)
voriconazole intravenous recon soln	T5	PA
voriconazole oral	T4	
VOSEVI	T5	PA; QL (28 EA per 28 days)
XIFAXAN ORAL TABLET 200 MG	T4	QL (27 EA per 365 days)
XIFAXAN ORAL TABLET 550 MG	T5	PA; QL (62 EA per 31 days)
XOCOVA	T5	QL (63 EA per 365 days)
XOFLUZA ORAL TABLET 40 MG, 80 MG	T3	QL (9 EA per 365 days)
zidovudine	T2	
Cardiovascular, Hipertensión / Lípidos		
acebutolol	T2	
aliskiren	T4	
amiloride	T2	
amiloride-hydrochlorothiazide	T2	
amiodarone oral	T2	
amlodipine	T1	
amlodipine-benazepril	T1	
amlodipine-olmesartan	T2	QL (31 EA per 31 days)
amlodipine-valsartan	T2	
aspirin-dipyridamole	T4	
atenolol	T1	
atenolol-chlorthalidone	T2	
atorvastatin	T1	
ATTRUBY	T5	PA; QL (124 EA per 31 days)
benazepril	T1	
benazepril-hydrochlorothiazide	T1	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
bisoprolol fumarate oral tablet 10 mg, 5 mg	T2	
bisoprolol-hydrochlorothiazide	T1	
bumetanide oral	T2	
candesartan	T2	
candesartan-hydrochlorothiazid	T2	
captopril	T1	
CARTIA XT	T2	
carvedilol	T1	
chlorthalidone oral tablet 25 mg, 50 mg	T1	
cholestyramine (with sugar) oral powder in packet	T2	
CHOLESTYRAMINE LIGHT ORAL POWDER IN PACKET	T2	
cilostazol	T2	
clonidine	T4	
clonidine hcl oral tablet 0.1 mg, 0.2 mg, 0.3 mg	T1	
clopidogrel	T1	
colesevelam	T4	
colestipol oral packet	T4	
colestipol oral tablet	T3	
dabigatran etexilate oral capsule 110 mg	T4	QL (124 EA per 31 days)
dabigatran etexilate oral capsule 150 mg, 75 mg	T4	QL (62 EA per 31 days)
digoxin oral solution	T3	QL (155 ML per 31 days)
digoxin oral tablet 125 mcg (0.125 mg)	T1	QL (62 EA per 31 days)
digoxin oral tablet 250 mcg (0.25 mg)	T2	QL (31 EA per 31 days)
diltiazem hcl oral capsule,extended release 12 hr	T2	
diltiazem hcl oral capsule,extended release 24 hr 360 mg, 420 mg	T2	
diltiazem hcl oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg	T2	
diltiazem hcl oral tablet	T2	
diltiazem hcl oral tablet extended release 24 hr	T2	
DILT-XR	T2	
dofetilide	T4	
doxazosin	T2	
ELIQUIS DVT-PE TREAT 30D START	T3	QL (74 EA per 30 days)
ELIQUIS ORAL TABLET 2.5 MG	T3	QL (60 EA per 30 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
ELIQUIS ORAL TABLET 5 MG	T3	QL (74 EA per 30 days)
ELIQUIS ORAL TABLET FOR SUSPENSION 0.5 MG	T3	QL (112 EA per 28 days)
ELIQUIS ORAL TABLET FOR SUSPENSION 1.5 MG (0.5 MG X 3)	T3	QL (336 EA per 28 days)
ELIQUIS ORAL TABLET FOR SUSPENSION 2 MG (0.5 MG X 4)	T3	QL (560 EA per 28 days)
ELIQUIS SPRINKLE	T3	QL (70 EA per 28 days)
eltrombopag olamine oral powder in packet 12.5 mg	T5	PA; QL (372 EA per 31 days)
eltrombopag olamine oral powder in packet 25 mg	T5	PA; QL (31 EA per 31 days)
eltrombopag olamine oral tablet 12.5 mg, 25 mg	T5	PA; QL (31 EA per 31 days)
eltrombopag olamine oral tablet 50 mg, 75 mg	T5	PA; QL (62 EA per 31 days)
enalapril maleate oral tablet	T1	
enalapril-hydrochlorothiazide	T1	
enoxaparin subcutaneous syringe	T4	
ENTRESTO ORAL TABLET 24-26 MG	T4	ST; QL (186 EA per 31 days)
ENTRESTO ORAL TABLET 49-51 MG	T4	ST; QL (93 EA per 31 days)
ENTRESTO ORAL TABLET 97-103 MG	T4	ST; QL (62 EA per 31 days)
ENTRESTO SPRINKLE	T3	PA; QL (248 EA per 31 days)
eplerenone	T4	
ethacrynic acid	T4	
ezetimibe	T2	
ezetimibe-simvastatin	T3	QL (31 EA per 31 days)
felodipine	T2	
fenofibrate micronized oral capsule 134 mg, 200 mg, 67 mg	T2	
fenofibrate nanocrystallized	T2	
fenofibrate oral tablet 160 mg, 54 mg	T2	
flecainide	T2	
fondaparinux subcutaneous syringe 10 mg/0.8 ml, 5 mg/0.4 ml, 7.5 mg/0.6 ml	T5	
fondaparinux subcutaneous syringe 2.5 mg/0.5 ml	T4	
fosinopril	T1	
fosinopril-hydrochlorothiazide	T1	
furosemide injection	T2	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
furosemide oral solution	T2	
furosemide oral tablet	T1	
gemfibrozil	T1	
heparin (porcine) injection solution	T3	PA-BvD
hydralazine oral	T1	
hydrochlorothiazide	T1	
icosapent ethyl oral capsule 0.5 gram	T4	QL (248 EA per 31 days)
icosapent ethyl oral capsule 1 gram	T4	QL (124 EA per 31 days)
indapamide	T1	
irbesartan	T1	QL (31 EA per 31 days)
irbesartan-hydrochlorothiazide	T1	QL (31 EA per 31 days)
isosorbide dinitrate oral tablet 10 mg, 20 mg, 30 mg, 5 mg	T2	
isosorbide mononitrate	T2	
isradipine	T4	
ivabradine oral tablet 5 mg	T4	PA; QL (93 EA per 31 days)
ivabradine oral tablet 7.5 mg	T4	PA; QL (62 EA per 31 days)
JANTOVEN	T1	
KERENDIA	T4	PA; QL (31 EA per 31 days)
labetalol oral tablet 100 mg, 200 mg, 300 mg	T2	
lisinopril	T1	
lisinopril-hydrochlorothiazide	T1	
losartan oral tablet 100 mg	T1	QL (31 EA per 31 days)
losartan oral tablet 25 mg	T1	QL (93 EA per 31 days)
losartan oral tablet 50 mg	T1	QL (62 EA per 31 days)
losartan-hydrochlorothiazide	T1	
lovastatin	T1	
metolazone	T2	
metoprolol succinate	T2	
metoprolol ta-hydrochlorothiaz	T2	
metoprolol tartrate oral tablet 100 mg, 25 mg, 50 mg	T1	
metoprolol tartrate oral tablet 37.5 mg, 75 mg	T2	
metyrosine	T5	PA
mexiletine	T3	
minoxidil oral	T2	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
moexipril	T1	
MULPLETA	T5	PA
MULTAQ	T4	
nadolol	T4	
nebivolol oral tablet 10 mg, 2.5 mg	T2	QL (93 EA per 31 days)
nebivolol oral tablet 20 mg	T2	QL (62 EA per 31 days)
nebivolol oral tablet 5 mg	T2	QL (217 EA per 31 days)
NEXLETOL	T4	PA; QL (31 EA per 31 days)
NEXLIZET	T4	PA; QL (31 EA per 31 days)
niacin oral tablet extended release 24 hr 1,000 mg, 750 mg	T4	
niacin oral tablet extended release 24 hr 500 mg	T4	QL (31 EA per 31 days)
nicardipine oral	T4	
nifedipine oral tablet extended release	T2	
nifedipine oral tablet extended release 24hr	T2	
nimodipine oral capsule	T4	
NITRO-BID	T2	
nitroglycerin sublingual	T2	
nitroglycerin transdermal patch 24 hour	T2	
nitroglycerin translingual	T4	
olmesartan oral tablet 20 mg, 40 mg	T1	QL (31 EA per 31 days)
olmesartan oral tablet 5 mg	T1	QL (93 EA per 31 days)
olmesartan-amlodipin-hcthiazid	T3	
olmesartan-hydrochlorothiazide	T1	QL (31 EA per 31 days)
omega-3 acid ethyl esters	T3	QL (124 EA per 31 days)
PACERONE ORAL TABLET 100 MG, 200 MG	T2	
pentoxifylline	T2	
perindopril erbumine	T2	
pindolol	T4	
pitavastatin calcium	T3	
prasugrel hcl	T3	
pravastatin	T1	
prazosin	T2	
PREVALITE ORAL POWDER IN PACKET	T4	
propafenone oral capsule,extended release 12 hr	T4	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
propafenone oral tablet	T2	
propranolol oral capsule,extended release 24 hr	T2	
propranolol oral tablet	T2	
quinapril	T1	
quinapril-hydrochlorothiazide	T1	
quinidine sulfate oral tablet	T2	
ramipril	T1	
ranolazine	T4	QL (62 EA per 31 days)
REPATHA SURECLICK	T3	PA; QL (3 ML per 28 days)
REPATHA SYRINGE	T3	PA; QL (3 ML per 28 days)
rosuvastatin	T1	
sacubitril-valsartan oral tablet 24-26 mg	T2	QL (186 EA per 31 days)
sacubitril-valsartan oral tablet 49-51 mg	T2	QL (93 EA per 31 days)
sacubitril-valsartan oral tablet 97-103 mg	T2	QL (62 EA per 31 days)
simvastatin	T1	
SOTALOL AF	T2	
sotalol oral	T2	
spironolactone oral tablet	T1	
spironolacton-hydrochlorothiaz	T2	
telmisartan	T1	
telmisartan-amlodipine	T2	
telmisartan-hydrochlorothiazid	T1	
terazosin	T1	
TIADYLT ER	T2	
ticagrelor	T2	
timolol maleate oral	T3	
torsemide oral	T1	
trandolapril	T1	
triamterene-hydrochlorothiazid	T1	
UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 400 MCG, 600 MCG, 800 MCG	T5	PA; QL (62 EA per 31 days)
UPTRAVI ORAL TABLET 200 MCG	T5	PA; QL (224 EA per 28 days)
UPTRAVI ORAL TABLETS,DOSE PACK	T5	PA; QL (400 EA per 365 days)
valsartan oral tablet 160 mg, 40 mg, 80 mg	T1	QL (62 EA per 31 days)
valsartan oral tablet 320 mg	T1	QL (31 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
valsartan-hydrochlorothiazide	T1	QL (31 EA per 31 days)
verapamil oral capsule, 24 hr er pellet ct	T4	
verapamil oral capsule,ext rel. pellets 24 hr 120 mg, 180 mg, 240 mg	T2	
verapamil oral capsule,ext rel. pellets 24 hr 360 mg	T4	
verapamil oral tablet	T2	
verapamil oral tablet extended release	T2	
VERQUVO	T4	PA; QL (31 EA per 31 days)
warfarin	T1	
XARELTO DVT-PE TREAT 30D START	T3	QL (51 EA per 30 days)
XARELTO ORAL SUSPENSION FOR RECONSTITUTION	T3	QL (930 ML per 31 days)
XARELTO ORAL TABLET 10 MG, 20 MG	T3	QL (31 EA per 31 days)
XARELTO ORAL TABLET 15 MG	T3	QL (52 EA per 31 days)
XARELTO ORAL TABLET 2.5 MG	T3	QL (62 EA per 31 days)
Dermatológicos/Terapia Tópica		
ACCUTANE ORAL CAPSULE 10 MG, 20 MG, 40 MG	T4	
acitretin	T4	PA
acyclovir topical ointment	T3	QL (30 GM per 30 days)
ALA-CORT TOPICAL CREAM	T1	
alclometasone	T2	
ammonium lactate	T2	
AMNESTEEM	T4	
ANZUPGO	T5	PA; QL (60 GM per 30 days)
betamethasone dipropionate topical cream	T2	
betamethasone dipropionate topical lotion	T2	
betamethasone valerate topical cream	T2	
betamethasone valerate topical lotion	T3	
betamethasone valerate topical ointment	T2	
betamethasone, augmented topical cream	T2	
betamethasone, augmented topical gel	T4	
betamethasone, augmented topical lotion	T4	
betamethasone, augmented topical ointment	T3	
calcipotriene scalp	T3	QL (60 ML per 28 days)
calcipotriene topical cream	T4	QL (60 GM per 28 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
calcipotriene topical ointment	T3	QL (60 GM per 28 days)
ciclopirox topical cream	T2	QL (90 GM per 28 days)
ciclopirox topical gel	T3	QL (45 GM per 28 days)
ciclopirox topical shampoo	T3	QL (120 ML per 28 days)
ciclopirox topical solution	T2	
ciclopirox topical suspension	T3	QL (60 ML per 28 days)
CLARAVIS	T4	
clindamycin phosphate topical gel	T2	QL (60 GM per 28 days)
clindamycin phosphate topical lotion	T2	QL (60 ML per 28 days)
clindamycin phosphate topical solution	T2	QL (60 ML per 28 days)
clindamycin phosphate topical swab	T2	
clindamycin-benzoyl peroxide topical gel 1.2 %(1 % base) -5 %	T2	
clotrimazole topical cream	T2	QL (45 GM per 28 days)
clotrimazole topical solution	T3	QL (30 ML per 28 days)
clotrimazole-betamethasone topical cream	T2	QL (45 GM per 28 days)
clotrimazole-betamethasone topical lotion	T3	QL (60 ML per 28 days)
COSENTYX (2 SYRINGES)	T5	PA; QL (2 ML per 28 days)
COSENTYX PEN (2 PENS)	T5	PA; QL (2 ML per 28 days)
COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML	T5	PA; QL (0.5 ML per 28 days)
COSENTYX UNOREADY PEN	T5	PA; QL (2 ML per 28 days)
desoximetasone topical cream	T4	QL (100 GM per 28 days)
desoximetasone topical gel	T4	QL (60 GM per 28 days)
diclofenac sodium topical gel 3 %	T4	PA; QL (100 GM per 28 days)
DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML	T5	PA; QL (2.28 ML per 28 days)
DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 300 MG/2 ML	T5	PA; QL (8 ML per 28 days)
DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 200 MG/1.14 ML	T5	PA; QL (2.28 ML per 28 days)
DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 300 MG/2 ML	T5	PA; QL (8 ML per 28 days)
ERY PADS	T3	
erythromycin with ethanol topical gel	T2	QL (60 GM per 28 days)
erythromycin with ethanol topical solution	T2	QL (60 ML per 28 days)
FILSUVEZ	T5	PA

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
fluocinolone and shower cap	T4	QL (118.28 ML per 28 days)
fluocinolone topical cream 0.01 %	T3	QL (60 GM per 28 days)
fluocinolone topical cream 0.025 %	T3	QL (120 GM per 28 days)
fluocinolone topical ointment	T3	QL (120 GM per 28 days)
fluocinolone topical solution	T3	QL (90 ML per 28 days)
fluocinonide topical cream 0.05 %	T2	QL (60 GM per 28 days)
fluocinonide topical gel	T3	QL (60 GM per 28 days)
fluocinonide topical ointment	T2	QL (60 GM per 28 days)
fluocinonide topical solution	T2	QL (60 ML per 28 days)
fluocinonide-emollient	T4	QL (60 GM per 28 days)
fluorouracil topical cream 5 %	T3	
fluorouracil topical solution 2 %	T2	
fluorouracil topical solution 5 %	T3	
fluticasone propionate topical cream	T2	
gentamicin topical	T3	QL (60 GM per 28 days)
halobetasol propionate topical cream	T4	QL (50 GM per 28 days)
halobetasol propionate topical ointment	T4	QL (50 GM per 28 days)
hydrocortisone topical cream 1 %	T1	
hydrocortisone topical lotion 2.5 %	T2	QL (118 ML per 28 days)
hydrocortisone topical ointment 1 %, 2.5 %	T1	
imiquimod topical cream in packet 5 %	T2	
ketoconazole topical cream	T2	QL (60 GM per 28 days)
ketoconazole topical shampoo	T2	QL (120 ML per 28 days)
lidocaine hcl mucous membrane solution 2 %	T2	
lidocaine hcl mucous membrane solution 4 % (40 mg/ml)	T2	PA; QL (50 ML per 28 days)
lidocaine topical adhesive patch,medicated 5 %	T4	PA; QL (93 EA per 31 days)
lidocaine topical ointment	T4	PA; QL (50 GM per 28 days)
lidocaine-prilocaine topical cream	T2	PA; QL (30 GM per 28 days)
malathion	T4	
metronidazole topical cream	T3	
metronidazole topical gel 0.75 %	T3	
metronidazole topical gel 1 %	T4	
metronidazole topical lotion	T4	
mometasone topical	T2	
mupirocin	T2	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
NYAMYC	T2	QL (60 GM per 28 days)
nystatin topical cream	T2	QL (30 GM per 28 days)
nystatin topical ointment	T2	QL (30 GM per 28 days)
nystatin topical powder	T2	QL (60 GM per 28 days)
NYSTOP	T2	QL (60 GM per 28 days)
PANRETIN	T5	PA-NC
penciclovir	T4	QL (5 GM per 28 days)
permethrin	T2	
podofilox topical solution	T4	
selenium sulfide topical lotion	T1	
SILIQ	T5	PA; QL (6 ML per 28 days)
silver sulfadiazine	T1	
SKYRIZI SUBCUTANEOUS PEN INJECTOR	T5	PA; QL (1 ML per 84 days)
SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML	T5	PA; QL (1 ML per 84 days)
SKYRIZI SUBCUTANEOUS SYRINGE 55 MG/0.37 ML	T5	PA; QL (0.37 ML per 84 days)
SSD	T4	
STELARA SUBCUTANEOUS SOLUTION	T5	PA; QL (0.5 ML per 84 days)
STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML	T5	PA; QL (0.5 ML per 84 days)
STELARA SUBCUTANEOUS SYRINGE 90 MG/ML	T5	PA; QL (1 ML per 56 days)
STEQEYMA SUBCUTANEOUS SOLUTION	T3	PA; QL (0.5 ML per 84 days)
STEQEYMA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML	T3	PA; QL (0.5 ML per 84 days)
STEQEYMA SUBCUTANEOUS SYRINGE 90 MG/ML	T5	PA; QL (1 ML per 56 days)
sulfacetamide sodium (acne)	T2	
SULFAMYLON TOPICAL CREAM	T3	
tacrolimus topical	T4	QL (100 GM per 28 days)
tazarotene topical cream	T4	PA; QL (60 GM per 28 days)
tretinoin topical cream	T2	PA; QL (45 GM per 28 days)
tretinoin topical gel 0.01 %, 0.025 %	T4	PA; QL (45 GM per 28 days)
triamcinolone acetonide topical cream	T2	
triamcinolone acetonide topical lotion	T2	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
triamcinolone acetonide topical ointment 0.025 %, 0.1 %, 0.5 %	T2	
TRIDERM TOPICAL CREAM 0.5 %	T4	
ustekinumab subcutaneous solution	T5	PA; QL (0.5 ML per 84 days)
ustekinumab subcutaneous syringe 45 mg/0.5 ml	T5	PA; QL (0.5 ML per 84 days)
ustekinumab subcutaneous syringe 90 mg/ml	T5	PA; QL (1 ML per 56 days)
VALCHLOR	T5	PA-NC
YESINTEK SUBCUTANEOUS SOLUTION	T3	PA; QL (0.5 ML per 84 days)
YESINTEK SUBCUTANEOUS SYRINGE 45 MG/0.5 ML	T3	PA; QL (0.5 ML per 84 days)
YESINTEK SUBCUTANEOUS SYRINGE 90 MG/ML	T5	PA; QL (1 ML per 56 days)
ZELSUVMI	T5	PA; QL (31 GM per 28 days)
ZORYVE TOPICAL CREAM 0.15 %	T4	PA; QL (60 GM per 28 days)
Diagnósticos / Agentes Varios		
acamprosate	T4	
anagrelide	T4	
bupropion hcl (smoking deter)	T2	QL (62 EA per 31 days)
carglumic acid	T5	PA
CHEMET	T4	
CLINIMIX 4.25%/D5W SULFIT FREE	T4	PA-BvD
d10 %-0.45 % sodium chloride	T2	
d2.5 %-0.45 % sodium chloride	T2	
d5 % and 0.9 % sodium chloride	T2	
d5 %-0.45 % sodium chloride	T2	
deferasirox oral tablet, dispersible 125 mg	T4	PA
deferasirox oral tablet, dispersible 250 mg, 500 mg	T5	PA
dextrose 10 % in water (d10w)	T2	
dextrose 5 % in water (d5w) intravenous parenteral solution	T2	
disulfiram	T3	
droxidopa oral capsule 100 mg	T5	PA; QL (465 EA per 31 days)
droxidopa oral capsule 200 mg, 300 mg	T5	PA; QL (186 EA per 31 days)
DUVYZAT	T5	PA; QL (420 ML per 35 days)
FABHALTA	T5	PA; QL (62 EA per 31 days)
glycerol phenylbutyrate	T5	PA

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
INCRELEX	T5	PA
JOENJA ORAL TABLET 70 MG	T5	PA; QL (60 EA per 30 days)
KIONEX ORAL SUSPENSION	T2	
KYGEVVI	T5	PA; QL (496 EA per 30 days)
levocarnitine (with sugar)	T4	PA-BvD
levocarnitine oral tablet	T4	PA-BvD
LITFULO	T5	PA; QL (28 EA per 28 days)
LOARGYS	T5	PA
LOKELMA	T3	PA; QL (93 EA per 31 days)
midodrine	T2	
NICOTROL NS	T4	
nitisinone	T5	PA
PHEBURANE	T5	PA; QL (620 GM per 31 days)
pilocarpine hcl oral	T3	
PROLASTIN-C INTRAVENOUS SOLUTION	T5	PA
REVCOVI	T5	
REZDIFFRA	T5	PA; QL (31 EA per 31 days)
riluzole	T4	
risedronate oral tablet 30 mg	T5	
sevelamer carbonate oral powder in packet	T4	PA-BvD
sevelamer carbonate oral tablet	T3	PA-BvD
sodium chloride 0.9 % intravenous parenteral solution	T2	
sodium chloride irrigation	T2	
sodium phenylbutyrate	T5	PA
sodium polystyrene sulfonate	T2	
SOHONOS ORAL CAPSULE 1 MG, 1.5 MG, 5 MG	T5	PA; QL (31 EA per 31 days)
SOHONOS ORAL CAPSULE 10 MG	T5	PA; QL (62 EA per 31 days)
SPS (WITH SORBITOL) ORAL	T2	
trientine oral capsule 250 mg	T5	QL (248 EA per 31 days)
varenicline tartrate oral tablet	T4	QL (60 EA per 30 days)
varenicline tartrate oral tablets,dose pack	T4	QL (106 EA per 365 days)
ZOKINVY	T5	PA
Endocrino/Diabetes		
acarbose	T2	QL (93 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
ALCOHOL PADS	T2	PA
cabergoline	T3	
calcitonin (salmon) nasal	T3	PA-BvD
calcitriol oral capsule	T2	PA-BvD
calcitriol oral solution	T4	PA-BvD
CERDELGA	T5	PA; QL (62 EA per 31 days)
cinacalcet oral tablet 30 mg, 60 mg	T4	PA-BvD; QL (62 EA per 31 days)
cinacalcet oral tablet 90 mg	T4	PA-BvD; QL (124 EA per 31 days)
danazol	T4	
dapagliflozin	T3	QL (31 EA per 31 days)
desmopressin nasal spray,non-aerosol 10 mcg/spray (0.1 ml)	T4	
desmopressin oral	T2	
dexamethasone oral solution	T2	
dexamethasone oral tablet	T1	
diazoxide	T4	
doxercalciferol oral	T4	PA-BvD
FIASP FLEXTOUCH U-100 INSULIN	T3	
FIASP PENFILL U-100 INSULIN	T3	
FIASP U-100 INSULIN	T3	
fludrocortisone	T2	
glimepiride oral tablet 1 mg, 2 mg, 4 mg	T1	
glipizide oral tablet 10 mg, 5 mg	T1	
glipizide oral tablet extended release 24hr	T1	
glipizide-metformin	T1	
GLUCAGON EMERGENCY KIT (HUMAN)	T3	
glyburide	T2	
glyburide-metformin	T2	
GLYXAMBI	T3	QL (31 EA per 31 days)
GVOKE	T3	
GVOKE HYPOPEN 2-PACK	T3	
GVOKE PFS 1-PACK SYRINGE SUBCUTANEOUS SYRINGE 1 MG/0.2 ML	T3	
HUMALOG JUNIOR KWIKPEN U-100	T3	
HUMALOG KWIKPEN INSULIN	T3	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
HUMALOG MIX 50-50 KWIKPEN	T3	
HUMALOG MIX 75-25 KWIKPEN	T3	
HUMALOG MIX 75-25(U-100)INSULN	T3	
HUMALOG U-100 INSULIN	T3	
HUMULIN 70/30 U-100 INSULIN	T3	
HUMULIN 70/30 U-100 KWIKPEN	T3	
HUMULIN N NPH INSULIN KWIKPEN	T3	
HUMULIN N NPH U-100 INSULIN	T3	
HUMULIN R REGULAR U-100 INSULN	T3	
HUMULIN R U-500 (CONC) KWIKPEN	T3	
hydrocortisone oral	T1	
insulin lispro	T3	
insulin lispro protamin-lispro	T3	
JANUMET	T3	QL (62 EA per 31 days)
JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 100-1,000 MG, 50-500 MG	T3	QL (31 EA per 31 days)
JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 50-1,000 MG	T3	QL (62 EA per 31 days)
JANUVIA ORAL TABLET 100 MG, 50 MG	T3	QL (31 EA per 31 days)
JANUVIA ORAL TABLET 25 MG	T3	QL (93 EA per 31 days)
JARDIANCE ORAL TABLET 10 MG	T3	QL (62 EA per 31 days)
JARDIANCE ORAL TABLET 25 MG	T3	QL (31 EA per 31 days)
JAVYGTOR	T5	PA
JENTADUETO ORAL TABLET 2.5-1,000 MG, 2.5-500 MG	T3	QL (62 EA per 31 days)
JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG	T3	QL (62 EA per 31 days)
JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 5-1,000 MG	T3	QL (31 EA per 31 days)
LANTUS SOLOSTAR U-100 INSULIN	T3	
LANTUS U-100 INSULIN	T3	
levothyroxine oral tablet	T1	
LEVOXYL ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG	T3	
LIOMNY	T2	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
liothyronine oral	T2	
liraglutide	T4	PA; QL (9 ML per 30 days)
metformin oral tablet 1,000 mg, 500 mg, 850 mg	T1	
metformin oral tablet extended release 24 hr	T1	
methimazole oral tablet 10 mg, 5 mg	T2	
methylprednisolone	T2	
mifepristone oral tablet 300 mg	T5	PA; QL (124 EA per 31 days)
miglustat	T5	PA; QL (93 EA per 31 days)
MOUNJARO	T3	PA; QL (2 ML per 28 days)
nateglinide	T1	QL (93 EA per 31 days)
NOVOLIN 70/30 U-100 INSULIN	T3	
NOVOLIN 70-30 FLEXPEN U-100	T3	
NOVOLIN N FLEXPEN	T3	
NOVOLIN N NPH U-100 INSULIN	T3	
NOVOLIN R FLEXPEN	T3	
NOVOLIN R REGULAR U100 INSULIN	T3	
NOVOLOG FLEXPEN U-100 INSULIN	T3	
NOVOLOG MIX 70-30 U-100 INSULN	T3	
NOVOLOG MIX 70-30FLEXPEN U-100	T3	
NOVOLOG PENFILL U-100 INSULIN	T3	
NOVOLOG U-100 INSULIN ASPART	T3	
OZEMPIC ORAL	T3	PA; QL (31 EA per 31 days)
OZEMPIC SUBCUTANEOUS	T3	PA; QL (3 ML per 28 days)
paricalcitol oral	T4	PA-BvD
pioglitazone	T1	QL (31 EA per 31 days)
pioglitazone-metformin	T2	QL (93 EA per 31 days)
prednisolone oral solution	T2	
prednisolone sodium phosphate oral solution 25 mg/5 ml (5 mg/ml), 5 mg base/5 ml (6.7 mg/5 ml)	T2	
prednisone oral solution	T3	
prednisone oral tablet	T1	
prednisone oral tablets,dose pack	T2	
propylthiouracil	T2	
RECORLEV	T5	
repaglinide oral tablet 0.5 mg, 1 mg	T2	QL (124 EA per 31 days)
repaglinide oral tablet 2 mg	T2	QL (248 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
sapropterin	T5	PA
sitagliptin oral tablet 100 mg, 50 mg	T3	QL (31 EA per 31 days)
sitagliptin oral tablet 25 mg	T3	QL (93 EA per 31 days)
sitagliptin phos-metformin oral tablet	T3	QL (62 EA per 31 days)
sitagliptin phos-metformin oral tablet, er multiphase 24 hr 100-1,000 mg, 50-500 mg	T3	QL (31 EA per 31 days)
sitagliptin phos-metformin oral tablet, er multiphase 24 hr 50-1,000 mg	T3	QL (62 EA per 31 days)
sitagliptin phosphate oral tablet 100 mg, 50 mg	T3	QL (31 EA per 31 days)
sitagliptin phosphate oral tablet 25 mg	T3	QL (93 EA per 31 days)
sitagliptin-metformin oral tablet	T3	QL (62 EA per 31 days)
sitagliptin-metformin oral tablet, er multiphase 24 hr 100-1,000 mg, 50-500 mg	T3	QL (31 EA per 31 days)
sitagliptin-metformin oral tablet, er multiphase 24 hr 50-1,000 mg	T3	QL (62 EA per 31 days)
SOLIQUA 100/33	T3	QL (18 ML per 30 days)
SOMAVERT	T5	PA
SYNAREL	T5	PA
SYNJARDY	T3	QL (62 EA per 31 days)
SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 12.5-1,000 MG, 5-1,000 MG	T3	QL (62 EA per 31 days)
SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 25-1,000 MG	T3	QL (31 EA per 31 days)
SYNTHROID	T3	
testosterone cypionate	T2	PA
testosterone enanthate	T3	PA
testosterone transdermal gel in metered-dose pump 20.25 mg/1.25 gram (1.62 %)	T4	PA
tolvaptan	T5	PA
tolvaptan (polycys kidney dis) oral tablet	T5	PA; QL (112 EA per 28 days)
tolvaptan (polycys kidney dis) oral tablets, sequential	T5	PA; QL (56 EA per 28 days)
TOUJEO MAX U-300 SOLOSTAR	T3	
TOUJEO SOLOSTAR U-300 INSULIN	T3	
TRADJENTA	T3	QL (31 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-5-1,000 MG, 25-5-1,000 MG	T3	QL (31 EA per 31 days)
TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 12.5-2.5-1,000 MG, 5-2.5-1,000 MG	T3	QL (62 EA per 31 days)
TRULICITY	T3	PA; QL (2 ML per 28 days)
UNITHROID	T3	
XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 10-500 MG, 5-500 MG	T3	QL (31 EA per 31 days)
XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG, 5-1,000 MG	T3	QL (62 EA per 31 days)
XULTOPHY 100/3.6	T3	QL (15 ML per 30 days)
YARGESA	T5	PA; QL (93 EA per 31 days)
YORVIPATH SUBCUTANEOUS PEN INJECTOR 168 MCG/0.56 ML	T5	PA; QL (1.12 ML per 28 days)
YORVIPATH SUBCUTANEOUS PEN INJECTOR 294 MCG/0.98 ML	T5	PA; QL (1.96 ML per 28 days)
YORVIPATH SUBCUTANEOUS PEN INJECTOR 420 MCG/1.4 ML	T5	PA; QL (2.8 ML per 28 days)
ZELVYSIA	T5	PA
Gastroenterología		
alosetron oral tablet 0.5 mg	T4	PA; QL (93 EA per 31 days)
alosetron oral tablet 1 mg	T5	PA; QL (62 EA per 31 days)
aprepitant oral capsule 125 mg	T5	PA-BvD
aprepitant oral capsule 40 mg, 80 mg	T4	PA-BvD
aprepitant oral capsule,dose pack	T4	PA-BvD
balsalazide	T4	
betaine	T5	
budesonide oral capsule,delayed,extend.release	T4	
budesonide oral tablet,delayed and ext.release	T5	
COMPRO	T4	
CONSTULOSE	T2	
CREON	T3	
cromolyn oral	T4	
dicyclomine oral capsule	T2	
dicyclomine oral solution	T2	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
dicyclomine oral tablet 20 mg	T2	
diphenoxylate-atropine oral liquid	T4	
diphenoxylate-atropine oral tablet	T2	
dronabinol oral capsule	T4	PA-BvD
ENULOSE	T2	
EOHILIA	T5	PA; QL (1800 ML per 365 days)
esomeprazole magnesium oral capsule,delayed release(dr/ec)	T2	QL (31 EA per 31 days)
famotidine oral suspension for reconstitution	T2	
famotidine oral tablet 20 mg, 40 mg	T1	
GATTEX 30-VIAL	T5	PA
GAVILYTE-C	T1	
GAVILYTE-G	T1	
GAVILYTE-N	T1	
GENERLAC	T2	
glycopyrrolate oral tablet 1 mg, 2 mg	T2	
granisetron hcl oral	T4	PA-BvD
hydrocortisone rectal	T4	
hydrocortisone topical cream with perineal applicator 2.5 %	T1	
lactulose oral solution	T2	
LINZESS	T3	QL (31 EA per 31 days)
loperamide oral capsule	T2	
lubiprostone	T4	QL (62 EA per 31 days)
meclizine oral tablet 12.5 mg, 25 mg	T2	
mesalamine oral capsule (with del rel tablets)	T4	QL (186 EA per 31 days)
mesalamine oral capsule,extended release 24hr	T4	QL (124 EA per 31 days)
mesalamine oral tablet,delayed release (dr/ec) 1.2 gram	T4	QL (124 EA per 31 days)
mesalamine rectal enema	T4	QL (1860 ML per 31 days)
metoclopramide hcl oral solution	T2	
metoclopramide hcl oral tablet	T2	
misoprostol	T2	
MOVANTIK	T3	QL (31 EA per 31 days)
nitroglycerin rectal	T4	
omeprazole oral capsule,delayed release(dr/ec)	T1	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
ondansetron hcl oral solution	T3	PA-BvD
ondansetron hcl oral tablet 4 mg, 8 mg	T2	PA-BvD
ondansetron oral tablet,disintegrating 4 mg, 8 mg	T2	PA-BvD
pantoprazole oral tablet,delayed release (dr/ec)	T1	
peg 3350-electrolytes	T1	
peg3350-sod sul-nacl-kcl-asb-c	T4	
peg-electrolyte soln	T1	
prochlorperazine	T4	
prochlorperazine maleate	T2	
PROCTO-MED HC	T2	
PROCTOSOL HC TOPICAL	T2	
PROCTOZONE-HC	T2	
rabeprazole oral tablet,delayed release (dr/ec)	T2	QL (62 EA per 31 days)
scopolamine base	T3	QL (10 EA per 30 days)
SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML)	T5	PA; QL (1.2 ML per 56 days)
SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 360 MG/2.4 ML (150 MG/ML)	T5	PA; QL (2.4 ML per 56 days)
sodium,potassium,mag sulfates	T4	
sucralfate oral suspension	T4	
sucralfate oral tablet	T2	
sulfasalazine	T2	
ursodiol oral capsule 300 mg	T4	
ursodiol oral tablet	T3	
VOWST	T5	PA; QL (12 EA per 14 days)
ZENPEP ORAL CAPSULE,DELAYED RELEASE(DR/EC) 10,000-32,000 -42,000 UNIT, 15,000-47,000 -63,000 UNIT, 20,000-63,000- 84,000 UNIT, 25,000-79,000- 105,000 UNIT, 3,000-10,000 -14,000-UNIT, 40,000-126,000- 168,000 UNIT, 5,000-17,000- 24,000 UNIT, 60,000-189,600- 252,600 UNIT	T3	
Inmunología, Vacunas / Biotecnología		
ABRYSVO (PF)	T3	QL (1 EA per 365 days)
ACTHIB (PF)	T3	
ACTIMMUNE	T5	PA
ADACEL(TDAP ADOLESN/ADULT)(PF)	T3	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
AREXVY (PF)	T3	QL (1 EA per 365 days)
AVONEX INTRAMUSCULAR PEN INJECTOR KIT	T5	PA; QL (1 EA per 28 days)
AVONEX INTRAMUSCULAR SYRINGE KIT	T5	PA; QL (1 EA per 28 days)
bcg vaccine, live (pf)	T3	
BESREMI	T5	PA-NC; QL (2 ML per 28 days)
BESREMI PEN	T5	PA-NC; QL (1 ML per 28 days)
BETASERON SUBCUTANEOUS KIT	T5	PA; QL (14 EA per 28 days)
BEXSERO	T3	
BOOSTRIX TDAP INTRAMUSCULAR SYRINGE	T3	
DAPTACEL (DTAP PEDIATRIC) (PF)	T3	
ENGERIX-B (PF)	T3	PA-BvD
ENGERIX-B PEDIATRIC (PF)	T3	PA-BvD
GAMMAGARD LIQUID	T5	PA
GAMMAGARD LIQUID ERC	T5	PA
GAMMAGARD S-D (IGA < 1 MCG/ML)	T5	PA
GARDASIL 9 (PF)	T3	
HAVRIX (PF)	T3	
HEPLISAV-B (PF)	T3	PA-BvD
HIBERIX (PF)	T3	
IMOVAX RABIES VACCINE (PF)	T3	PA-BvD
INFANRIX (DTAP) (PF)	T3	
IPOL	T3	
IXIARO (PF)	T3	
JYNNEOS (PF)	T3	PA-BvD
KINRIX (PF)	T3	
LEUKINE INJECTION RECON SOLN	T5	PA
MENQUADFI (PF)	T4	
MENVEO A-C-Y-W-135-DIP (PF) INTRAMUSCULAR KIT	T3	
M-M-R II (PF)	T3	
MRESVIA (PF)	T3	QL (1 ML per 365 days)
NIVESTYM	T5	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
NORDITROPIN FLEXPRO SUBCUTANEOUS PEN INJECTOR 10 MG/1.5 ML (6.7 MG/ML), 15 MG/1.5 ML (10 MG/ML), 5 MG/1.5 ML (3.3 MG/ML)	T5	PA
PEDIARIX (PF)	T3	
PEDVAX HIB (PF)	T3	
PEGASYS	T5	PA
PENBRAYA (PF)	T3	
PENMENVY MEN A-B-C-W-Y (PF)	T3	
PENTACEL (PF)	T3	
PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML	T5	PA; QL (1 ML per 28 days)
PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML	T5	PA; QL (1 ML per 28 days)
PRIORIX (PF)	T3	
PRIVIGEN	T5	PA
PROCRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML	T3	PA-BvD
PROCRIT INJECTION SOLUTION 20,000 UNIT/ML, 40,000 UNIT/ML	T5	PA-BvD
PROQUAD (PF)	T3	
QUADRACEL (PF)	T3	
RABAVERT (PF)	T3	PA-BvD
RECOMBIVAX HB (PF)	T3	PA-BvD
RETACRIT	T3	PA-BvD
ROTARIX	T3	
ROTATEQ VACCINE	T3	
SHINGRIX (PF)	T3	QL (2 EA per 999 days)
TENIVAC (PF)	T3	
TICOVAC	T3	
TRUMENBA	T3	
TWINRIX (PF)	T3	
TYPHIM VI INTRAMUSCULAR SYRINGE	T3	
VAQTA (PF)	T3	
VARIVAX (PF)	T3	
VAXCHORA VACCINE	T3	QL (200 ML per 365 days)
VIMKUNYA (PF)	T3	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
VIVOTIF	T3	
XOLREMDI	T5	PA; QL (124 EA per 31 days)
YF-VAX (PF)	T3	
ZARXIO	T5	
Medicamentos Antineoplásicos E Inmunosupresores		
abiraterone oral tablet 250 mg	T5	PA-NC; QL (124 EA per 31 days)
abiraterone oral tablet 500 mg	T5	PA-NC; QL (62 EA per 31 days)
ABIRTEGA	T3	PA-NC; QL (124 EA per 31 days)
AKEEGA	T5	PA-NC; QL (62 EA per 31 days)
ALECENSA	T5	PA-NC; QL (248 EA per 31 days)
ALUNBRIG ORAL TABLET 180 MG, 90 MG	T5	PA-NC; QL (31 EA per 31 days)
ALUNBRIG ORAL TABLET 30 MG	T5	PA-NC; QL (186 EA per 31 days)
ALUNBRIG ORAL TABLETS,DOSE PACK	T5	PA-NC; QL (60 EA per 365 days)
anastrozole	T2	
AUGTYRO ORAL CAPSULE 160 MG	T5	PA-NC; QL (62 EA per 31 days)
AUGTYRO ORAL CAPSULE 40 MG	T5	PA-NC; QL (186 EA per 31 days)
AVMAPKI-FAKZYNJA	T5	PA-NC; QL (66 EA per 28 days)
AYVAKIT	T5	PA-NC; QL (31 EA per 31 days)
azathioprine oral tablet 50 mg	T2	PA-BvD
BALVERSA	T5	PA-NC
bexarotene oral	T5	PA-NC
bexarotene topical	T5	PA-NC; QL (60 GM per 28 days)
bicalutamide	T2	
BOSULIF ORAL CAPSULE 100 MG	T5	PA-NC; QL (186 EA per 31 days)
BOSULIF ORAL CAPSULE 50 MG	T5	PA-NC; QL (341 EA per 31 days)
BOSULIF ORAL TABLET 100 MG	T5	PA-NC; QL (93 EA per 31 days)
BOSULIF ORAL TABLET 400 MG, 500 MG	T5	PA-NC; QL (31 EA per 31 days)
bosutinib oral tablet 400 mg	T5	PA-NC; QL (31 EA per 31 days)
BRAFTOVI	T5	PA-NC; QL (186 EA per 31 days)
BRUKINSA ORAL TABLET	T5	PA-NC; QL (62 EA per 31 days)
CABOMETYX	T5	PA-NC; QL (31 EA per 31 days)
CALQUENCE (ACALABRUTINIB MAL)	T5	PA-NC; QL (62 EA per 31 days)
CAPRELSA ORAL TABLET 100 MG	T5	PA-NC; QL (62 EA per 31 days)
CAPRELSA ORAL TABLET 300 MG	T5	PA-NC; QL (31 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1)	T5	PA-NC; QL (56 EA per 28 days)
COMETRIQ ORAL CAPSULE 140 MG/DAY(80 MG X1-20 MG X3)	T5	PA-NC; QL (112 EA per 28 days)
COMETRIQ ORAL CAPSULE 60 MG/DAY (20 MG X 3/DAY)	T5	PA-NC; QL (84 EA per 28 days)
COPIKTRA	T5	PA-NC; QL (62 EA per 31 days)
COTELLIC	T5	PA-NC; LA; QL (63 EA per 28 days)
cyclophosphamide oral capsule	T3	PA-BvD
cyclophosphamide oral tablet 50 mg	T3	PA-BvD
cyclosporine modified oral capsule	T2	PA-BvD
cyclosporine modified oral solution	T5	PA-BvD
cyclosporine oral capsule	T2	PA-BvD
DANZITEN	T5	PA-NC; QL (124 EA per 31 days)
dasatinib oral tablet 100 mg, 140 mg, 50 mg, 70 mg, 80 mg	T5	PA-NC; QL (31 EA per 31 days)
dasatinib oral tablet 20 mg	T5	PA-NC; QL (93 EA per 31 days)
DAURISMO ORAL TABLET 100 MG	T5	PA-NC; QL (31 EA per 31 days)
DAURISMO ORAL TABLET 25 MG	T5	PA-NC; QL (62 EA per 31 days)
ELIGARD	T4	QL (1 EA per 30 days)
ELIGARD (3 MONTH)	T4	QL (1 EA per 90 days)
ELIGARD (4 MONTH)	T4	QL (1 EA per 120 days)
ELIGARD (6 MONTH)	T4	QL (1 EA per 180 days)
ENSACOVE	T5	PA-NC; QL (62 EA per 31 days)
ENVARSUS XR ORAL TABLET EXTENDED RELEASE 24 HR 0.75 MG, 1 MG	T4	PA-BvD
ENVARSUS XR ORAL TABLET EXTENDED RELEASE 24 HR 4 MG	T5	PA-BvD
ERIVEDGE	T5	PA-NC; QL (31 EA per 31 days)
ERLEADA ORAL TABLET 240 MG	T5	PA-NC; QL (31 EA per 31 days)
ERLEADA ORAL TABLET 60 MG	T5	PA-NC; QL (93 EA per 31 days)
erlotinib	T5	PA-NC; QL (31 EA per 31 days)
EULEXIN	T4	
everolimus (antineoplastic) oral tablet	T5	PA-NC; QL (31 EA per 31 days)
everolimus (antineoplastic) oral tablet for suspension 2 mg, 5 mg	T5	PA-NC; QL (62 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
everolimus (antineoplastic) oral tablet for suspension 3 mg	T5	PA-NC; QL (93 EA per 31 days)
everolimus (immunosuppressive) oral tablet 0.25 mg	T4	PA-BvD
everolimus (immunosuppressive) oral tablet 0.5 mg, 0.75 mg, 1 mg	T5	PA-BvD
exemestane	T4	
FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 120 MG	T5	PA-NC
FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 80 MG	T4	PA-NC
FOTIVDA	T5	PA-NC; QL (21 EA per 28 days)
FRUZAQLA ORAL CAPSULE 1 MG	T5	PA-NC; QL (84 EA per 28 days)
FRUZAQLA ORAL CAPSULE 5 MG	T5	PA-NC; QL (21 EA per 28 days)
GAVRETO	T5	PA-NC; QL (124 EA per 31 days)
gefitinib	T5	PA-NC; QL (31 EA per 31 days)
GENGRAF ORAL CAPSULE	T2	PA-BvD
GILOTRIF	T5	PA-NC; QL (31 EA per 31 days)
GOMEKLI ORAL CAPSULE 1 MG	T5	PA-NC; QL (126 EA per 28 days)
GOMEKLI ORAL CAPSULE 2 MG	T5	PA-NC; QL (84 EA per 28 days)
GOMEKLI ORAL TABLET FOR SUSPENSION	T5	PA-NC; QL (168 EA per 28 days)
HERNEXEOS	T5	PA-NC; QL (93 EA per 31 days)
hydroxyurea	T2	
HYRNUO	T5	PA-NC; QL (124 EA per 31 days)
IBRANCE ORAL CAPSULE 125 MG	T5	PA-NC; QL (21 EA per 28 days)
IBRANCE ORAL TABLET	T5	PA-NC; QL (21 EA per 28 days)
IBTROZI	T5	PA-NC; QL (93 EA per 31 days)
ICLUSIG	T5	PA-NC; QL (31 EA per 31 days)
IDHIFA	T5	PA-NC; QL (31 EA per 31 days)
imatinib oral tablet 100 mg	T5	PA-NC; QL (93 EA per 31 days)
imatinib oral tablet 400 mg	T5	PA-NC; QL (62 EA per 31 days)
IMBRUVICA ORAL CAPSULE 140 MG	T5	PA-NC; QL (124 EA per 31 days)
IMBRUVICA ORAL CAPSULE 70 MG	T5	PA-NC; QL (31 EA per 31 days)
IMBRUVICA ORAL SUSPENSION	T5	PA-NC; QL (216 ML per 25 days)
IMBRUVICA ORAL TABLET	T5	PA-NC; QL (31 EA per 31 days)
IMKELDI	T5	PA-NC; QL (280 ML per 28 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
INLURIYO	T5	PA-NC; QL (62 EA per 31 days)
INLYTA	T5	PA-NC; QL (124 EA per 31 days)
INQOVI	T5	PA-NC; QL (5 EA per 28 days)
INREBIC	T5	PA-NC; QL (124 EA per 31 days)
ITOVEBI ORAL TABLET 3 MG	T5	PA-NC; QL (62 EA per 31 days)
ITOVEBI ORAL TABLET 9 MG	T5	PA-NC; QL (31 EA per 31 days)
IWILFIN	T5	PA-NC; QL (248 EA per 31 days)
JAKAFI	T5	PA-NC; QL (62 EA per 31 days)
JAYPIRCA ORAL TABLET 100 MG	T5	PA-NC; QL (62 EA per 31 days)
JAYPIRCA ORAL TABLET 50 MG	T5	PA-NC; QL (31 EA per 31 days)
JIDEYTRO ORAL TABLET 100 MG	T5	PA-NC; QL (31 EA per 31 days)
JIDEYTRO ORAL TABLET 25 MG	T5	PA-NC; QL (93 EA per 31 days)
KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1)	T5	PA-NC; QL (21 EA per 28 days)
KISQALI ORAL TABLET 400 MG/DAY (200 MG X 2)	T5	PA-NC; QL (42 EA per 28 days)
KISQALI ORAL TABLET 600 MG/DAY (200 MG X 3)	T5	PA-NC; QL (63 EA per 28 days)
KOMZIFTI	T5	PA-NC; QL (90 EA per 30 days)
KOSELUGO ORAL CAPSULE 10 MG	T5	PA-NC; QL (279 EA per 31 days)
KOSELUGO ORAL CAPSULE 25 MG	T5	PA-NC; QL (124 EA per 31 days)
KOSELUGO ORAL CAPSULE, SPRINKLE 5 MG	T5	PA-NC; QL (600 EA per 30 days)
KOSELUGO ORAL CAPSULE, SPRINKLE 7.5 MG	T5	PA-NC; QL (360 EA per 30 days)
KRAZATI	T5	PA-NC; QL (186 EA per 31 days)
lapatinib	T5	PA-NC; QL (186 EA per 31 days)
LAZCLUZE ORAL TABLET 240 MG	T5	PA-NC; QL (30 EA per 30 days)
LAZCLUZE ORAL TABLET 80 MG	T5	PA-NC; QL (60 EA per 30 days)
lenalidomide	T5	PA-NC; QL (21 EA per 28 days)
LENVIMA	T5	PA-NC
letrozole	T2	
leucovorin calcium oral tablet 10 mg, 15 mg, 25 mg	T3	
leucovorin calcium oral tablet 5 mg	T2	
LEUKERAN	T5	
leuprolide subcutaneous kit	T4	QL (2 EA per 28 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
LIFYORLI ORAL CAPSULE 125 MG/DAY(100 MG X1-25MG X1), 125 MG/DAY(100 MG X1-25MG X3), 125 MG/DAY(100 MG X1-25MG X9)	T5	PA-NC; QL (18 EA per 28 days)
LIFYORLI ORAL CAPSULE 150 MG/DAY(100 MG X1-25MG X2), 150 MG/DAY(100 MG X1-25MG X3), 150 MG/DAY(100 MG X1-25MG X9)	T5	PA-NC; QL (27 EA per 28 days)
lomustine oral capsule 10 mg, 40 mg	T4	PA-NC
lomustine oral capsule 100 mg	T5	PA-NC
LONSURF	T5	PA-NC
LORBRENA ORAL TABLET 100 MG	T5	PA-NC; QL (31 EA per 31 days)
LORBRENA ORAL TABLET 25 MG	T5	PA-NC; QL (93 EA per 31 days)
LUMAKRAS ORAL TABLET 120 MG, 240 MG	T5	PA-NC; QL (62 EA per 31 days)
LUMAKRAS ORAL TABLET 320 MG	T5	PA-NC; QL (93 EA per 31 days)
LUPRON DEPOT (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG	T5	QL (1 EA per 90 days)
LUPRON DEPOT INTRAMUSCULAR SYRINGE KIT 3.75 MG	T5	QL (1 EA per 30 days)
LYNPARZA	T5	PA-NC; QL (124 EA per 31 days)
LYSODREN	T5	
LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3)	T5	PA-NC; QL (93 EA per 31 days)
LYTGOBI ORAL TABLET 16 MG/DAY (4 MG X 4)	T5	PA-NC; QL (124 EA per 31 days)
LYTGOBI ORAL TABLET 20 MG/DAY (4 MG X 5)	T5	PA-NC; QL (155 EA per 31 days)
MATULANE	T5	
megestrol oral suspension 400 mg/10 ml (40 mg/ml)	T2	PA
megestrol oral suspension 625 mg/5 ml (125 mg/ml)	T4	PA
megestrol oral tablet	T2	PA-NC
MEKINIST ORAL RECON SOLN	T5	PA-NC; QL (1260 ML per 31 days)
MEKINIST ORAL TABLET 0.5 MG	T5	PA-NC; QL (93 EA per 31 days)
MEKINIST ORAL TABLET 2 MG	T5	PA-NC; QL (31 EA per 31 days)
MEKTOVI	T5	PA-NC; QL (186 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
mercaptopurine oral suspension	T5	
mercaptopurine oral tablet	T2	
mesna oral	T4	
methotrexate sodium	T2	PA-BvD
methotrexate sodium (pf) injection solution	T2	PA-BvD
MODEYSO	T5	PA-NC; QL (20 EA per 28 days)
mycophenolate mofetil oral capsule	T2	PA-BvD
mycophenolate mofetil oral suspension for reconstitution	T5	PA-BvD
mycophenolate mofetil oral tablet	T2	PA-BvD
mycophenolate sodium	T4	PA-BvD
NEMLUVIO	T5	PA; QL (2 EA per 28 days)
NERLYNX	T5	PA-NC; QL (186 EA per 31 days)
nilotinib hcl	T5	PA-NC; QL (124 EA per 31 days)
nilutamide	T5	
NINLARO	T5	PA-NC; QL (3 EA per 28 days)
NUBEQA	T5	PA-NC; QL (124 EA per 31 days)
octreotide acetate injection solution	T4	PA
ODOMZO	T5	PA-NC; LA; QL (31 EA per 31 days)
OGSIVEO ORAL TABLET 100 MG, 150 MG	T5	PA-NC; QL (62 EA per 31 days)
OJEMDA ORAL SUSPENSION FOR RECONSTITUTION	T5	PA-NC; QL (96 ML per 28 days)
OJEMDA ORAL TABLET 400 MG/WEEK (100 MG X 4)	T5	PA-NC; QL (16 EA per 28 days)
OJEMDA ORAL TABLET 500 MG/WEEK (100 MG X 5)	T5	PA-NC; QL (20 EA per 28 days)
OJEMDA ORAL TABLET 600 MG/WEEK (100 MG X 6)	T5	PA-NC; QL (24 EA per 28 days)
OJJAARA	T5	PA-NC; QL (31 EA per 31 days)
ONUREG	T5	PA-NC; QL (14 EA per 28 days)
ORGOVYX	T5	PA-NC; QL (31 EA per 31 days)
ORSERDU ORAL TABLET 345 MG	T5	PA-NC; QL (31 EA per 31 days)
ORSERDU ORAL TABLET 86 MG	T5	PA-NC; QL (93 EA per 31 days)
pazopanib oral tablet 200 mg	T5	PA-NC; QL (124 EA per 31 days)
PEMAZYRE	T5	PA-NC; QL (14 EA per 21 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1)	T5	PA-NC; QL (28 EA per 28 days)
PIQRAY ORAL TABLET 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2)	T5	PA-NC; QL (56 EA per 28 days)
pomalidomide	T5	PA-NC; QL (21 EA per 28 days)
PROGRAF ORAL GRANULES IN PACKET	T4	PA-BvD
QINLOCK	T5	PA-NC; QL (93 EA per 31 days)
RETEVMO ORAL TABLET 120 MG, 160 MG, 80 MG	T5	PA-NC; QL (62 EA per 31 days)
RETEVMO ORAL TABLET 40 MG	T5	PA-NC; QL (93 EA per 31 days)
REVUFORJ ORAL TABLET 110 MG	T5	PA-NC; QL (124 EA per 31 days)
REVUFORJ ORAL TABLET 160 MG	T5	PA-NC; QL (62 EA per 31 days)
REVUFORJ ORAL TABLET 25 MG	T5	PA-NC; QL (248 EA per 31 days)
REZLIDHIA	T5	PA-NC; QL (62 EA per 31 days)
ROMVIMZA	T5	PA-NC; QL (8 EA per 28 days)
ROZLYTREK ORAL CAPSULE 100 MG	T5	PA-NC; QL (155 EA per 31 days)
ROZLYTREK ORAL CAPSULE 200 MG	T5	PA-NC; QL (93 EA per 31 days)
ROZLYTREK ORAL PELLETS IN PACKET	T5	PA-NC; QL (372 EA per 31 days)
RUBRACA	T5	PA-NC; QL (124 EA per 31 days)
RYDAPT	T5	PA-NC; QL (248 EA per 31 days)
SCEMBLIX ORAL TABLET 100 MG	T5	PA-NC; QL (124 EA per 31 days)
SCEMBLIX ORAL TABLET 20 MG	T5	PA-NC; QL (62 EA per 31 days)
SCEMBLIX ORAL TABLET 40 MG	T5	PA-NC; QL (248 EA per 31 days)
SIGNIFOR	T5	PA
sirolimus	T4	PA-BvD
SOLTAMOX	T4	
sorafenib	T5	PA-NC; QL (124 EA per 31 days)
STIVARGA	T5	PA-NC; QL (84 EA per 28 days)
sunitinib malate	T5	PA-NC; QL (31 EA per 31 days)
TABLOID	T4	
TABRECTA	T5	PA-NC; QL (124 EA per 31 days)
tacrolimus oral capsule 0.5 mg, 1 mg	T2	PA-BvD
tacrolimus oral capsule 5 mg	T4	PA-BvD
TAFINLAR ORAL CAPSULE	T5	PA-NC; QL (124 EA per 31 days)
TAFINLAR ORAL TABLET FOR SUSPENSION	T5	PA-NC; QL (930 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
TAGRISSO	T5	PA-NC; LA; QL (31 EA per 31 days)
TALZENNA	T5	PA-NC; QL (31 EA per 31 days)
tamoxifen	T1	
TEPMETKO	T5	PA-NC; QL (62 EA per 31 days)
THALOMID ORAL CAPSULE 100 MG	T5	PA-NC; QL (112 EA per 28 days)
THALOMID ORAL CAPSULE 50 MG	T5	PA-NC; QL (28 EA per 28 days)
TIBSOVO	T5	PA-NC; QL (62 EA per 31 days)
toremifene	T4	
TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 11.25 MG	T4	QL (1 EA per 84 days)
TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 22.5 MG	T4	QL (1 EA per 168 days)
TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 3.75 MG	T4	QL (1 EA per 28 days)
tretinoin (antineoplastic)	T5	
TRUQAP	T5	PA-NC; QL (64 EA per 28 days)
TUKYSA ORAL TABLET 150 MG	T5	PA-NC; QL (124 EA per 31 days)
TUKYSA ORAL TABLET 50 MG	T5	PA-NC; QL (248 EA per 31 days)
TURALIO	T5	PA-NC; QL (124 EA per 31 days)
VANFLYTA	T5	PA-NC; QL (62 EA per 31 days)
VENCLEXTA ORAL TABLET 10 MG	T3	PA-NC; QL (62 EA per 31 days)
VENCLEXTA ORAL TABLET 100 MG	T5	PA-NC; QL (186 EA per 31 days)
VENCLEXTA ORAL TABLET 50 MG	T5	PA-NC; QL (31 EA per 31 days)
VENCLEXTA STARTING PACK	T5	PA-NC; QL (84 EA per 365 days)
VERZENIO	T5	PA-NC; QL (62 EA per 31 days)
VIJOICE ORAL GRANULES IN PACKET	T5	PA-NC; QL (31 EA per 31 days)
VIJOICE ORAL TABLET 125 MG, 50 MG	T5	PA-NC; QL (28 EA per 28 days)
VIJOICE ORAL TABLET 250 MG/DAY (200 MG X1-50 MG X1)	T5	PA-NC; QL (56 EA per 28 days)
VITRAKVI ORAL CAPSULE 100 MG	T5	PA-NC; QL (62 EA per 31 days)
VITRAKVI ORAL CAPSULE 25 MG	T5	PA-NC; QL (186 EA per 31 days)
VITRAKVI ORAL SOLUTION	T5	PA-NC; QL (310 ML per 31 days)
VONJO	T5	PA-NC; QL (124 EA per 31 days)
VORANIGO ORAL TABLET 10 MG	T5	PA-NC; QL (62 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
VORANIGO ORAL TABLET 40 MG	T5	PA-NC; QL (31 EA per 31 days)
WELIREG	T5	PA-NC; QL (93 EA per 31 days)
WYOST	T3	PA-NC
XALKORI ORAL CAPSULE	T5	PA-NC; QL (124 EA per 31 days)
XALKORI ORAL PELLET 150 MG	T5	PA-NC; QL (186 EA per 31 days)
XALKORI ORAL PELLET 20 MG, 50 MG	T5	PA-NC; QL (124 EA per 31 days)
XATMEP	T4	PA-BvD
XERMELO	T5	PA; QL (93 EA per 31 days)
XGEVA	T5	PA-NC
XOSPATA	T5	PA-NC; QL (124 EA per 31 days)
XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40MG TWICE WEEK (40 MG X 2), 80 MG/WEEK (40 MG X 2)	T5	PA-NC; QL (8 EA per 28 days)
XPOVIO ORAL TABLET 40 MG/WEEK (10 MG X 4)	T5	PA-NC; QL (16 EA per 28 days)
XPOVIO ORAL TABLET 60 MG/WEEK (60 MG X 1), 80 MG/WEEK (80 MG X 1)	T5	PA-NC; QL (4 EA per 28 days)
XPOVIO ORAL TABLET 60MG TWICE WEEK (120 MG/WEEK)	T5	PA-NC; QL (24 EA per 28 days)
XPOVIO ORAL TABLET 80MG TWICE WEEK (160 MG/WEEK)	T5	PA-NC; QL (32 EA per 28 days)
XTANDI ORAL CAPSULE	T5	PA-NC; QL (124 EA per 31 days)
XTANDI ORAL TABLET 40 MG	T5	PA-NC; QL (124 EA per 31 days)
XTANDI ORAL TABLET 80 MG	T5	PA-NC; QL (62 EA per 31 days)
XTRENBO	T3	PA-NC
YONSA	T5	PA-NC; QL (124 EA per 31 days)
YULITHIRA	T3	PA-NC; QL (31 EA per 31 days)
ZEJULA	T5	PA-NC; QL (31 EA per 31 days)
ZELBORAF	T5	PA-NC; QL (248 EA per 31 days)
ZENBEXUS	T5	PA-NC; QL (21 EA per 28 days)
ZOLINZA	T5	PA-NC
ZYKADIA	T5	PA-NC; QL (93 EA per 31 days)
Medicamentos Autonómicos/Snc, Neurología/Psico		
ABILIFY MAINTENA	T5	QL (1 EA per 28 days)
acetaminophen-codeine oral solution 120-12 mg/5 ml	T2	PA; QL (5167 ML per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
acetaminophen-codeine oral tablet	T2	PA; QL (403 EA per 31 days)
AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 140 MG/ML	T3	PA; QL (1 ML per 28 days)
AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 70 MG/ML	T3	PA; QL (2 ML per 28 days)
alprazolam oral tablet 0.25 mg, 0.5 mg	T2	PA; QL (93 EA per 31 days)
alprazolam oral tablet 1 mg, 2 mg	T2	PA; QL (155 EA per 31 days)
amitriptyline	T2	PA-NC
amoxapine	T2	
aripiprazole oral solution	T4	PA-NC
aripiprazole oral tablet	T3	
aripiprazole oral tablet,disintegrating 10 mg	T4	PA-NC
aripiprazole oral tablet,disintegrating 15 mg	T5	PA-NC
armodafinil	T4	PA; QL (31 EA per 31 days)
asenapine maleate	T4	PA-NC; QL (62 EA per 31 days)
atomoxetine oral capsule 10 mg, 25 mg, 40 mg	T3	QL (62 EA per 31 days)
atomoxetine oral capsule 100 mg, 60 mg, 80 mg	T3	QL (31 EA per 31 days)
atomoxetine oral capsule 18 mg	T3	QL (124 EA per 31 days)
AUSTEDO ORAL TABLET 12 MG, 6 MG	T5	PA; QL (124 EA per 31 days)
AUSTEDO ORAL TABLET 9 MG	T5	PA; QL (155 EA per 31 days)
AUSTEDO XR	T5	PA; QL (31 EA per 31 days)
AUSTEDO XR TITRATION KT(WK1-4) ORAL TABLET, EXT REL 24HR DOSE PACK 12-18-24-30 MG	T5	PA; QL (56 EA per 365 days)
AUVELITY ORAL TABLET, IR AND ER, BIPHASIC	T5	PA-NC; QL (62 EA per 31 days)
baclofen oral tablet 10 mg, 20 mg	T2	
BAFIERTAM	T5	PA; QL (124 EA per 31 days)
benztropine oral	T2	PA
brivaracetam oral solution	T5	QL (620 ML per 31 days)
brivaracetam oral tablet	T5	QL (62 EA per 31 days)
bromocriptine	T4	
buprenorphine	T4	PA; QL (4 EA per 28 days)
buprenorphine hcl sublingual	T3	
buprenorphine-naloxone sublingual film	T2	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
buprenorphine-naloxone sublingual tablet	T4	
bupropion hcl oral tablet	T2	
bupropion hcl oral tablet extended release 24 hr 150 mg	T2	QL (93 EA per 31 days)
bupropion hcl oral tablet extended release 24 hr 300 mg	T2	QL (31 EA per 31 days)
bupropion hcl oral tablet sustained-release 12 hr	T2	QL (62 EA per 31 days)
buspirone oral tablet 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg	T2	
butorphanol nasal	T4	QL (5 ML per 28 days)
CAPLYTA	T5	PA-NC; QL (31 EA per 31 days)
carbamazepine oral capsule, er multiphase 12 hr	T3	
carbamazepine oral suspension 100 mg/5 ml	T2	
carbamazepine oral tablet	T2	
carbamazepine oral tablet extended release 12 hr	T3	
carbamazepine oral tablet,chewable 100 mg	T2	
carbidopa-levodopa oral tablet	T2	
carbidopa-levodopa oral tablet extended release	T2	
carbidopa-levodopa oral tablet,disintegrating	T2	
carbidopa-levodopa-entacapone	T4	
celecoxib oral capsule 100 mg, 200 mg, 50 mg	T2	QL (62 EA per 31 days)
celecoxib oral capsule 400 mg	T3	QL (62 EA per 31 days)
chlorpromazine oral	T4	
citalopram oral solution	T3	
citalopram oral tablet	T1	
clobazam oral suspension	T4	PA-NC; QL (496 ML per 31 days)
clobazam oral tablet	T3	PA-NC; QL (62 EA per 31 days)
clomipramine	T4	PA-NC
clonazepam oral tablet 0.5 mg	T2	PA-NC; QL (93 EA per 31 days)
clonazepam oral tablet 1 mg	T2	PA-NC; QL (124 EA per 31 days)
clonazepam oral tablet 2 mg	T2	PA-NC; QL (310 EA per 31 days)
clonazepam oral tablet,disintegrating 0.125 mg, 0.25 mg, 0.5 mg	T2	PA-NC; QL (93 EA per 31 days)
clonazepam oral tablet,disintegrating 1 mg	T2	PA-NC; QL (124 EA per 31 days)
clonazepam oral tablet,disintegrating 2 mg	T2	PA-NC; QL (310 EA per 31 days)
clorazepate dipotassium oral tablet 15 mg	T3	PA-NC; QL (186 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
clorazepate dipotassium oral tablet 3.75 mg, 7.5 mg	T3	PA-NC; QL (93 EA per 31 days)
clozapine oral tablet 100 mg	T3	QL (279 EA per 31 days)
clozapine oral tablet 200 mg	T3	QL (124 EA per 31 days)
clozapine oral tablet 25 mg	T2	QL (279 EA per 31 days)
clozapine oral tablet 50 mg	T2	QL (93 EA per 31 days)
clozapine oral tablet,disintegrating 100 mg, 25 mg	T4	QL (279 EA per 31 days)
clozapine oral tablet,disintegrating 12.5 mg	T4	QL (93 EA per 31 days)
clozapine oral tablet,disintegrating 150 mg	T4	QL (186 EA per 31 days)
clozapine oral tablet,disintegrating 200 mg	T4	QL (124 EA per 31 days)
COBENFY	T5	PA-NC; QL (62 EA per 31 days)
COBENFY STARTER PACK	T5	PA-NC; QL (112 EA per 365 days)
COPAXONE SUBCUTANEOUS SYRINGE 20 MG/ML	T5	PA; QL (31 ML per 31 days)
COPAXONE SUBCUTANEOUS SYRINGE 40 MG/ML	T5	PA; QL (12 ML per 28 days)
cyclobenzaprine oral tablet 10 mg	T2	QL (93 EA per 31 days)
cyclobenzaprine oral tablet 5 mg	T2	QL (155 EA per 31 days)
dalfampridine	T5	PA; QL (62 EA per 31 days)
dantrolene oral	T4	
desipramine oral tablet 10 mg, 25 mg	T3	
desipramine oral tablet 100 mg, 150 mg, 50 mg, 75 mg	T4	
desvenlafaxine succinate	T3	QL (31 EA per 31 days)
dexmethylphenidate oral capsule,er biphasic 50-50	T4	QL (31 EA per 31 days)
dexmethylphenidate oral tablet 10 mg	T2	QL (62 EA per 31 days)
dexmethylphenidate oral tablet 2.5 mg, 5 mg	T2	QL (93 EA per 31 days)
dextroamphetamine-amphetamine oral capsule,extended release 24hr	T3	QL (31 EA per 31 days)
dextroamphetamine-amphetamine oral tablet 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg	T1	QL (62 EA per 31 days)
dextroamphetamine-amphetamine oral tablet 20 mg	T1	QL (93 EA per 31 days)
dextromethorphan-quinidine	T5	PA; QL (62 EA per 31 days)
DIACOMIT ORAL CAPSULE 250 MG	T5	PA-NC; QL (341 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
DIACOMIT ORAL CAPSULE 500 MG	T5	PA-NC; QL (186 EA per 31 days)
DIACOMIT ORAL POWDER IN PACKET 250 MG	T5	PA-NC; QL (341 EA per 31 days)
DIACOMIT ORAL POWDER IN PACKET 500 MG	T5	PA-NC; QL (186 EA per 31 days)
DIAZEPAM INTENSOL	T2	PA-NC; QL (248 ML per 31 days)
diazepam oral solution 5 mg/5 ml (1 mg/ml)	T2	PA-NC; QL (1500 ML per 31 days)
diazepam oral tablet	T2	PA-NC; QL (124 EA per 31 days)
diazepam rectal	T4	
diclofenac potassium oral tablet 50 mg	T2	
diclofenac sodium oral	T2	
diclofenac sodium topical drops	T2	QL (450 ML per 28 days)
diflunisal	T2	
dihydroergotamine nasal	T5	PA; QL (8 ML per 28 days)
DILANTIN	T3	
dimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg	T4	PA; QL (62 EA per 31 days)
dimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg (14)- 240 mg (46)	T5	PA; QL (120 EA per 365 days)
dimethyl fumarate oral capsule,delayed release(dr/ec) 240 mg	T5	PA; QL (62 EA per 31 days)
divalproex oral capsule, delayed rel sprinkle	T2	
divalproex oral tablet extended release 24 hr 250 mg	T2	
divalproex oral tablet extended release 24 hr 500 mg	T3	
divalproex oral tablet,delayed release (dr/ec)	T2	
donepezil oral tablet 10 mg, 5 mg	T1	
donepezil oral tablet 23 mg	T3	QL (31 EA per 31 days)
donepezil oral tablet,disintegrating	T2	
doxepin oral capsule	T2	PA-NC
doxepin oral concentrate	T2	PA-NC
doxepin oral tablet	T3	PA
DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 20 MG	T3	PA-NC; QL (93 EA per 31 days)
DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 30 MG, 60 MG	T3	PA-NC; QL (62 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 40 MG	T3	PA-NC; QL (31 EA per 31 days)
duloxetine oral capsule,delayed release(dr/ec) 20 mg, 60 mg	T2	QL (62 EA per 31 days)
duloxetine oral capsule,delayed release(dr/ec) 30 mg	T2	QL (31 EA per 31 days)
EMGALITY PEN	T3	PA; QL (1 ML per 28 days)
EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML	T3	PA; QL (1 ML per 28 days)
EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 300 MG/3 ML (100 MG/ML X 3)	T5	PA; QL (3 ML per 28 days)
EMSAM	T5	QL (30 EA per 30 days)
entacapone	T3	
EPIDIOLEX	T5	PA-NC
ergotamine-caffeine	T3	PA
escitalopram oxalate oral capsule	T4	PA-NC; QL (31 EA per 31 days)
escitalopram oxalate oral solution	T4	QL (620 ML per 31 days)
escitalopram oxalate oral tablet 10 mg	T2	QL (45 EA per 30 days)
escitalopram oxalate oral tablet 20 mg, 5 mg	T2	QL (30 EA per 30 days)
eslicarbazepine oral tablet 200 mg	T4	QL (186 EA per 31 days)
eslicarbazepine oral tablet 400 mg	T5	QL (93 EA per 31 days)
eslicarbazepine oral tablet 600 mg, 800 mg	T5	QL (62 EA per 31 days)
ethosuximide oral capsule	T3	
ethosuximide oral solution	T4	
etodolac oral capsule	T3	
etodolac oral tablet	T2	
etodolac oral tablet extended release 24 hr 400 mg, 500 mg	T3	
etodolac oral tablet extended release 24 hr 600 mg	T4	
EXXUA ORAL TABLET EXTENDED RELEASE 24 HR	T4	PA-NC; QL (31 EA per 31 days)
EXXUA ORAL TABLET, EXT REL 24HR DOSE PACK	T4	PA-NC; QL (64 EA per 365 days)
FANAPT ORAL TABLET 1 MG	T4	PA-NC; QL (62 EA per 31 days)
FANAPT ORAL TABLET 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG	T5	PA-NC; QL (62 EA per 31 days)
FANAPT TITRATION PACK A	T4	PA-NC; QL (16 EA per 365 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
FANAPT TITRATION PACK B	T4	PA-NC; QL (24 EA per 365 days)
FANAPT TITRATION PACK C	T4	PA-NC; QL (16 EA per 365 days)
felbamate	T4	
fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 75 mcg/hr	T4	PA; QL (10 EA per 30 days)
fentanyl transdermal patch 72 hour 25 mcg/hr, 50 mcg/hr	T2	PA; QL (10 EA per 30 days)
FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK 20 MG (2)- 40 MG (26)	T4	PA-NC; QL (56 EA per 365 days)
FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 40 MG, 80 MG	T4	PA-NC; QL (31 EA per 31 days)
FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 20 MG	T4	PA-NC; QL (93 EA per 31 days)
fingolimod	T5	PA; QL (31 EA per 31 days)
FINTEPLA	T5	PA-NC; QL (360 ML per 30 days)
fluoxetine (pmdd)	T2	
fluoxetine oral capsule	T1	
fluoxetine oral solution	T3	
fluoxetine oral tablet 10 mg, 20 mg	T2	
fluphenazine decanoate	T3	
fluphenazine hcl injection	T4	
fluphenazine hcl oral concentrate	T4	
fluphenazine hcl oral elixir	T4	
fluphenazine hcl oral tablet 1 mg, 2.5 mg, 5 mg	T2	
fluphenazine hcl oral tablet 10 mg	T4	
flurbiprofen oral tablet 100 mg	T2	
fluvoxamine oral tablet	T2	
gabapentin oral capsule 100 mg, 400 mg	T2	QL (270 EA per 30 days)
gabapentin oral capsule 300 mg	T2	QL (360 EA per 30 days)
gabapentin oral solution 250 mg/5 ml	T4	QL (2160 ML per 30 days)
gabapentin oral tablet 600 mg	T2	QL (180 EA per 30 days)
gabapentin oral tablet 800 mg	T2	QL (120 EA per 30 days)
galantamine oral capsule,ext rel. pellets 24 hr	T3	
galantamine oral solution	T4	
galantamine oral tablet	T3	
glatiramer subcutaneous syringe 20 mg/ml	T5	PA; QL (31 ML per 31 days)
glatiramer subcutaneous syringe 40 mg/ml	T5	PA; QL (12 ML per 28 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
GLATOPA SUBCUTANEOUS SYRINGE 20 MG/ML	T5	PA; QL (31 ML per 31 days)
GLATOPA SUBCUTANEOUS SYRINGE 40 MG/ML	T5	PA; QL (12 ML per 28 days)
guanfacine oral tablet extended release 24 hr	T2	PA
haloperidol	T2	
haloperidol decanoate	T2	
haloperidol lactate injection	T1	
haloperidol lactate oral	T2	
hydrocodone-acetaminophen oral tablet 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg	T2	PA; QL (372 EA per 31 days)
hydromorphone oral liquid	T4	PA; QL (1240 ML per 31 days)
hydromorphone oral tablet 2 mg, 4 mg	T2	PA; QL (186 EA per 31 days)
hydromorphone oral tablet 8 mg	T3	PA; QL (155 EA per 31 days)
IBU ORAL TABLET 600 MG, 800 MG	T1	
ibuprofen oral tablet 400 mg, 600 mg, 800 mg	T1	
imipramine hcl	T2	PA-NC
indomethacin oral capsule	T2	
indomethacin oral capsule, extended release	T2	
INGREZZA INITIATION PK(TARDIV)	T5	PA; QL (56 EA per 365 days)
INGREZZA ORAL CAPSULE 40 MG	T5	PA; QL (62 EA per 31 days)
INGREZZA ORAL CAPSULE 60 MG, 80 MG	T5	PA; QL (31 EA per 31 days)
INGREZZA SPRINKLE	T5	PA; QL (31 EA per 31 days)
INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,092 MG/3.5 ML	T5	QL (3.5 ML per 180 days)
INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,560 MG/5 ML	T5	QL (5 ML per 180 days)
INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 117 MG/0.75 ML	T5	QL (0.75 ML per 28 days)
INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 156 MG/ML	T5	QL (1 ML per 28 days)
INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 234 MG/1.5 ML	T5	QL (1.5 ML per 28 days)
INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 39 MG/0.25 ML	T4	QL (0.25 ML per 28 days)
INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 78 MG/0.5 ML	T5	QL (0.5 ML per 28 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
INVEGA TRINZA INTRAMUSCULAR SYRINGE 273 MG/0.88 ML	T5	QL (0.88 ML per 84 days)
INVEGA TRINZA INTRAMUSCULAR SYRINGE 410 MG/1.32 ML	T5	QL (1.32 ML per 84 days)
INVEGA TRINZA INTRAMUSCULAR SYRINGE 546 MG/1.75 ML	T5	QL (1.75 ML per 84 days)
INVEGA TRINZA INTRAMUSCULAR SYRINGE 819 MG/2.63 ML	T5	QL (2.63 ML per 84 days)
KESIMPTA PEN	T5	PA; QL (0.4 ML per 28 days)
KLOXXADO	T3	
lacosamide oral	T4	
lamotrigine oral tablet	T2	
lamotrigine oral tablet extended release 24hr	T4	
lamotrigine oral tablet, chewable dispersible	T2	
levetiracetam oral solution 100 mg/ml	T2	
levetiracetam oral tablet	T2	
levetiracetam oral tablet extended release 24 hr	T2	
lithium carbonate oral capsule	T1	
lithium carbonate oral tablet	T1	
lithium carbonate oral tablet extended release	T2	
lithium citrate oral solution	T2	
lofexidine	T5	
LORAZEPAM INTENSOL	T2	PA; QL (155 ML per 31 days)
lorazepam oral tablet 0.5 mg	T2	PA; QL (124 EA per 31 days)
lorazepam oral tablet 1 mg	T2	PA; QL (186 EA per 31 days)
lorazepam oral tablet 2 mg	T2	PA; QL (155 EA per 31 days)
loxapine succinate	T2	
lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg	T4	PA-NC; QL (31 EA per 31 days)
lurasidone oral tablet 80 mg	T4	PA-NC; QL (62 EA per 31 days)
LYBALVI	T5	PA-NC; QL (31 EA per 31 days)
MARPLAN	T4	
meloxicam oral tablet	T1	
memantine oral capsule,sprinkle,er 24hr	T4	
memantine oral solution	T4	
memantine oral tablet	T2	
memantine-donepezil	T4	PA

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
methadone oral solution 10 mg/5 ml	T2	PA; QL (620 ML per 31 days)
methadone oral solution 5 mg/5 ml	T2	PA; QL (1240 ML per 31 days)
methadone oral tablet 10 mg	T2	PA; QL (124 EA per 31 days)
methadone oral tablet 5 mg	T2	PA; QL (248 EA per 31 days)
methsuximide	T4	
methylphenidate hcl oral tablet	T2	QL (93 EA per 31 days)
mirtazapine oral tablet 15 mg, 30 mg, 45 mg	T2	
mirtazapine oral tablet 7.5 mg	T3	
mirtazapine oral tablet,disintegrating	T3	
modafinil	T3	PA; QL (31 EA per 31 days)
molindone	T4	
morphine concentrate oral solution	T2	PA; QL (310 ML per 31 days)
morphine oral solution 10 mg/5 ml (2 mg/ml)	T2	PA; QL (2800 ML per 31 days)
morphine oral solution 20 mg/5 ml (4 mg/ml)	T2	PA; QL (1400 ML per 31 days)
morphine oral tablet	T2	PA; QL (186 EA per 31 days)
morphine oral tablet extended release 100 mg	T3	PA; QL (62 EA per 31 days)
morphine oral tablet extended release 15 mg, 30 mg, 60 mg	T3	PA; QL (100 EA per 31 days)
morphine oral tablet extended release 200 mg	T3	PA; QL (31 EA per 31 days)
nabumetone	T2	
naloxone injection solution	T2	
naloxone injection syringe	T2	
naltrexone	T2	
naproxen oral tablet	T1	
naproxen oral tablet,delayed release (dr/ec) 375 mg	T2	
naproxen oral tablet,delayed release (dr/ec) 500 mg	T4	
naproxen sodium oral tablet 550 mg	T2	
naratriptan oral tablet 1 mg	T3	QL (20 EA per 28 days)
naratriptan oral tablet 2.5 mg	T3	QL (9 EA per 28 days)
NAYZILAM	T4	PA-NC; QL (10 EA per 30 days)
nefazodone	T4	
nortriptyline	T2	
NUEDEXTA	T5	PA; QL (62 EA per 31 days)
NUPLAZID	T5	PA-NC; QL (31 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
NURTEC ODT	T5	PA; QL (18 EA per 28 days)
olanzapine intramuscular	T4	
olanzapine oral tablet	T2	QL (31 EA per 31 days)
olanzapine oral tablet,disintegrating	T4	QL (31 EA per 31 days)
OPIPZA	T5	PA-NC
oxcarbazepine oral suspension	T4	
oxcarbazepine oral tablet	T2	
oxycodone oral capsule	T3	PA; QL (186 EA per 31 days)
oxycodone oral concentrate	T4	PA; QL (180 ML per 31 days)
oxycodone oral tablet 10 mg, 15 mg, 20 mg, 5 mg	T3	PA; QL (186 EA per 31 days)
oxycodone oral tablet 30 mg	T3	PA; QL (138 EA per 31 days)
oxycodone-acetaminophen oral tablet 10-325 mg, 2.5-325 mg	T3	PA; QL (372 EA per 31 days)
oxycodone-acetaminophen oral tablet 5-325 mg, 7.5-325 mg	T2	PA; QL (372 EA per 31 days)
paliperidone oral tablet extended release 24hr 1.5 mg, 3 mg, 9 mg	T4	QL (31 EA per 31 days)
paliperidone oral tablet extended release 24hr 6 mg	T4	QL (62 EA per 31 days)
paroxetine hcl oral suspension	T4	PA-NC
paroxetine hcl oral tablet	T1	PA-NC
perampanel oral suspension	T5	QL (744 ML per 31 days)
perampanel oral tablet 10 mg, 12 mg, 4 mg, 6 mg, 8 mg	T5	QL (31 EA per 31 days)
perampanel oral tablet 2 mg	T4	QL (31 EA per 31 days)
perphenazine	T4	
phenelzine	T2	
phenobarbital	T2	PA-NC
PHENYTEK	T3	
phenytoin oral suspension 125 mg/5 ml	T2	
phenytoin oral tablet,chewable	T2	
phenytoin sodium extended oral capsule 100 mg	T2	
pimozide	T4	
piroxicam	T2	
pramipexole oral tablet	T2	
pregabalin oral capsule 100 mg, 150 mg, 200 mg, 25 mg, 50 mg, 75 mg	T2	PA-NC; QL (93 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
pregabalin oral capsule 225 mg, 300 mg	T2	PA-NC; QL (62 EA per 31 days)
pregabalin oral solution	T2	PA-NC; QL (930 ML per 31 days)
primidone oral tablet 125 mg	T3	
primidone oral tablet 250 mg, 50 mg	T2	
protriptyline	T4	
pyridostigmine bromide oral tablet 60 mg	T3	
pyridostigmine bromide oral tablet extended release 180 mg	T4	
quetiapine oral tablet 100 mg, 200 mg, 300 mg, 400 mg, 50 mg	T2	QL (62 EA per 31 days)
quetiapine oral tablet 150 mg	T3	QL (62 EA per 31 days)
quetiapine oral tablet 25 mg	T1	QL (62 EA per 31 days)
quetiapine oral tablet extended release 24 hr	T3	QL (62 EA per 31 days)
QULIPTA	T3	PA; QL (31 EA per 31 days)
RALDESY	T5	
ramelteon	T4	QL (31 EA per 31 days)
rasagiline	T4	
RELGAABI ORAL CAPSULE 300 MG	T2	QL (360 EA per 30 days)
RELGAABI ORAL CAPSULE 400 MG	T2	QL (270 EA per 30 days)
REXULTI ORAL TABLET	T5	PA-NC; QL (31 EA per 31 days)
REZENOPY	T3	
risperidone microspheres intramuscular suspension,extended rel recon 12.5 mg/2 ml	T4	QL (2 EA per 28 days)
risperidone microspheres intramuscular suspension,extended rel recon 25 mg/2 ml, 37.5 mg/2 ml, 50 mg/2 ml	T5	QL (2 EA per 28 days)
risperidone oral solution	T2	QL (496 ML per 31 days)
risperidone oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg	T2	QL (31 EA per 31 days)
risperidone oral tablet 3 mg	T2	QL (93 EA per 31 days)
risperidone oral tablet 4 mg	T2	QL (124 EA per 31 days)
risperidone oral tablet,disintegrating 0.25 mg, 0.5 mg, 1 mg, 2 mg	T4	QL (31 EA per 31 days)
risperidone oral tablet,disintegrating 3 mg	T4	QL (93 EA per 31 days)
risperidone oral tablet,disintegrating 4 mg	T4	QL (124 EA per 31 days)
rivastigmine	T4	QL (30 EA per 30 days)
rivastigmine tartrate	T3	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
rizatriptan oral tablet 10 mg	T2	QL (12 EA per 28 days)
rizatriptan oral tablet 5 mg	T2	QL (24 EA per 28 days)
rizatriptan oral tablet,disintegrating 10 mg	T2	QL (12 EA per 28 days)
rizatriptan oral tablet,disintegrating 5 mg	T2	QL (24 EA per 28 days)
ropinirole oral tablet	T2	
ROWEEPRA	T2	
rufinamide oral suspension	T5	PA-NC
rufinamide oral tablet 200 mg	T4	PA-NC
rufinamide oral tablet 400 mg	T5	PA-NC
RYTARY	T3	ST
SECUADO	T5	PA-NC; QL (31 EA per 31 days)
selegiline hcl	T2	
sertraline oral concentrate	T2	
sertraline oral tablet	T1	
SKYCLARYS	T5	PA; QL (93 EA per 31 days)
sodium oxybate	T5	PA; QL (540 ML per 30 days)
SPRITAM ORAL TABLET FOR SUSPENSION 250 MG, 500 MG	T4	
SUBVENITE ORAL SUSPENSION	T5	
SUBVENITE ORAL TABLET	T2	
sulindac	T2	
sumatriptan nasal spray,non-aerosol 20 mg/actuation	T4	QL (8 EA per 28 days)
sumatriptan nasal spray,non-aerosol 5 mg/actuation	T4	QL (32 EA per 28 days)
sumatriptan succinate oral tablet 100 mg	T2	QL (9 EA per 28 days)
sumatriptan succinate oral tablet 25 mg	T2	QL (36 EA per 28 days)
sumatriptan succinate oral tablet 50 mg	T2	QL (18 EA per 28 days)
sumatriptan succinate subcutaneous pen injector 6 mg/0.5 ml	T4	QL (4 ML per 28 days)
sumatriptan succinate subcutaneous solution	T4	QL (4 ML per 28 days)
SYMPAZAN ORAL FILM 10 MG, 20 MG	T5	PA-NC; QL (62 EA per 31 days)
SYMPAZAN ORAL FILM 5 MG	T4	PA-NC; QL (62 EA per 31 days)
TASCENSO ODT	T5	PA; QL (31 EA per 31 days)
tasimelteon	T5	PA; QL (31 EA per 31 days)
teriflunomide	T5	PA; QL (31 EA per 31 days)
tetrabenazine oral tablet 12.5 mg	T5	PA; QL (93 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
tetrabenazine oral tablet 25 mg	T5	PA; QL (124 EA per 31 days)
thioridazine	T2	
thiothixene oral capsule 1 mg, 2 mg	T2	
thiothixene oral capsule 10 mg, 5 mg	T3	
tiagabine	T4	
tizanidine oral tablet	T2	
topiramate oral capsule, sprinkle 15 mg, 25 mg	T2	
topiramate oral solution	T4	PA-NC; QL (496 ML per 31 days)
topiramate oral tablet	T2	
tramadol oral tablet 50 mg	T2	PA; QL (240 EA per 30 days)
tramadol-acetaminophen	T2	PA; QL (372 EA per 31 days)
tranylcypromine	T4	
trazodone oral tablet 100 mg, 150 mg, 50 mg	T1	
trifluoperazine	T2	
trimipramine oral capsule 100 mg	T4	PA-NC
trimipramine oral capsule 25 mg, 50 mg	T3	PA-NC
TRINTELLIX	T4	PA-NC
UBRELVY ORAL TABLET 100 MG	T5	PA; QL (17 EA per 28 days)
UBRELVY ORAL TABLET 50 MG	T5	PA; QL (34 EA per 28 days)
valproic acid	T2	
valproic acid (as sodium salt) oral solution 250 mg/5 ml	T2	
VALTOCO	T5	PA-NC; QL (10 EA per 30 days)
venlafaxine oral capsule,extended release 24hr 150 mg, 37.5 mg	T2	QL (31 EA per 31 days)
venlafaxine oral capsule,extended release 24hr 75 mg	T2	QL (93 EA per 31 days)
venlafaxine oral tablet	T2	
VERSACLOZ	T5	QL (558 ML per 31 days)
vigabatrin	T5	PA-NC
VIGADRONE	T5	PA-NC
vilazodone	T3	PA-NC; QL (31 EA per 31 days)
VIVITROL	T5	
VRAYLAR	T5	PA-NC; QL (31 EA per 31 days)
VUMERITY	T5	PA; QL (124 EA per 31 days)
XCOPRI	T5	PA-NC

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
XCOPRI MAINTENANCE PACK	T5	PA-NC
XCOPRI TITRATION PACK ORAL TABLETS,DOSE PACK 12.5 MG (14)- 25 MG (14)	T4	PA-NC
XCOPRI TITRATION PACK ORAL TABLETS,DOSE PACK 150 MG (14)- 200 MG (14), 50 MG (14)- 100 MG (14)	T5	PA-NC
zaleplon oral capsule 10 mg	T4	PA; QL (62 EA per 31 days)
zaleplon oral capsule 5 mg	T4	PA; QL (93 EA per 31 days)
ZAVZPRET	T5	PA; QL (8 EA per 30 days)
ZEPOSIA	T5	PA; QL (31 EA per 31 days)
ZEPOSIA STARTER KIT (28-DAY)	T5	PA; QL (56 EA per 365 days)
ZEPOSIA STARTER PACK (7-DAY)	T5	PA; QL (14 EA per 365 days)
ZILBRYSQ SUBCUTANEOUS SYRINGE 16.6 MG/0.416 ML	T5	PA; QL (11.648 ML per 28 days)
ZILBRYSQ SUBCUTANEOUS SYRINGE 23 MG/0.574 ML	T5	PA; QL (16.072 ML per 28 days)
ZILBRYSQ SUBCUTANEOUS SYRINGE 32.4 MG/0.81 ML	T5	PA; QL (22.68 ML per 28 days)
ziprasidone hcl	T3	QL (62 EA per 31 days)
ziprasidone mesylate	T4	
zolpidem oral tablet	T2	PA; QL (31 EA per 31 days)
ZONISADE	T5	PA-NC; QL (930 ML per 31 days)
zonisamide	T2	
ZTALMY	T5	PA-NC; QL (1100 ML per 30 days)
ZUBSOLV	T3	
ZURZUVAE ORAL CAPSULE 20 MG, 25 MG	T5	PA-NC; QL (28 EA per 180 days)
ZURZUVAE ORAL CAPSULE 30 MG	T5	PA-NC; QL (14 EA per 180 days)
Medicamentos Para Oídos, Nariz Y Garganta		
acetic acid otic (ear)	T2	
azelastine nasal spray,non-aerosol 137 mcg (0.1 %)	T2	QL (30 ML per 25 days)
chlorhexidine gluconate mucous membrane	T1	
ciprofloxacin-dexamethasone	T4	
fluocinolone acetonide oil	T4	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
ipratropium bromide nasal spray,non-aerosol 21 mcg (0.03 %)	T2	QL (30 ML per 28 days)
ipratropium bromide nasal spray,non-aerosol 42 mcg (0.06 %)	T2	QL (15 ML per 28 days)
KOURZEQ	T2	
neomycin-polymyxin-hc otic (ear)	T3	
ofloxacin otic (ear)	T2	
olopatadine nasal	T3	QL (30.5 GM per 30 days)
PERIOGARD	T1	
triamcinolone acetonide dental	T2	
Musculoesquelético / Reumatología		
ACTEMRA ACTPEN	T5	PA; QL (3.6 ML per 28 days)
ACTEMRA SUBCUTANEOUS	T5	PA; QL (3.6 ML per 28 days)
alendronate oral tablet 10 mg, 35 mg, 70 mg	T1	
allopurinol oral tablet 100 mg, 300 mg	T1	
BENLYSTA SUBCUTANEOUS	T5	PA; QL (4 ML per 28 days)
colchicine oral tablet	T2	QL (62 EA per 31 days)
ENBREL MINI	T5	PA; QL (8 ML per 28 days)
ENBREL SUBCUTANEOUS SOLUTION	T5	PA; QL (4 ML per 28 days)
ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5)	T5	PA; QL (4 ML per 28 days)
ENBREL SUBCUTANEOUS SYRINGE 50 MG/ML (1 ML)	T5	PA; QL (8 ML per 28 days)
ENBREL SURECLICK	T5	PA; QL (8 ML per 28 days)
ENOBY	T3	PA; QL (1 ML per 180 days)
HADLIMA	T5	PA; QL (1.6 ML per 28 days)
HADLIMA PUSHTOUCH	T5	PA; QL (1.6 ML per 28 days)
HADLIMA(CF)	T5	PA; QL (0.8 ML per 28 days)
HADLIMA(CF) PUSHTOUCH	T5	PA; QL (0.8 ML per 28 days)
ibandronate oral	T2	
JUBBONTI	T3	PA; QL (1 ML per 180 days)
KINERET	T5	PA; QL (18.76 ML per 28 days)
leflunomide	T3	
ORENCIA CLICKJECT	T5	PA; QL (4 ML per 28 days)
ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML	T5	PA; QL (4 ML per 28 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
ORENCIA SUBCUTANEOUS SYRINGE 50 MG/0.4 ML	T5	PA; QL (1.6 ML per 28 days)
ORENCIA SUBCUTANEOUS SYRINGE 87.5 MG/0.7 ML	T5	PA; QL (2.8 ML per 28 days)
OTEZLA	T5	PA; QL (62 EA per 31 days)
OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)- 20 MG (51), 10 MG (4)-20 MG (4)-30 MG (47)	T5	PA; QL (110 EA per 365 days)
OTEZLA XR	T5	PA; QL (30 EA per 30 days)
OTEZLA XR INITIATION	T5	PA; QL (82 EA per 365 days)
penicillamine oral tablet	T5	
probenecid	T2	
probenecid-colchicine	T2	
PROLIA	T4	PA; QL (1 ML per 180 days)
raloxifene	T3	
RINVOQ LQ	T5	PA; QL (372 ML per 31 days)
RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG	T5	PA; QL (31 EA per 31 days)
RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 45 MG	T5	PA; QL (168 EA per 365 days)
risedronate oral tablet 150 mg, 35 mg, 35 mg (12 pack), 35 mg (4 pack), 5 mg	T4	
risedronate oral tablet,delayed release (dr/ec)	T4	
SIMLANDI(CF) AUTOINJECTOR	T5	PA; QL (2 EA per 28 days)
SIMLANDI(CF) SUBCUTANEOUS SYRINGE KIT 20 MG/0.2 ML, 40 MG/0.4 ML	T5	PA; QL (2 EA per 28 days)
teriparatide subcutaneous pen injector 20 mcg/dose (560mcg/2.24ml)	T5	PA; QL (2.48 ML per 28 days)
tofacitinib oral solution	T5	PA; QL (310 ML per 31 days)
tofacitinib oral tablet	T4	PA; QL (62 EA per 31 days)
tofacitinib oral tablet extended release 24 hr 11 mg	T4	PA; QL (31 EA per 31 days)
tofacitinib oral tablet extended release 24 hr 22 mg	T5	PA; QL (31 EA per 31 days)
TYMLOS	T5	PA; QL (1.56 ML per 30 days)
YUFLYMA(CF) AI CROHN'S-UC-HS	T5	PA; QL (6 EA per 365 days)
YUFLYMA(CF) AUTOINJECTOR	T5	PA; QL (2 EA per 28 days)
YUFLYMA(CF) SUBCUTANEOUS SYRINGE KIT 40 MG/0.4 ML	T5	PA; QL (2 EA per 28 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
Obstetricia / Ginecología		
ABIGALE	T2	
ALTAVERA (28)	T2	
ALYACEN 1/35 (28)	T2	
APRI	T2	
ARANELLE (28)	T2	
AVIANE	T2	
AZURETTE (28)	T2	
BALZIVA (28)	T2	
BLISOVI FE 1.5/30 (28)	T2	
BRIELLYN	T2	
CAMILA	T2	
clindamycin phosphate vaginal	T2	
CRYSELLE (28)	T2	
CYRED EQ	T2	
DEPO-SUBQ PROVERA 104	T3	
drospirenone-ethinyl estradiol	T2	
ENSKYCE	T2	
ERRIN	T2	
ESTARYLLA	T2	
estradiol oral	T2	
estradiol transdermal patch weekly 0.025 mg/24 hr, 0.06 mg/24 hr, 0.1 mg/24 hr	T3	
estradiol transdermal patch weekly 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr	T2	
estradiol vaginal cream	T2	
estradiol vaginal tablet	T4	
estradiol-norethindrone acet	T2	
etonogestrel-ethinyl estradiol	T3	
GALLIFREY	T2	
HAILEY 24 FE	T2	
HEATHER	T2	
ICLEVIA	T2	
IMVEXXY MAINTENANCE PACK	T3	
IMVEXXY STARTER PACK	T3	
INCASSIA	T2	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
INTROVALE	T2	
ISIBLOOM	T2	
JASMIEL (28)	T2	
JINTELI	T4	
JULEBER	T2	
JUNEL 1.5/30 (21)	T2	
JUNEL 1/20 (21)	T2	
JUNEL FE 1.5/30 (28)	T2	
JUNEL FE 1/20 (28)	T2	
JUNEL FE 24	T2	
KARIVA (28)	T2	
KELNOR 1/35 (28)	T2	
KURVELO (28)	T2	
LESSINA	T2	
LEVONEST (28)	T2	
levonorgestrel-ethinyl estrad oral tablet 0.1-20 mg-mcg	T2	
levonorgestrel-ethinyl estrad oral tablets,dose pack,3 month	T2	
levonorg-eth estrad triphasic	T2	
LILETTA	T3	
LORYNA (28)	T2	
LOW-OGESTREL (28)	T2	
LUIZZA	T2	
LYLEQ	T2	
LYZA	T2	
MARLISSA (28)	T2	
medroxyprogesterone	T2	
metronidazole vaginal gel 0.75 % (37.5mg/5 gram)	T3	
MICONAZOLE-3 VAGINAL SUPPOSITORY	T2	
MICROGESTIN 1.5/30 (21)	T2	
MICROGESTIN 1/20 (21)	T2	
MICROGESTIN FE 1.5/30 (28)	T2	
MICROGESTIN FE 1/20 (28)	T2	
MILI	T2	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
NECON 0.5/35 (28)	T2	
NEXPLANON	T3	
norethindrone (contraceptive)	T2	
norethindrone acetate	T2	
norethindrone ac-eth estradiol oral tablet 0.5-2.5 mg-mcg, 1-5 mg-mcg	T3	
norethindrone ac-eth estradiol oral tablet 1-20 mg-mcg	T2	
norgestimate-ethinyl estradiol oral tablet 0.18/0.215/0.25 mg-0.035mg (28), 0.25-0.035 mg	T2	
NORTREL 0.5/35 (28)	T2	
NORTREL 1/35 (21)	T2	
NORTREL 1/35 (28)	T2	
NORTREL 7/7/7 (28)	T2	
NYLIA 1/35 (28)	T2	
NYLIA 7/7/7 (28)	T2	
PIMTREA (28)	T2	
PORTIA 28	T2	
PREMARIN VAGINAL	T3	
RECLIPSEN (28)	T2	
SETLAKIN	T2	
SPRINTEC (28)	T2	
SYEDA	T2	
terconazole	T2	
tranexamic acid oral	T3	
TRI-ESTARYLLA	T2	
TRI-MILI	T2	
TRI-SPRINTEC (28)	T2	
TRI-VYLIBRA	T2	
TURQOZ (28)	T2	
VALTYA	T2	
VELIVET TRIPHASIC REGIMEN (28)	T2	
VESTURA (28)	T2	
VIENVA	T2	
VIORELE (28)	T2	
VYFEMLA (28)	T2	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
VYLIBRA	T2	
XELRIA FE	T2	
YUVAFEM	T4	
ZAFEMY	T3	
ZOVIA 1-35 (28)	T2	
Oftalmología		
acetazolamide	T3	
ALPHAGAN P OPHTHALMIC (EYE) DROPS 0.1 %	T3	
apraclonidine	T3	
azelastine ophthalmic (eye)	T2	
bacitracin-polymyxin b	T2	
BESIVANCE	T4	
betaxolol ophthalmic (eye)	T3	
bimatoprost ophthalmic (eye) drops 0.03 %	T2	
brimonidine ophthalmic (eye) drops 0.1 %	T3	
brimonidine ophthalmic (eye) drops 0.15 %	T4	
brimonidine ophthalmic (eye) drops 0.2 %	T2	
brimonidine-timolol	T3	
brinzolamide	T4	
carteolol	T2	
ciprofloxacin hcl ophthalmic (eye)	T2	
COMBIGAN	T3	
cromolyn ophthalmic (eye)	T2	
cyclosporine ophthalmic (eye)	T3	QL (60 EA per 30 days)
CYSTARAN	T5	PA; QL (60 ML per 28 days)
dexamethasone sodium phosphate ophthalmic (eye)	T2	
diclofenac sodium ophthalmic (eye)	T2	
difluprednate	T4	
dorzolamide	T2	
dorzolamide-timolol	T2	
erythromycin ophthalmic (eye)	T2	
fluorometholone	T3	
flurbiprofen sodium	T2	
gatifloxacin	T3	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
gentamicin ophthalmic (eye) drops	T2	
ketorolac ophthalmic (eye) drops 0.4 %	T3	
ketorolac ophthalmic (eye) drops 0.5 %	T2	
latanoprost	T1	
levobunolol ophthalmic (eye) drops 0.5 %	T2	
LUMIGAN OPHTHALMIC (EYE) DROPS 0.01 %	T3	QL (5 ML per 31 days)
methazolamide	T4	
moxifloxacin ophthalmic (eye) drops	T3	
neomycin-bacitracin-poly-hc	T3	
neomycin-bacitracin-polymyxin	T2	
neomycin-polymyxin b-dexameth	T2	
neomycin-polymyxin-gramicidin	T3	
neomycin-polymyxin-hc ophthalmic (eye)	T3	
ofloxacin ophthalmic (eye)	T2	
pilocarpine hcl ophthalmic (eye) drops 1 %, 2 %, 4 %	T3	
polymyxin b sulf-trimethoprim	T1	
prednisolone acetate	T2	
prednisolone sodium phosphate ophthalmic (eye)	T2	
RESTASIS	T3	QL (60 EA per 30 days)
RESTASIS MULTIDOSE	T3	QL (5.5 ML per 27 days)
RHOPRESSA	T4	ST
ROCKLATAN	T4	ST
SIMBRINZA	T4	
sulfacetamide sodium ophthalmic (eye) drops	T2	
sulfacetamide-prednisolone	T2	
timolol maleate ophthalmic (eye) drops	T1	
timolol maleate ophthalmic (eye) gel forming solution	T3	
tobramycin ophthalmic (eye)	T1	
tobramycin-dexamethasone	T3	
travoprost	T3	
trifluridine	T3	
XDEMVY	T5	PA; QL (10 ML per 42 days)
XIIDRA	T3	QL (60 EA per 30 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
ZIRGAN	T4	ST
Respiratorio Y Alergia		
acetylcysteine	T2	PA-BvD
ADEMPAS	T5	PA; QL (93 EA per 31 days)
ADVAIR HFA	T3	QL (12 GM per 30 days)
albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation	T3	QL (17 GM per 30 days)
albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (nda020503)	T3	QL (13.4 GM per 30 days)
albuterol sulfate inhalation solution for nebulization 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 2.5 mg/0.5 ml	T2	PA-BvD
albuterol sulfate oral syrup	T1	
ambrisentan	T5	PA; QL (31 EA per 31 days)
ANORO ELLIPTA	T3	QL (60 EA per 30 days)
ASMANEX HFA	T3	QL (13 GM per 30 days)
ASMANEX TWISTHALER INHALATION AEROSOL POWDR BREATH ACTIVATED 110 MCG/ ACTUATION (30), 220 MCG/ ACTUATION (120), 220 MCG/ ACTUATION (30), 220 MCG/ ACTUATION (60)	T3	QL (1 EA per 30 days)
ATROVENT HFA	T4	QL (25.8 GM per 30 days)
azelastine-fluticasone	T4	QL (23 GM per 30 days)
BREO ELLIPTA	T3	QL (60 EA per 30 days)
BREYNA	T3	QL (10.3 GM per 30 days)
BREZTRI AEROSPHERE	T3	QL (10.7 GM per 30 days)
BRINSUPRI	T5	PA; QL (31 EA per 31 days)
budesonide inhalation	T4	PA-BvD
budesonide-formoterol	T3	QL (10.2 GM per 30 days)
CINRYZE	T5	PA; QL (20 EA per 28 days)
COMBIVENT RESPIMAT	T3	QL (4 GM per 30 days)
cromolyn inhalation	T4	PA-BvD
cyproheptadine oral tablet	T2	PA
desloratadine oral tablet	T2	QL (31 EA per 31 days)
DULERA	T3	QL (13 GM per 30 days)
epinephrine injection auto-injector 0.15 mg/0.3 ml, 0.3 mg/0.3 ml	T3	
FASENRA PEN	T5	PA; QL (1 ML per 28 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
FASENRA SUBCUTANEOUS SYRINGE 10 MG/0.5 ML	T5	PA; QL (0.5 ML per 56 days)
FASENRA SUBCUTANEOUS SYRINGE 30 MG/ML	T5	PA; QL (1 ML per 28 days)
flunisolide	T3	QL (50 ML per 25 days)
fluticasone furoate-vilanterol	T3	QL (60 EA per 30 days)
fluticasone propionate inhalation blister with device 100 mcg/actuation, 50 mcg/actuation	T4	ST; QL (60 EA per 30 days)
fluticasone propionate inhalation blister with device 250 mcg/actuation	T4	ST; QL (240 EA per 30 days)
fluticasone propionate inhalation hfa aerosol inhaler 110 mcg/actuation	T4	ST; QL (12 GM per 30 days)
fluticasone propionate inhalation hfa aerosol inhaler 220 mcg/actuation	T4	ST; QL (24 GM per 30 days)
fluticasone propionate inhalation hfa aerosol inhaler 44 mcg/actuation	T4	ST; QL (10.6 GM per 30 days)
fluticasone propionate nasal	T1	QL (16 GM per 30 days)
fluticasone propion-salmeterol inhalation blister with device	T3	QL (60 EA per 30 days)
hydroxyzine hcl oral tablet	T2	PA
icatibant	T5	PA; QL (18 ML per 30 days)
ipratropium bromide inhalation solution	T2	PA-BvD
ipratropium-albuterol	T2	PA-BvD
JASCAYD	T5	PA; QL (62 EA per 31 days)
KALYDECO ORAL GRANULES IN PACKET 13.4 MG, 5.8 MG, 50 MG, 75 MG	T5	PA; QL (56 EA per 28 days)
KALYDECO ORAL GRANULES IN PACKET 25 MG	T5	PA; QL (62 EA per 31 days)
KALYDECO ORAL TABLET	T5	PA; QL (62 EA per 31 days)
levalbuterol hcl inhalation solution for nebulization 1.25 mg/3 ml	T3	PA-BvD
levalbuterol tartrate	T3	QL (30 GM per 30 days)
levocetirizine oral solution	T4	QL (310 ML per 31 days)
levocetirizine oral tablet	T1	QL (31 EA per 31 days)
macitentan	T4	PA; QL (31 EA per 31 days)
mometasone nasal	T3	QL (34 GM per 30 days)
montelukast oral tablet	T2	QL (31 EA per 31 days)
montelukast oral tablet,chewable	T2	QL (31 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
nintedanib	T5	PA; QL (62 EA per 31 days)
OPSUMIT	T5	PA; QL (31 EA per 31 days)
OPSYNVI	T5	PA; QL (31 EA per 31 days)
ORKAMBI ORAL GRANULES IN PACKET	T5	PA; QL (62 EA per 31 days)
ORKAMBI ORAL TABLET	T5	PA; QL (124 EA per 31 days)
pirfenidone oral capsule	T5	PA; QL (279 EA per 31 days)
pirfenidone oral tablet	T5	PA; QL (93 EA per 31 days)
promethazine oral tablet	T4	PA
PULMOZYME	T5	PA
QVAR REDIHALER INHALATION HFA AEROSOL BREATH ACTIVATED 40 MCG/ACTUATION	T3	QL (10.6 GM per 30 days)
QVAR REDIHALER INHALATION HFA AEROSOL BREATH ACTIVATED 80 MCG/ACTUATION	T3	QL (21.2 GM per 30 days)
roflumilast	T4	QL (31 EA per 31 days)
SAJAZIR	T5	PA; QL (18 ML per 30 days)
SEREVENT DISKUS	T3	QL (60 EA per 30 days)
sildenafil (pulm.hypertension) oral tablet	T3	PA; QL (372 EA per 31 days)
SPIRIVA RESPIMAT	T3	QL (4 GM per 30 days)
STIOLTO RESPIMAT	T3	QL (4 GM per 30 days)
STRIVERDI RESPIMAT	T4	QL (4 GM per 30 days)
tadalafil (pulm. hypertension)	T5	PA; QL (62 EA per 31 days)
terbutaline oral	T4	
TEZSPIRE SUBCUTANEOUS PEN INJECTOR	T5	PA; QL (1.91 ML per 28 days)
THEO-24	T3	
theophylline oral solution	T2	
theophylline oral tablet extended release 12 hr	T2	
theophylline oral tablet extended release 24 hr	T2	
TRELEGY ELLIPTA	T3	QL (60 EA per 30 days)
TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL	T5	PA; QL (56 EA per 28 days)
TRIKAFTA ORAL TABLETS, SEQUENTIAL	T5	PA; QL (84 EA per 28 days)
VENTOLIN HFA	T3	QL (36 GM per 30 days)
WINREVAIR	T5	PA

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
WIXELA INHUB	T3	QL (60 EA per 30 days)
XOLAIR	T5	PA
Suministros Variados		
ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2"	T4	
GAUZE PAD TOPICAL BANDAGE 2 X 2 "	T2	PA
insulin syringe-needle u-100 syringe 0.3 ml 29 gauge, 1 ml 29 gauge x 1/2", 1/2 ml 28 gauge	T3	
pen needle, diabetic needle 29 gauge x 1/2"	T4	
Urológicos		
alfuzosin	T2	QL (31 EA per 31 days)
bethanechol chloride oral tablet 10 mg, 25 mg, 5 mg	T2	
bethanechol chloride oral tablet 50 mg	T3	
CYSTAGON	T4	
dutasteride	T2	QL (31 EA per 31 days)
dutasteride-tamsulosin	T4	QL (31 EA per 31 days)
ELMIRON	T4	
finasteride oral tablet 5 mg	T2	
GEMTESA	T4	QL (31 EA per 31 days)
MYRBETRIQ ORAL SUSPENSION,EXTENDED REL RECON	T3	QL (300 ML per 30 days)
MYRBETRIQ ORAL TABLET EXTENDED RELEASE 24 HR	T3	QL (31 EA per 31 days)
oxybutynin chloride oral syrup	T2	
oxybutynin chloride oral tablet	T2	
oxybutynin chloride oral tablet extended release 24hr 10 mg, 5 mg	T2	QL (31 EA per 31 days)
oxybutynin chloride oral tablet extended release 24hr 15 mg	T3	QL (62 EA per 31 days)
potassium citrate oral tablet extended release	T3	
RIVFLOZA SUBCUTANEOUS SOLUTION	T5	PA; QL (1 ML per 28 days)
RIVFLOZA SUBCUTANEOUS SYRINGE 128 MG/0.8 ML	T5	PA; QL (0.8 ML per 28 days)
RIVFLOZA SUBCUTANEOUS SYRINGE 160 MG/ML	T5	PA; QL (1 ML per 28 days)
silodosin	T4	
solifenacin	T4	QL (31 EA per 31 days)

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
tadalafil oral tablet 2.5 mg	T4	PA; QL (62 EA per 31 days)
tadalafil oral tablet 5 mg	T4	PA; QL (31 EA per 31 days)
tamsulosin	T1	
tolterodine oral capsule,extended release 24hr	T3	QL (31 EA per 31 days)
tolterodine oral tablet	T3	QL (62 EA per 31 days)
trospium oral tablet	T2	QL (93 EA per 31 days)
Vitaminas, Hematinicos / Electrolitos		
calcium acetate(phosphat bind)	T2	PA-BvD
CLINIMIX 5%/D15W SULFITE FREE	T4	PA-BvD
CLINIMIX 4.25%/D10W SULF FREE	T4	PA-BvD
CLINIMIX 5%-D20W(SULFITE-FREE)	T4	PA-BvD
fluoride (sodium) oral tablet	T2	
INTRALIPID INTRAVENOUS EMULSION 20 %	T4	PA-BvD
ISOLYTE S PH 7.4	T3	PA-BvD
ISOLYTE-P IN 5 % DEXTROSE	T4	PA-BvD
KLOR-CON	T4	
KLOR-CON M10	T2	
KLOR-CON M15	T2	
KLOR-CON M20	T2	
magnesium sulfate injection	T2	
PLENAMINE	T3	PA-BvD
potassium chlorid-d5-0.45%nacl	T2	
potassium chloride in 0.9%nacl intravenous parenteral solution 20 meq/l, 40 meq/l	T2	
potassium chloride in 5 % dex intravenous parenteral solution 20 meq/l	T2	
potassium chloride in lr-d5	T2	
potassium chloride in water intravenous piggyback 10 meq/100 ml, 20 meq/100 ml, 40 meq/100 ml	T2	
potassium chloride intravenous	T2	
potassium chloride oral capsule, extended release	T2	
potassium chloride oral liquid	T2	
potassium chloride oral tablet extended release 10 meq, 20 meq, 8 meq	T2	

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Nombre del medicamento	Nivel de medicamento	Requisitos/Límites
potassium chloride oral tablet,er particles/crystals	T2	
potassium chloride-0.45 % nacl	T2	
potassium chloride-d5-0.2%nacl	T2	
potassium chloride-d5-0.9%nacl	T2	
PRENATAL VITAMIN PLUS LOW IRON	T2	PA
PROSOL 20 %	T4	PA-BvD
sodium chloride 0.45 % intravenous	T2	
sodium chloride 3 % hypertonic	T2	
sodium chloride 5 % hypertonic	T2	
TRAVASOL 10 %	T4	PA-BvD
TROPHAMINE 10 %	T4	PA-BvD

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Puede encontrar información sobre el significado de los símbolos y abreviaturas de esta tabla yendo al principio de la misma.

Índice de drogas

abacavir 3
abacavir-lamivudine 3
ABIGALE 57
ABILIFY MAINTENA 40
abiraterone 32
ABIRTEGA 32
ABRYSVO (PF) 29
acamprosate 21
acarbose 22
ACCUTANE 17
acebutolol 11
acetaminophen-codeine 40, 41
acetazolamide 60
acetic acid 54
acetylcysteine 62
acitretin 17
ACTEMRA 55
ACTEMRA ACTPEN 55
ACTHIB (PF) 29
ACTIMMUNE 29
acyclovir 3, 17
acyclovir sodium 3
ADACEL(TDAP ADOLESN/ADULT)(PF) 29
adefovir 3
ADEMPAS 62
ADVAIR HFA 62
AIMOVIG AUTOINJECTOR 41
AKEEGA 32
ALA-CORT 17
albendazole 3
albuterol sulfate 62
alclometasone 17
ALCOHOL PADS 23
ALECENSA 32
alendronate 55
alfuzosin 65
aliskiren 11
allopurinol 55
alosetron 27
ALPHAGAN P 60
alprazolam 41
ALTAVERA (28) 57
ALUNBRIG 32
ALYACEN 1/35 (28) 57
amantadine hcl 3
ambrisentan 62
amikacin 3
amiloride 11
amiloride-hydrochlorothiazide 11
amiodarone 11
amitriptyline 41
amlodipine 11
amlodipine-benazepril 11
amlodipine-olmesartan 11
amlodipine-valsartan 11
ammonium lactate 17
AMNESTEEM 17
amoxapine 41
amoxicillin 3
amoxicillin-pot clavulanate 4
amphotericin b 4
amphotericin b liposome 4
ampicillin 4
ampicillin sodium 4
ampicillin-sulbactam 4
anagrelide 21
anastrozole 32
ANORO ELLIPTA 62
ANZUPGO 17
apraclonidine 60
aprepitant 27
APRI 57
APTIVUS 4
ARANELLE (28) 57
AREXVY (PF) 30
ARIKAYCE 4
aripiprazole 41
armodafinil 41
asenapine maleate 41
ASMANEX HFA 62
ASMANEX TWISTHALER 62
aspirin-dipyridamole 11
ASSURE ID INSULIN SAFETY 65
atazanavir 4
atenolol 11
atenolol-chlorthalidone 11
atomoxetine 41
atorvastatin 11
atovaquone 4
atovaquone-proguanil 4
ATROVENT HFA 62
ATTRUBY 11
AUGTYRO 32
AUSTEDO 41
AUSTEDO XR 41
AUSTEDO XR TITRATION KT(WK1-4) 41
AUVELITY 41
AVIANE 57
AVMAPKI-FAKZYNJA 32
AVONEX 30
AYVAKIT 32
azathioprine 32
azelastine 54, 60
azelastine-fluticasone 62
azithromycin 4
aztreonam 4
AZURETTE (28) 57
bacitracin-polymyxin b 60
baclofen 41
BAFIERTAM 41
balsalazide 27
BALVERSA 32
BALZIVA (28) 57
bcg vaccine, live (pf) 30
benazepril 11
benazepril-hydrochlorothiazide 11
BENLYSTA 55
benztropine 41
BESIVANCE 60
BESREMI 30
BESREMI PEN 30
betaine 27
betamethasone dipropionate 17
betamethasone valerate 17
betamethasone, augmented 17
BETASERON 30
betaxolol 60
bethanechol chloride 65
bexarotene 32
BEXSERO 30
bicalutamide 32
BICILLIN C-R 4
BICILLIN L-A 4
BIKTARVY 4
bimatoprost 60
bisoprolol fumarate 12
bisoprolol-hydrochlorothiazide 12
BLISOVI FE 1.5/30 (28) 57
BLUJEPA 4
BOOSTRIX TDAP 30
BOSULIF 32
bosutinib 32
BRAFTOVI 32
BREO ELLIPTA 62
BREYNA 62
BREZTRI AEROSPHERE 62
BRIELLYN 57
brimonidine 60
brimonidine-timolol 60
BRINSUPRI 62

brinzolamide 60
brivaracetam 41
bromocriptine 41
BRUKINSA 32
budesonide 27, 62
budesonide-formoterol 62
bumetanide 12
buprenorphine 41
buprenorphine hcl 41
buprenorphine-naloxone 41, 42
bupropion hcl 42
bupropion hcl (smoking deter) 21
buspirone 42
butorphanol 42
cabergoline 23
CABOMETYX 32
calcipotriene 17, 18
calcitonin (salmon) 23
calcitriol 23
calcium acetate(phosphat bind) 66
CALQUENCE (ACALABRUTINIB MAL) 32
CAMILA 57
candesartan 12
candesartan-hydrochlorothiazid 12
CAPLYTA 42
CAPRELSA 32
captopril 12
carbamazepine 42
carbidopa-levodopa 42
carbidopa-levodopa-entacapone 42
carglumic acid 21
carteolol 60
CARTIA XT 12
carvedilol 12
caspofungin 4
CAYSTON 4
cefaclor 4
cefadroxil 4
cefazolin 4
cefdinir 4
cefepime 4
cefixime 5
cefoxitin 5
cefpodoxime 5
cefprozil 5
ceftaroline fosamil 5
ceftazidime 5
ceftriaxone 5
cefuroxime axetil 5
cefuroxime sodium 5
celecoxib 42
cephalexin 5
CERDELGA 23
CHEMET 21
chlorhexidine gluconate 54
chloroquine phosphate 5
chlorpromazine 42
chlorthalidone 12
cholestyramine (with sugar) 12
CHOLESTYRAMINE LIGHT 12
ciclopirox 18
cilostazol 12
CIMDUO 5
cinacalcet 23
CINRYZE 62
ciprofloxacin hcl 5, 60
ciprofloxacin in 5 % dextrose 5
ciprofloxacin-dexamethasone 54
citalopram 42
CLARAVIS 18
clarithromycin 5
clindamycin hcl 5
clindamycin in 5 % dextrose 5
CLINDAMYCIN PEDIATRIC 5
clindamycin phosphate 5, 18, 57
clindamycin-benzoyl peroxide 18
CLINIMIX 5%/D15W SULFITE FREE 66
CLINIMIX 4.25%/D10W SULF FREE 66
CLINIMIX 4.25%/D5W SULFIT FREE 21
CLINIMIX 5%-D20W(SULFITE-FREE) 66
clobazam 42
clomipramine 42
clonazepam 42
clonidine 12
clonidine hcl 12
clopidogrel 12
clorazepate dipotassium 42, 43
clotrimazole 5, 18
clotrimazole-betamethasone 18
clozapine 43
COARTEM 5
COBENFY 43
COBENFY STARTER PACK 43
colchicine 55
colesevelam 12
colestipol 12
colistin (colistimethate na) 5
COMBIGAN 60
COMBIVENT RESPIMAT 62
COMETRIQ 33
COMPRO 27
CONSTULOSE 27
COPAXONE 43
COPIKTRA 33
COSENTYX 18
COSENTYX (2 SYRINGES) 18
COSENTYX PEN (2 PENS) 18
COSENTYX UNOREADY PEN 18
COTELLIC 33
CREON 27
CRESEMBA 5
cromolyn 27, 60, 62
CRYSELLE (28) 57
cyclobenzaprine 43
cyclophosphamide 33
cyclosporine 33, 60
cyclosporine modified 33
cyproheptadine 62
CYRED EQ 57
CYSTAGON 65
CYSTARAN 60
d10 %-0.45 % sodium chloride 21
d2.5 %-0.45 % sodium chloride 21
d5 % and 0.9 % sodium chloride 21
d5 %-0.45 % sodium chloride 21
dabigatran etexilate 12
dalfampridine 43
danazol 23
dantrolene 43
DANZITEN 33
dapagliflozin 23
dapsone 5
DAPTACEL (DTAP PEDIATRIC) (PF) 30
daptomycin 6
darunavir 6
dasatinib 33
DAURISMO 33
deferasirox 21
DELSTRIGO 6
DEPO-SUBQ PROVERA 104 57
DESCOVY 6
desipramine 43
desloratadine 62
desmopressin 23
desoximetasone 18
desvenlafaxine succinate 43

dexamethasone 23
dexamethasone sodium phosphate 60
dexmethylphenidate 43
dextroamphetamine-amphetamine 43
dextromethorphan-quinidine 43
dextrose 10 % in water (d10w) ... 21
dextrose 5 % in water (d5w) 21
DIACOMIT 43, 44
diazepam 44
DIAZEPAM INTENSOL 44
diazoxide 23
diclofenac potassium 44
diclofenac sodium 18, 44, 60
dicloxacillin 6
dicyclomine 27, 28
diflunisal 44
difluprednate 60
digoxin 12
dihydroergotamine 44
DILANTIN 44
diltiazem hcl 12
DILT-XR 12
dimethyl fumarate 44
diphenoxylate-atropine 28
disulfiram 21
divalproex 44
dofetilide 12
donepezil 44
dorzolamide 60
dorzolamide-timolol 60
DOVATO 6
doxazosin 12
doxepin 44
doxercalciferol 23
DOXY-100 6
doxycycline hyclate 6
doxycycline monohydrate 6
DRIZALMA SPRINKLE ... 44, 45
dronabinol 28
drospirenone-ethinyl estradiol ... 57
droxidopa 21
DULERA 62
duloxetine 45
DUPIXENT PEN 18
DUPIXENT SYRINGE 18
dutasteride 65
dutasteride-tamsulosin 65
DUVYZAT 21
EDURANT PED 6
efavirenz 6
efavirenz-emtricitabin-tenofov 6
efavirenz-lamivu-tenofov disop 6
ELIGARD 33
ELIGARD (3 MONTH) 33
ELIGARD (4 MONTH) 33
ELIGARD (6 MONTH) 33
ELIQUIS 12, 13
ELIQUIS DVT-PE TREAT 30D START 12
ELIQUIS SPRINKLE 13
ELMIRON 65
eltrombopag olamine 13
EMGALITY PEN 45
EMGALITY SYRINGE 45
EMSAM 45
emtricitabine 6
emtricitabine-tenofovir (tdf) 6
emtricita-rilpivirine-tenof df 6
EMTRIVA 6
enalapril maleate 13
enalapril-hydrochlorothiazide 13
ENBREL 55
ENBREL MINI 55
ENBREL SURECLICK 55
ENGERIX-B (PF) 30
ENGERIX-B PEDIATRIC (PF) 30
ENOBY 55
enoxaparin 13
ENSACOVE 33
ENSKYCE 57
entacapone 45
entecavir 6
ENTRESTO 13
ENTRESTO SPRINKLE 13
ENULOSE 28
ENVARSUS XR 33
EOHILIA 28
EPIDIOLEX 45
epinephrine 62
eplerenone 13
ergotamine-caffeine 45
ERIVEDGE 33
ERLEADA 33
erlotinib 33
ERRIN 57
ertapenem 6
ERY PADS 18
erythromycin 6, 60
erythromycin with ethanol 18
escitalopram oxalate 45
eslicarbazepine 45
esomeprazole magnesium 28
ESTARYLLA 57
estradiol 57
estradiol-norethindrone acet 57
ethacrynic acid 13
ethambutol 6
ethosuximide 45
etodolac 45
etonogestrel-ethinyl estradiol 57
etravirine 6
EULEXIN 33
everolimus (antineoplastic) ... 33, 34
everolimus (immunosuppressive) 34
EVOTAZ 6
exemestane 34
EXXUA 45
ezetimibe 13
ezetimibe-simvastatin 13
FABHALTA 21
famciclovir 6
famotidine 28
FANAPT 45
FANAPT TITRATION PACK A 45
FANAPT TITRATION PACK B 46
FANAPT TITRATION PACK C 46
FASENRA 63
FASENRA PEN 62
felbamate 46
felodipine 13
fenofibrate 13
fenofibrate micronized 13
fenofibrate nanocrystallized 13
fentanyl 46
FETZIMA 46
FIASP FLEXTOUCH U-100 INSULIN 23
FIASP PENFILL U-100 INSULIN 23
FIASP U-100 INSULIN 23
fidaxomicin 6
FILSUVEZ 18
finasteride 65
fingolimod 46
FINTEPLA 46
FIRMAGON KIT W DILUENT SYRINGE 34
flecainide 13
fluconazole 7

fluconazole in nacl (iso-osm).....7
flucytosine.....7
fludrocortisone.....23
flunisolide.....63
fluocinolone.....19
fluocinolone acetonide oil.....54
fluocinolone and shower cap.....19
fluocinonide.....19
fluocinonide-emollient.....19
fluoride (sodium).....66
fluorometholone.....60
fluorouracil.....19
fluoxetine.....46
fluoxetine (pmdd).....46
fluphenazine decanoate.....46
fluphenazine hcl.....46
flurbiprofen.....46
flurbiprofen sodium.....60
fluticasone furoate-vilanterol.....63
fluticasone propionate.....19, 63
fluticasone propion-salmeterol...63
fluvoxamine.....46
fondaparinux.....13
fosamprenavir.....7
fosfomycin tromethamine.....7
fosinopril.....13
fosinopril-hydrochlorothiazide...13
FOTIVDA.....34
FRUZAQLA.....34
furosemide.....13, 14
gabapentin.....46
galantamine.....46
GALLIFREY.....57
GAMMAGARD LIQUID.....30
GAMMAGARD LIQUID ERC.....30
GAMMAGARD S-D (IGA < 1 MCG/ML).....30
GARDASIL 9 (PF).....30
gatifloxacin.....60
GATTEX 30-VIAL.....28
GAUZE PAD.....65
GAVILYTE-C.....28
GAVILYTE-G.....28
GAVILYTE-N.....28
GAVRETO.....34
gefitinib.....34
gemfibrozil.....14
GEMTESA.....65
GENERLAC.....28
GENGRAF.....34
gentamicin.....7, 19, 61
gentamicin in nacl (iso-osm).....7
GENVOYA.....7
GILOTRIF.....34
glatiramer.....46
GLATOPA.....47
glimepiride.....23
glipizide.....23
glipizide-metformin.....23
GLUCAGON EMERGENCY KIT (HUMAN).....23
glyburide.....23
glyburide-metformin.....23
glycerol phenylbutyrate.....21
glycopyrrolate.....28
GLYXAMBI.....23
GOMEKLI.....34
granisetron hcl.....28
griseofulvin microsize.....7
griseofulvin ultramicrosize.....7
guanfacine.....47
GVOKE.....23
GVOKE HYPOPEN 2-PACK.23
GVOKE PFS 1-PACK SYRINGE.....23
HADLIMA.....55
HADLIMA PUSHTOUCH.....55
HADLIMA(CF).....55
HADLIMA(CF) PUSHTOUCH.....55
HAILEY 24 FE.....57
halobetasol propionate.....19
haloperidol.....47
haloperidol decanoate.....47
haloperidol lactate.....47
HAVRIX (PF).....30
HEATHER.....57
heparin (porcine).....14
HEPCLUDEX.....7
HEPLISAV-B (PF).....30
HERNEXEOS.....34
HIBERIX (PF).....30
HUMALOG JUNIOR KWIKPEN U-100.....23
HUMALOG KWIKPEN INSULIN.....23
HUMALOG MIX 50-50 KWIKPEN.....24
HUMALOG MIX 75-25 KWIKPEN.....24
HUMALOG MIX 75-25(U-100)INSULN.....24
HUMALOG U-100 INSULIN..24
HUMULIN 70/30 U-100 INSULIN.....24
HUMULIN 70/30 U-100 KWIKPEN.....24
HUMULIN N NPH INSULIN KWIKPEN.....24
HUMULIN N NPH U-100 INSULIN.....24
HUMULIN R REGULAR U-100 INSULN.....24
HUMULIN R U-500 (CONC) KWIKPEN.....24
hydralazine.....14
hydrochlorothiazide.....14
hydrocodone-acetaminophen.....47
hydrocortisone.....19, 24, 28
hydromorphone.....47
hydroxychloroquine.....7
hydroxyurea.....34
hydroxyzine hcl.....63
HYRNUO.....34
ibandronate.....55
IBRANCE.....34
IBTROZI.....34
IBU.....47
ibuprofen.....47
icatibant.....63
ICLEVIA.....57
ICLUSIG.....34
icosapent ethyl.....14
IDHIFA.....34
IDVYNSO.....7
imatinib.....34
IMBRUVICA.....34
imipenem-cilastatin.....7
imipramine hcl.....47
imiquimod.....19
IMKELDI.....34
IMOVAX RABIES VACCINE (PF).....30
IMVEXXY MAINTENANCE PACK.....57
IMVEXXY STARTER PACK.57
INCASSIA.....57
INCRELEX.....22
indapamide.....14
indomethacin.....47
INFANRIX (DTAP) (PF).....30
INGREZZA.....47
INGREZZA INITIATION PK(TARDIV).....47
INGREZZA SPRINKLE.....47

INLURIYO 35
INLYTA 35
INQOVI 35
INREBIC 35
insulin lispro 24
insulin lispro protamin-lispro 24
insulin syringe-needle u-100 65
INTELENCE 7
INTRALIPID 66
INTROVALE 58
INVEGA HAFYERA 47
INVEGA SUSTENNA 47
INVEGA TRINZA 48
IPOL 30
ipratropium bromide 55, 63
ipratropium-albuterol 63
irbesartan 14
irbesartan-hydrochlorothiazide 14
ISENTRESS 7
ISENTRESS HD 7
ISIBLOOM 58
ISOLYTE S PH 7.4 66
ISOLYTE-P IN 5 % DEXTROSE 66
isoniazid 7
isosorbide dinitrate 14
isosorbide mononitrate 14
isradipine 14
ITOVEBI 35
itraconazole 7
ivabradine 14
ivermectin 7
IWILFIN 35
IXIARO (PF) 30
JAKAFI 35
JANTOVEN 14
JANUMET 24
JANUMET XR 24
JANUVIA 24
JARDIANCE 24
JASCAYD 63
JASMIEL (28) 58
JAVYGTOR 24
JAYPIRCA 35
JENTADUETO 24
JENTADUETO XR 24
JIDEYTRO 35
JINTELI 58
JOENJA 22
JUBBONTI 55
JULEBER 58
JULUCA 7
JUNEL 1.5/30 (21) 58
JUNEL 1/20 (21) 58
JUNEL FE 1.5/30 (28) 58
JUNEL FE 1/20 (28) 58
JUNEL FE 24 58
JYNNEOS (PF) 30
KALYDECO 63
KARIVA (28) 58
KELNOR 1/35 (28) 58
KERENDIA 14
KESIMPTA PEN 48
ketoconazole 7, 19
ketorolac 61
KINERET 55
KINRIX (PF) 30
KIONEX 22
KISQALI 35
KLOR-CON 66
KLOR-CON M10 66
KLOR-CON M15 66
KLOR-CON M20 66
KLOXXADO 48
KOMZIFTI 35
KOSELUGO 35
KOURZEQ 55
KRAZATI 35
KURVELO (28) 58
KYGEVVI 22
labetalol 14
lacosamide 48
lactulose 28
LAGEVRIO (EUA) 7
lamivudine 7, 8
lamivudine-zidovudine 8
lamotrigine 48
LANTUS SOLOSTAR U-100 INSULIN 24
LANTUS U-100 INSULIN 24
lapatinib 35
latanoprost 61
LAZCLUZE 35
leflunomide 55
lenalidomide 35
LENVIMA 35
LESSINA 58
letrozole 35
leucovorin calcium 35
LEUKERAN 35
LEUKINE 30
leuprolide 35
levalbuterol hcl 63
levalbuterol tartrate 63
levetiracetam 48
levobunolol 61
levocarnitine 22
levocarnitine (with sugar) 22
levocetirizine 63
levofloxacin 8
levofloxacin in d5w 8
LEVONEST (28) 58
levonorgestrel-ethinyl estrad 58
levonorg-eth estrad triphasic 58
levothyroxine 24
LEVOXYL 24
lidocaine 19
lidocaine hcl 19
lidocaine-prilocaine 19
LIFYORLI 36
LILETTA 58
linezolid 8
linezolid in dextrose 5% 8
LINZESS 28
LIOMNY 24
liothyronine 25
liraglutide 25
lisinopril 14
lisinopril-hydrochlorothiazide 14
LITFULO 22
lithium carbonate 48
lithium citrate 48
LIVTENCITY 8
LOARGYS 22
lofexidine 48
LOKELMA 22
lomustine 36
LONSURF 36
loperamide 28
lopinavir-ritonavir 8
lorazepam 48
LORAZEPAM INTENSOL 48
LORBRENA 36
LORYNA (28) 58
losartan 14
losartan-hydrochlorothiazide 14
lovastatin 14
LOW-OGESTREL (28) 58
loxapine succinate 48
lubiprostone 28
LUIZZA 58
LUMAKRAS 36
LUMIGAN 61
LUPRON DEPOT 36
LUPRON DEPOT (3 MONTH) 36

lurasidone 48
LYBALVI 48
LYLEQ 58
LYNPARZA 36
LYSODREN 36
LYTGOBI 36
LYZA 58
macitentan 63
magnesium sulfate 66
malathion 19
maraviroc 8
MARLISSA (28) 58
MARPLAN 48
MATULANE 36
MAVYRET 8
meclizine 28
medroxyprogesterone 58
mefloquine 8
megestrol 36
MEKINIST 36
MEKTOVI 36
meloxicam 48
memantine 48
memantine-donepezil 48
MENQUADFI (PF) 30
MENVEO A-C-Y-W-135-DIP (PF) 30
mercaptopurine 37
meropenem 8
mesalamine 28
mesna 37
metformin 25
methadone 49
methazolamide 61
methenamine hippurate 8
methimazole 25
methotrexate sodium 37
methotrexate sodium (pf) 37
methsuximide 49
methylphenidate hcl 49
methylprednisolone 25
metoclopramide hcl 28
metolazone 14
metoprolol succinate 14
metoprolol ta-hydrochlorothiaz 14
metoprolol tartrate 14
metronidazole 8, 19, 58
metronidazole in nacl (iso-os) 8
metyrosine 14
mexiletine 14
micafungin 8
MICONAZOLE-3 58
MICROGESTIN 1.5/30 (21) 58
MICROGESTIN 1/20 (21) 58
MICROGESTIN FE 1.5/30 (28) 58
MICROGESTIN FE 1/20 (28) 58
midodrine 22
mifepristone 25
miglustat 25
MILI 58
minocycline 8
minoxidil 14
mirtazapine 49
misoprostol 28
M-M-R II (PF) 30
modafinil 49
MODEYSO 37
moexipril 15
molindone 49
mometasone 19, 63
montelukast 63
morphine 49
morphine concentrate 49
MOUNJARO 25
MOVANTIK 28
moxifloxacin 8, 61
moxifloxacin-sod.chloride(iso) 8
MRESVIA (PF) 30
MULPLETA 15
MULTAQ 15
mupirocin 19
mycophenolate mofetil 37
mycophenolate sodium 37
MYRBETRIQ 65
nabumetone 49
nadolol 15
nafcillin 8
naloxone 49
naltrexone 49
naproxen 49
naproxen sodium 49
naratriptan 49
nateglinide 25
NAYZILAM 49
nebivolol 15
NECON 0.5/35 (28) 59
nefazodone 49
NEMLUVIO 37
neomycin 8
neomycin-bacitracin-poly-hc 61
neomycin-bacitracin-polymyxin 61
neomycin-polymyxin b-dexameth 61
neomycin-polymyxin-gramicidin 61
neomycin-polymyxin-hc 55, 61
NERLYNX 37
nevirapine 8
NEXLETOL 15
NEXLIZET 15
NEXPLANON 59
niacin 15
nicardipine 15
NICOTROL NS 22
nifedipine 15
nilotinib hcl 37
nilutamide 37
nimodipine 15
NINLARO 37
nintedanib 64
nitazoxanide 8
nitisinone 22
NITRO-BID 15
nitrofurantoin macrocrystal 8
nitrofurantoin monohyd/m-cryst 8
nitroglycerin 15, 28
NIVESTYM 30
NORDITROPIN FLEXPRO 31
norethindrone (contraceptive) 59
norethindrone acetate 59
norethindrone ac-eth estradiol 59
norgestimate-ethinyl estradiol 59
NORTREL 0.5/35 (28) 59
NORTREL 1/35 (21) 59
NORTREL 1/35 (28) 59
NORTREL 7/7/7 (28) 59
nortriptyline 49
NOVOLIN 70/30 U-100 INSULIN 25
NOVOLIN 70-30 FLEXPEN U-100 25
NOVOLIN N FLEXPEN 25
NOVOLIN N NPH U-100 INSULIN 25
NOVOLIN R FLEXPEN 25
NOVOLIN R REGULAR U100 INSULIN 25
NOVOLOG FLEXPEN U-100 INSULIN 25
NOVOLOG MIX 70-30 U-100 INSULN 25
NOVOLOG MIX 70-30FLEXPEN U-100 25
NOVOLOG PENFILL U-100 INSULIN 25

NOVOLOG U-100 INSULIN ASPART 25
NUBEQA 37
NUEDEXTA 49
NUPLAZID 49
NURTEC ODT 50
NYAMYC 20
NYLIA 1/35 (28) 59
NYLIA 7/7/7 (28) 59
nystatin 9, 20
NYSTOP 20
octreotide acetate 37
ODEFSEY 9
ODOMZO 37
ofloxacin 9, 55, 61
OGSIVEO 37
OJEMDA 37
OJJAARA 37
olanzapine 50
olmesartan 15
olmesartan-amlodipin-hcthiazid 15
olmesartan-hydrochlorothiazide 15
olopatadine 55
omega-3 acid ethyl esters 15
omeprazole 28
ondansetron 29
ondansetron hcl 29
ONUREG 37
OPIPZA 50
OPSUMIT 64
OPSYNVI 64
ORENCIA 55, 56
ORENCIA CLICKJECT 55
ORGOVYX 37
ORKAMBI 64
ORLYNVAH 9
ORSERDU 37
oseltamivir 9
OTEZLA 56
OTEZLA STARTER 56
OTEZLA XR 56
OTEZLA XR INITIATION 56
oxacillin 9
oxcarbazepine 50
oxybutynin chloride 65
oxycodone 50
oxycodone-acetaminophen 50
OZEMPIC 25
PACERONE 15
paliperidone 50
PANRETIN 20
pantoprazole 29
paricalcitol 25
paroxetine hcl 50
PAXLOVID 9
pazopanib 37
PEDIARIX (PF) 31
PEDVAX HIB (PF) 31
peg 3350-electrolytes 29
peg3350-sod sul-nacl-kcl-asb-c 29
PEGASYS 31
peg-electrolyte soln 29
PEMAZYRE 37
pen needle, diabetic 65
PENBRAYA (PF) 31
penciclovir 20
penicillamine 56
penicillin g pot in dextrose 9
penicillin g potassium 9
penicillin v potassium 9
PENMENVY MEN A-B-C-W-Y (PF) 31
PENTACEL (PF) 31
pentamidine 9
pentoxifylline 15
perampanel 50
perindopril erbumine 15
PERIOGARD 55
permethrin 20
perphenazine 50
PHEBURANE 22
phenelzine 50
phenobarbital 50
PHENYTEK 50
phenytoin 50
phenytoin sodium extended 50
PIFELTRO 9
pilocarpine hcl 22, 61
pimozide 50
PIMTREA (28) 59
pindolol 15
pioglitazone 25
pioglitazone-metformin 25
piperacillin-tazobactam 9
PIQRAY 38
pirfenidone 64
piroxicam 50
pitavastatin calcium 15
PLEGRIDY 31
PLENAMINE 66
podofilox 20
polymyxin b sulf-trimethoprim 61
pomalidomide 38
PORTIA 28 59
posaconazole 9
potassium chlorid-d5-0.45%nacl 66
potassium chloride 66, 67
potassium chloride in 0.9%nacl 66
potassium chloride in 5 % dex 66
potassium chloride in lr-d5 66
potassium chloride in water 66
potassium chloride-0.45 % nacl 67
potassium chloride-d5-0.2%nacl 67
potassium chloride-d5-0.9%nacl 67
potassium citrate 65
pramipexole 50
prasugrel hcl 15
pravastatin 15
praziquantel 9
prazosin 15
prednisolone 25
prednisolone acetate 61
prednisolone sodium phosphate 25, 61
prednisone 25
pregabalin 50, 51
PREMARIN 59
PRENATAL VITAMIN PLUS LOW IRON 67
PREVALITE 15
PREVYMIS 9
PREZCOBIX 9
PREZISTA 9
primaquine 9
primidone 51
PRIORIX (PF) 31
PRIVIGEN 31
probenecid 56
probenecid-colchicine 56
prochlorperazine 29
prochlorperazine maleate 29
PROCRIT 31
PROCTO-MED HC 29
PROCTOSOL HC 29
PROCTOZONE-HC 29
PROGRAF 38
PROLASTIN-C 22
PROLIA 56
promethazine 64
propafenone 15, 16
propranolol 16
propylthiouracil 25
PROQUAD (PF) 31

PROSOL 20 % 67
protriptyline 51
PULMOZYME 64
pyrazinamide 9
pyridostigmine bromide 51
pyrimethamine 9
QINLOCK 38
QUADRACEL (PF) 31
quetiapine 51
quinapril 16
quinapril-hydrochlorothiazide 16
quinidine sulfate 16
quinine sulfate 9
QULIPTA 51
QVAR REDIHALER 64
RABAVERT (PF) 31
rabeprazole 29
RALDESY 51
raloxifene 56
ramelteon 51
ramipril 16
ranolazine 16
rasagiline 51
RECLIPSEN (28) 59
RECOMBIVAX HB (PF) 31
RECORLEV 25
RELENZA DISKHALER 10
RELGAABI 51
repaglinide 25
REPATHA SURECLICK 16
REPATHA SYRINGE 16
RESTASIS 61
RESTASIS MULTIDOSE 61
RETACRIT 31
RETEVMO 38
REVCOVI 22
REVUFORJ 38
REXULTI 51
REYATAZ 10
REZDIFFRA 22
REZENOPY 51
REZLIDHIA 38
RHOPRESSA 61
ribavirin 10
rifabutin 10
rifampin 10
rifapentine 10
rilpivirine hcl 10
riluzole 22
rimantadine 10
RINVOQ 56
RINVOQ LQ 56
risedronate 22, 56
risperidone 51
risperidone microspheres 51
ritonavir 10
rivastigmine 51
rivastigmine tartrate 51
RIVFLOZA 65
rizatriptan 52
ROCKLATAN 61
roflumilast 64
ROMVIMZA 38
ropinirole 52
rosuvastatin 16
ROTARIX 31
ROTATEQ VACCINE 31
ROWEEPRA 52
ROZLYTREK 38
RUBRACA 38
rufinamide 52
RUKOBIA 10
RYDAPT 38
RYTARY 52
sacubitril-valsartan 16
SAJAZIR 64
sapropterin 26
SCEMBLIX 38
scopolamine base 29
SECUADO 52
selegiline hcl 52
selenium sulfide 20
SEREVENT DISKUS 64
sertraline 52
SETLAKIN 59
sevelamer carbonate 22
SHINGRIX (PF) 31
SIGNIFOR 38
sildenafil (pulm.hypertension) 64
SILIQ 20
silodosin 65
silver sulfadiazine 20
SIMBRINZA 61
SIMLANDI(CF) 56
SIMLANDI(CF) AUTOINJECTOR 56
simvastatin 16
sirolimus 38
SIRTURO 10
sitagliptin 26
sitagliptin phos-metformin 26
sitagliptin phosphate 26
sitagliptin-metformin 26
SKYCLARYS 52
SKYRIZI 20, 29
sodium chloride 22
sodium chloride 0.45 % 67
sodium chloride 0.9 % 22
sodium chloride 3 % hypertonic 67
sodium chloride 5 % hypertonic 67
sodium oxybate 52
sodium phenylbutyrate 22
sodium polystyrene sulfonate 22
sodium,potassium,mag sulfates 29
sofosbuvir-velpatasvir 10
SOHONOS 22
solifenacin 65
SOLIQUA 100/33 26
SOLTAMOX 38
SOMAVERT 26
sorafenib 38
sotalol 16
SOTALOL AF 16
SPIRIVA RESPIMAT 64
spironolactone 16
spironolacton-hydrochlorothiaz 16
SPRINTEC (28) 59
SPRITAM 52
SPS (WITH SORBITOL) 22
SSD 20
STELARA 20
STEQEYMA 20
STIOLTO RESPIMAT 64
STIVARGA 38
streptomycin 10
STRIBILD 10
STRIVERDI RESPIMAT 64
SUBVENITE 52
sucralfate 29
sulfacetamide sodium 61
sulfacetamide sodium (acne) 20
sulfacetamide-prednisolone 61
sulfadiazine 10
sulfamethoxazole-trimethoprim 10
SULFAMYLON 20
sulfasalazine 29
sulindac 52
sumatriptan 52
sumatriptan succinate 52
sunitinib malate 38
SUNLENCA 10
SYEDA 59
SYMPAZAN 52
SYMTUZA 10
SYNAREL 26
SYNJARDY 26

SYNJARDY XR 26
SYNTHROID 26
TABLOID 38
TABRECTA 38
tacrolimus 20, 38
tadalafil 66
tadalafil (pulm. hypertension) 64
TAFINLAR 38
TAGRISSO 39
TALZENNA 39
tamoxifen 39
tamsulosin 66
TASCENSO ODT 52
tasimelteon 52
tazarotene 20
telmisartan 16
telmisartan-amlodipine 16
telmisartan-hydrochlorothiazid .. 16
TENIVAC (PF) 31
tenofovir disoproxil fumarate 10
TEPMETKO 39
terazosin 16
terbinafine hcl 10
terbutaline 64
terconazole 59
teriflunomide 52
teriparatide 56
testosterone 26
testosterone cypionate 26
testosterone enanthate 26
tetrabenazine 52, 53
tetracycline 10
TEZSPIRE 64
THALOMID 39
THEO-24 64
theophylline 64
thioridazine 53
thiothixene 53
TIADYLT ER 16
tiagabine 53
TIBSOVO 39
ticagrelor 16
TICOVAC 31
tigecycline 10
timolol maleate 16, 61
tinidazole 10
TIVICAY 10
TIVICAY PD 10
tizanidine 53
TOBI PODHALER 10
tobramycin 10, 61
tobramycin in 0.225 % nacl 10
tobramycin sulfate 10
tobramycin-dexamethasone 61
tofacitinib 56
tolterodine 66
tolvaptan 26
tolvaptan (polycys kidney dis) 26
topiramate 53
toremifene 39
torsemide 16
TOUJEO MAX U-300 SOLOSTAR 26
TOUJEO SOLOSTAR U-300 INSULIN 26
TRADJENTA 26
tramadol 53
tramadol-acetaminophen 53
trandolapril 16
tranexamic acid 59
tranylcypromine 53
TRAVASOL 10 % 67
travoprost 61
trazodone 53
TRELEGY ELLIPTA 64
TRELSTAR 39
tretinoin 20
tretinoin (antineoplastic) 39
triamcinolone acetonide . 20, 21, 55
triamterene-hydrochlorothiazid .. 16
TRIDERM 21
trientine 22
TRI-ESTARYLLA 59
trifluoperazine 53
trifluridine 61
TRIJARDY XR 27
TRIKAFTA 64
trimethoprim 10
TRI-MILI 59
trimipramine 53
TRINTELLIX 53
TRI-SPRINTEC (28) 59
TRIUMEQ 10
TRIUMEQ PD 10
TRI-VYLIBRA 59
TROPHAMINE 10 % 67
trospium 66
TRULICITY 27
TRUMENBA 31
TRUQAP 39
TUKYSA 39
TURALIO 39
TURQOZ (28) 59
TWINRIX (PF) 31
TYMLOS 56
TYPHIM VI 31
UBRELVY 53
UNITHROID 27
UPTRAVI 16
ursodiol 29
ustekinumab 21
valacyclovir 10
VALCHLOR 21
valganciclovir 10, 11
valproic acid 53
valproic acid (as sodium salt) 53
valsartan 16
valsartan-hydrochlorothiazide ... 17
VALTOCO 53
VALTYA 59
vancomycin 11
VANFLYTA 39
VAQTA (PF) 31
varenicline tartrate 22
VARIVAX (PF) 31
VAXCHORA VACCINE 31
VELIVET TRIPHASIC REGIMEN (28) 59
VEMLIDY 11
VENCLEXTA 39
VENCLEXTA STARTING PACK 39
venlafaxine 53
VENTOLIN HFA 64
verapamil 17
VERQUVO 17
VERSACLOZ 53
VERZENIO 39
VESTURA (28) 59
VIENVA 59
vigabatrin 53
VIGADRONE 53
VIJOICE 39
vilazodone 53
VIMKUNYA (PF) 31
VIORELE (28) 59
VIRACEPT 11
VIREAD 11
VITRAKVI 39
VIVITROL 53
VIVJOA 11
VIVOTIF 32
VONJO 39
VORANIGO 39, 40
voriconazole 11
VOSEVI 11

VOWST 29
VRAYLAR 53
VUMERITY 53
VYFEMLA (28) 59
VYLIBRA 60
warfarin 17
WELIREG 40
WINREVAIR 64
WIXELA INHUB 65
WYOST 40
XALKORI 40
XARELTO 17
XARELTO DVT-PE TREAT 30D START 17
XATMEP 40
XCOPRI 53
XCOPRI MAINTENANCE PACK 54
XCOPRI TITRATION PACK 54
XDEMVY 61
XELRIA FE 60
XERMELO 40
XGEVA 40
XIFAXAN 11
XIGDUO XR 27
XIIDRA 61
XOCOVA 11
XOFLUZA 11
XOLAIR 65
XOLREMDI 32
XOSPATA 40
XPOVIO 40
XTANDI 40
XTRENBO 40
XULTOPHY 100/3.6 27
YARGESA 27
YESINTEK 21
YF-VAX (PF) 32
YONSA 40
YORVIPATH 27
YUFLYMA(CF) 56
YUFLYMA(CF) AI CROHN'S-UC-HS 56
YUFLYMA(CF) AUTOINJECTOR 56
YULITHIRA 40
YUVAFEM 60
ZAFEMY 60
zaleplon 54
ZARXIO 32
ZAVZPRET 54
ZEJULA 40
ZELBORAF 40
ZELSUVMI 21
ZELVYSIA 27
ZENBEXUS 40
ZENPEP 29
ZEPOSIA 54
ZEPOSIA STARTER KIT (28-DAY) 54
ZEPOSIA STARTER PACK (7-DAY) 54
zidovudine 11
ZILBRYSQ 54
ziprasidone hcl 54
ziprasidone mesylate 54
ZIRGAN 62
ZOKINVY 22
ZOLINZA 40
zolpidem 54
ZONISADE 54
zonisamide 54
ZORYVE 21
ZOVIA 1-35 (28) 60
ZTALMY 54
ZUBSOLV 54
ZURZUVAE 54
ZYKADIA 40

Sección:
Autorización previa

Acitretin

Products Affected

- *acitretin*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Actimmune

Products Affected

- **ACTIMMUNE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ADHD Drugs

Products Affected

- *guanfacine oral tablet extended release 24 hr*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of ADHD -AND- trial/failure, intolerance or contraindication to a stimulant
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Afinitor

Products Affected

- *everolimus (antineoplastic) oral tablet*
- *everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg*
- **YULITHIRA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For everolimus only, documentation of advanced, hormone receptor-positive, HER2-negative breast cancer -AND- all of the following (1-3): 1) member is a postmenopausal woman 2) using in combination with exemestane 3) therapeutic failure or intolerance to prior treatment with letrozole or anastrozole. For everolimus only, documentation of non-functional neuroendocrine tumors -AND- all of the following (1-2): 1) disease is classified as progressive, well-differentiated, non-functional 2) disease is of gastrointestinal or lung origin that are unresectable, locally advanced or metastatic. For everolimus only, documentation of advanced renal cell carcinoma -AND- therapeutic failure or intolerance to prior treatment with sunitinib or sorafenib. For everolimus only, documentation of renal angiomyolipoma and tuberous sclerosis complex (TSC), member does not require immediate surgery. For everolimus and everolimus tablets for oral suspension, documentation of TSC with Subependymal Giant Cell Astrocytoma -AND- member is not a candidate for curative surgical resection. For everolimus only, documentation of progressive neuroendocrine tumors of pancreatic origin -AND- disease is unresectable, locally advanced or metastatic. For everolimus tablets for oral suspension only, documentation of use for adjunctive treatment of TSC-associated partial-onset seizures.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Aimovig

Products Affected

- **AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 140 MG/ML, 70 MG/ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For Episodic Migraine, defined as 4-14 migraine days per month OR Chronic Migraine, defined as 15 or more headaches per month, the following criteria will apply (1-2): 1) Documentation of average monthly migraine days. 2) Attestation that headaches are not caused by medication rebound or overutilization (e.g. not taking triptans exceeding more than 18 doses per month) or lifestyle factors (e.g. sleep patterns, caffeine use).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of reduction in migraine frequency
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Akeega

Products Affected

- **AKEEGA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. -AND- Concomitant therapy with prednisone. -AND- Concomitant therapy with a gonadotropin-releasing hormone analog or a bilateral orchiectomy, -AND- For metastatic castration-sensitive prostate cancer, disease harbors a deleterious or suspected deleterious BRCA2 mutation based on an FDA-approved test. -AND- For metastatic castration-resistant prostate cancer, BRCA mutations.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Alecensa

Products Affected

- **ALECENSA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive as detected by an FDA-approved test -AND- One of the following (1-2): 1) metastatic disease, 2) will be used as adjuvant treatment following tumor resection of node positive or greater than or equal to 4 cm tumor(s).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Alpha1-Proteinase Inhibitors

Products Affected

- **PROLASTIN-C INTRAVENOUS SOLUTION**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of panacinar emphysema AND documentation of a decline in forced expiratory volume in 1 second (fev1) despite medical therapy (bronchodilators, corticosteroids) AND documentation of phenotype (pi*zz, pi*znull or pi*nullnull) associated with causing serum alpha 1-antitrypsin of less than 80 mg/dl AND documentation of an alpha 1-antitrypsin serum level below the value of 35% of normal (less than 80 mg/dl).
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Covered under Part B when furnished incident to a physician service and is not self-administered.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Alunbrig

Products Affected

- **ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG**
- **ALUNBRIG ORAL TABLETS,DOSE PACK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive as detected by an FDA-approved test.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ampyra

Products Affected

- *dalfampridine*

PA Criteria	Criteria Details
Exclusion Criteria	History of seizure disorder, Cr Cl less than 50ml/min
Required Medical Information	Documentation of diagnosis -AND- documentation that the patient is ambulatory and has walking impairment as evidenced by one of the following. 1. Functional status score (EDSS score). 2. Timed 25-foot Walk Test (T25W).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, documentation supporting improvement in walking impairment from baseline is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Anticholinergic Meds

Products Affected

- *paroxetine hcl oral suspension*
- *paroxetine hcl oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- Attestation of counseling on risk-benefit profile and potential anticholinergic adverse effects -AND- Therapeutic failure, contraindication, or intolerance to 2 other antidepressants (i.e., SSRI, SNRI).
Age Restrictions	Automatic approval if less than 65 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Anzupgo

Products Affected

- **ANZUPGO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of chronic hand eczema (CHE) -AND- symptoms persisting for more than 3 months or recurring at least twice within a 12-month timeframe -AND- therapeutic failure, contraindication, or intolerance to 1 generic, on-formulary, medium/high/super-high potency topical corticosteroid.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Arikayce

Products Affected

- **ARIKAYCE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Mycobacterium avium complex lung disease -AND- Attestation of not achieving negative sputum cultures despite at least 6 months with a multidrug background regimen containing 2 of the following: 1) macrolide 2) rifamycin or 3) ethambutal -AND- Arikayce will be used in conjunction with a background multidrug regimen.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of positive sputum cultures -OR- negative sputum cultures for insufficient period of time (e.g. less than 12 months).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

ATTR-CM drugs

Products Affected

- **ATTRUBY**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitantly with transthyretin-lowering agents
Required Medical Information	Documentation of cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM) with amyloid deposits on cardiac biopsy or scintigraphy with heart contralateral greater than 1.5 (Grade III) or visual grade 2 to 3 - AND- Cardiac involvement supported by cardiac magnetic resonance, echocardiography or serum cardiac biomarker (e.g. B-type natriuretic peptide, cardiac troponin) -AND- ATTR-CM type is wild-type or variant
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	For reauthorization, attestation of improvement or delayed disease progression from baseline demonstrated by 6-minute walk test, cardiac function (e.g. LVEF, NYHA class), Kansas City Cardiomyopathy Questionnaire-Overall Summary, number of cardiovascular-related hospitalizations or serum cardiac biomarkers (e.g. B-type natriuretic peptide, cardiac troponin)
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Atypical Antipsychotics

Products Affected

- *aripiprazole oral solution*
- *aripiprazole oral tablet,disintegrating*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. If medication is being used for major depressive disorder, documentation of adjunctive therapy and therapeutic failure, contraindication or intolerance to one other generic antidepressant in addition to the antidepressant currently being used for the treatment of MDD (e.g. SSRI, SNRI, NDRIs, TCA, MAOI).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Aubagio

Products Affected

- *teriflunomide*

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other disease modifying agents such as fingolimod, interferons, Copaxone, Tysabri
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Augtyro

Products Affected

- **AUGTYRO ORAL CAPSULE 160 MG, 40 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ROS1-positive. Documentation of solid tumors -AND- disease harbors a NTRK gene fusion -AND- one of the following (1-2): 1) disease is locally advanced or metastatic, or 2) surgical resection is likely to result in severe morbidity -AND- one of the following (3-4): 3) disease has progressed following treatment, or 4) the member has no satisfactory alternative therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Austedo

Products Affected

- **AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG**
- **AUSTEDO XR**
- **AUSTEDO XR TITRATION KT(WK1-4)**
- **ORAL TABLET, EXT REL 24HR DOSE PACK 12-18-24-30 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of all of the following (1-3) 1) Chorea associated with Huntington's disease 2) In patients with comorbid depression, attestation of adequate treatment for depression is required. 3) Attestation that patient is not actively suicidal. -OR- 4) Tardive Dyskinesia
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Auvelity

Products Affected

- **AUVELITY ORAL TABLET, IR AND ER, BIPHASIC**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of major depressive disorder (MDD) -AND- Therapeutic failure or intolerance to generic bupropion hydrochloride tablets -AND- Therapeutic failure, intolerance or contraindication to one other generic antidepressant (e.g. SNRI, SSRI). Documentation of Alzheimer's disease (AD) -AND- Experiencing agitation associated with dementia due to AD.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Avmapki-Fakzynja

Products Affected

- **AVMAPKI-FAKZYNJA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For recurrent low-grade serous ovarian cancer (LGSOC), disease is KRAS-mutated -AND- member has received at least one prior systemic therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ayvakit

Products Affected

- **AYVAKIT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of unresectable or metastatic gastrointestinal stromal tumor -AND- tumors harbor a PDGFRA exon 18 mutation. Documentation of agressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, mast cell leukemia, or indolent systemic mastocytosis -AND- platelet count greater than or equal to 50 x 10*9/L.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Bafiertam

Products Affected

- **BAFIERTAM**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other disease modifying agents such as interferons, Copaxone, Tysabri, Aubagio, Gilenya
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) -AND- Therapeutic failure or intolerance to generic dimethyl fumarate
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Balversa

Products Affected

- **BALVERSA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following: 1) FGFR3 mutation status as detected by an FDA approved test 2) disease progression on or after at least on prior line of systemic therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Banzel

Products Affected

- *rufinamide*

PA Criteria	Criteria Details
Exclusion Criteria	Patients with familial short QT syndrome
Required Medical Information	Documentation of seizures due to Lennox-Gastaut Syndrome -AND- documentation of adjunctive therapy -AND- therapeutic failure or intolerance of a previous antiepileptic therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Benlysta

Products Affected

- **BENLYSTA SUBCUTANEOUS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For diagnosis of active systemic lupus erythematosus (SLE), both of the following (1-2): 1) Documentation of positive anti-nuclear antibody (ANA) titer (greater than or equal to 1:80) or anti-double-stranded DNA antibody (anti-dsDNA) greater than or equal to 30IU/mL, 2) member will continue to receive concomitant standard of care treatment with use of at least one of the following (alone or in combination) (a-c): a) corticosteroids (e.g. prednisone), b) antimalarials (e.g. hydroxychloroquine), c) immunosuppressants (e.g. azathioprine, mycophenolate mofetil, or methotrexate). For diagnosis of active lupus nephritis (LN), one of the following (3 or 4): 3) Diagnosis confirmed by renal biopsy, 4) Contraindication to renal biopsy, laboratory findings specific to LN (e.g., elevated serum creatinine, abnormal urine analysis, decreased eGFR). -AND- Member will continue to receive concomitant standard of care treatment which includes corticosteroids (e.g. prednisone) with at least one of the following (d or e): d) mycophenolate for induction followed by mycophenolate for maintenance, e) cyclophosphamide for induction followed by azathioprine for maintenance.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	For SLE reauthorization, attestation of disease stability or improvement -AND- attestation the member will continue to receive standard of care therapy with corticosteroids, antimalarials, or immunosuppressives. For active LN reauthorization, attestation of disease stability or improvement -AND- attestation the member will continue to receive standard of care therapy with mycophenolate or azathioprine. For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens per indication.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Besremi

Products Affected

- **BESREMI**
- **BESREMI PEN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of polycythemia vera
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Bosulif

Products Affected

- **BOSULIF ORAL CAPSULE 100 MG, 50 MG**
- **BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For members 18 years of age and older, one of the following (1, 2): 1) newly diagnosed Philadelphia chromosome (PH) -positive CML in the chronic phase 2) diagnosis of Ph-positive CML in the chronic, accelerated, or blast phase and no longer responding to or intolerant to at least 1 prior therapy. For pediatric patients 1 year of age and older, one of the following (3, 4): 3) newly diagnosed PH-positive CML in the chronic phase 4) diagnosis of Ph-positive CML in the chronic phase and no longer responding to or intolerant to at least 1 prior therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For capsules and 18 years of age or older, intolerance to generic bosutinib tablets or inability to swallow tablets is required. For tablets and 18 years of age or older, intolerance to generic bosutinib tablets is required. For Bosutinib 100mg capsules and pediatric 1 year of age or older, inability to swallow tablets is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Bosutinib

Products Affected

- *bosutinib oral tablet 400 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For members 18 years of age and older, one of the following (1, 2): 1) newly diagnosed Philadelphia chromosome (PH) -positive CML in the chronic phase 2) diagnosis of Ph-positive CML in the chronic, accelerated, or blast phase and no longer responding to or intolerant to at least 1 prior therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Braftovi

Products Affected

- **BRAFTOVI**

PA Criteria	Criteria Details
Exclusion Criteria	Use in wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC.
Required Medical Information	Documentation of diagnosis. For metastatic colorectal cancer (mCRC) and using in combination with cetuximab, all of the following (1-3): 1) BRAF V600E mutation status as detected by an FDA-authorized test 2) using in combination with cetuximab 3) member has received prior therapy for CRC. For mCRC and using in combination with cetuximab and fluorouracil-based chemotherapy, all of the following (4-5): 4) BRAF V600E mutation status, as detected by an FDA-authorized test 5) using in combination with cetuximab and fluorouracil-based chemotherapy. For unresectable or metastatic melanoma, all of the following (6-7): 6) BRAF V600E or V600K mutation status, as detected by an FDA-authorized test 7) using in combination with binimetinib. For metastatic non-small cell lung cancer, all of the following (8-9): 8) BRAF V600E mutation status, as detected by an FDA-authorized test 9) using in combination with binimetinib.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Brinsupri

Products Affected

- **BRINSUPRI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of non-cystic fibrosis bronchiectasis (NCFB) confirmed by computed tomography (CT) -AND- at least 1 of the following symptoms consistent with bronchiectasis (1-8): 1) cough on most days of the week, 2) chronic sputum production, 3) history of recurrent respiratory infections, 4) dyspnea, 5) wheezing, 6) rhinosinusitis, 7) hemoptysis, 8) recurrent pleurisy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Brukinsa

Products Affected

- **BRUKINSA ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For mantle cell lymphoma (MCL), previous treatment with at least 1 prior therapy. For marginal zone lymphoma (MZL), previous treatment with at least 1 anti-CD20-based regimen. For follicular lymphoma (FL), using in combination with obinutuzumab and previous treatment with at least 2 prior lines of systemic therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Buphenyl

Products Affected

- *sodium phenylbutyrate*

PA Criteria	Criteria Details
Exclusion Criteria	Treatment of acute hyperammonemia in urea cycle disorders
Required Medical Information	Documentation of chronic management of urea cycle disorders involving deficiencies of carbamylphosphate synthetase, argininosuccinic acid synthetase, or ornithine transcarbamylase.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Cabometyx

Products Affected

- **CABOMETYX**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- one of the following (1-6): 1) diagnosis of advanced renal cell carcinoma (RCC), 2) diagnosis of advanced RCC and using as a first-line treatment in combination with nivolumab, 3) member has previously been treated with sorafenib for hepatocellular carcinoma, 4) member has experienced disease progression following prior VEGFR-targeted therapy and is either radioactive iodine-refractory or is ineligible for radioactive iodine therapy for locally advanced or metastatic differentiated thyroid cancer, 5) diagnosis of previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET), 6) diagnosis of previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic neuroendocrine tumors (epNET)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Calquence

Products Affected

- **CALQUENCE (ACALABRUTINIB MAL)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For mantle cell lymphoma, member has received at least one prior therapy -OR- all of the following (1-3): 1) member has not received prior therapy for MCL, 2) member is ineligible for autologous hematopoietic stem cell transplantation (HSCT), and 3) using in combination with bendamustine and rituximab.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Caplyta

Products Affected

- **CAPLYTA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For schizophrenia, bipolar I disorder, and bipolar II disorder, therapeutic failure, intolerance, or contraindication to one other generic atypical antipsychotic (e.g. quetiapine). For major depressive disorder, documentation of adjunctive therapy and therapeutic failure, contraindication or intolerance to one other generic antidepressant in addition to the antidepressant currently being used for the treatment of MDD (e.g. SSRI, SNRI, NDRIs, TCA, MAOI).
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Caprelsa

Products Affected

- **CAPRELSA ORAL TABLET 100 MG, 300 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Carbaglu

Products Affected

- *carglumic acid*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of use as an adjunct therapy for acute hyperammonemia due to hepatic enzyme N-acetylglutamate synthase (NAGS) deficiency, propionic acidemia (PA), or methylmalonic acidemia (MMA) -OR- maintenance therapy for chronic hyperammonemia due to hepatic enzyme N-acetylglutamate synthase (NAGS) deficiency
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Cayston

Products Affected

- **CAYSTON**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of cystic fibrosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of decrease in sputum density of pseudomonas aeruginosa, increase in FEV1 or decrease in number of hospitalizations or pulmonary exacerbations
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Cerdelga

Products Affected

- **CERDELGA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of type 1 Gaucher disease confirmed by the following A. or B. A) With one of the following symptoms (1, 2, 3, 4, or, 5): 1)Hepatomegaly. 2)Splenomegaly. 3)Bone disease (i.e. osteonecrosis, osteopenia, secondary pathologic fractures, bone infarct). 4)Bone marrow complications as defined by anemia with hemoglobin less than or equal to 11.5 g/dL for females or 12.5 g/dL for males or thrombocytopenia with platelet count less than or equal to 120,000/mm*3. 5)Symptomatic disease (e.g. bone pain, exertional limitation, cachexia). -OR- B) Attestation of deficiency in glucocerebrosidase activity in peripheral leukocytes or genetic testing confirms mutant alleles -AND- Documentation of CYP2D6 metabolizer status (e.g. intermediate metabolizer).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

CF drugs

Products Affected

- **TOBI PODHALER**
- *tobramycin in 0.225 % nacl*
- *tobramycin inhalation*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of cystic fibrosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Inhalation solutions covered under Part B when administered in the home setting using a covered nebulizer (i.e. DME). For reauthorization of tobramycin products, attestation of decrease in sputum density of pseudomonas aeruginosa, increase in FEV1 or decrease in number of hospitalizations or pulmonary exacerbations.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Cialis

Products Affected

- *tadalafil oral tablet 2.5 mg, 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of benign prostatic hyperplasia (BPH) and trial/failure of at least two alternative medications in the following classes (alpha-1 adrenergic blockers and/or 5-alpha reductase inhibitors)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Cinryze

Products Affected

- **CINRYZE**

PA Criteria	Criteria Details
Exclusion Criteria	Member should not be on two prophylactic therapies simultaneously.
Required Medical Information	For the prophylactic treatment of abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) due to deficiency of C1INH (type I & II) with the following (1-3): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. For the prophylactic treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) with normal C1INH (type III) with the following (4-7): 4) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 5) Documentation of family history of HAE, FXII mutation, angiopoietin-1 mutation, plasminogen mutation, kininogen-1 mutation, myoferlin mutation, or heparin sulfate-glucosamine 3-O-sulfotransferas 6 mutation. 6) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 7) Medications known to cause angioedema have been evaluated and discontinued.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Cobenfy

Products Affected

- **COBENFY**
- **COBENFY STARTER PACK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- therapeutic failure, intolerance, or contraindication to one other generic atypical antipsychotic (e.g. quetiapine).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Cometriq

Products Affected

- **COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1), 140 MG/DAY(80 MG X1-20 MG X3), 60 MG/DAY (20 MG X 3/DAY)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of progressive, metastatic medullary thyroid cancer
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Copiktra

Products Affected

- **COPIKTRA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- member is no longer responding or is intolerant to at least 2 prior therapies for chronic lymphocytic leukemia and small lymphocytic leukemia.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Corlanor

Products Affected

- *ivabradine oral tablet 5 mg, 7.5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- All of the following: 1) Normal sinus rhythm, 2) Resting heart rate greater than or equal to 70 beats per minute, 3) For adults, left ventricular ejection fraction less than or equal to 35 percent, 4) For adults, concurrent use of 1 beta-blocker used for treatment of heart failure (i.e. bisoprolol, carvedilol, metoprolol succinate) or therapeutic failure, intolerance, or contraindication to the maximum tolerated dose of 2 beta-blockers used for treatment of heart failure.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Cosentyx

Products Affected

- **COSENTYX (2 SYRINGES)**
- **COSENTYX PEN (2 PENS)**
- **COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML**
- **COSENTYX UNOREADY PEN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID) or all are contraindicated. For non-radiographic axial spondyloarthritis, inadequate response or intolerance to 2 NSAIDs or all are contraindicated.
Age Restrictions	Deny if less than 6 years of age for moderate to severe plaque psoriasis -OR- less than 2 years of age for psoriatic arthritis -OR- less than 4 years of age for enthesitis-related arthritis -OR- less than 12 years of age for hidradenitis suppurativa and ankylosing spondylitis -OR- less than 18 years of age for non-radiographic axial spondyloarthritis
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens per indication. For hidradenitis suppurativa, doses above plan quantity limit will be approved to align with recommended dosing regimen.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

Cotellic

Products Affected

- **COTELLIC**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following for unresectable or metastatic melanoma (1-2): 1) BRAF V600E or V600K mutation status 2) Concomitant therapy with vemurafenib. For cobimetinib monotherapy, documentation of histiocytic neoplasms.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Cysteamine Ophthalmic Drops

Products Affected

- **CYSTARAN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cystinosis -AND- Attestation of accumulation of corneal cystine crystals
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Danziten

Products Affected

- **DANZITEN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For Ph+ chronic myeloid leukemia (CML), member's CML is in the chronic or accelerated phase and the member is no longer responding to or is intolerant to imatinib -OR- member is newly diagnosed in the chronic phase.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Daraprim

Products Affected

- *pyrimethamine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For primary prophylaxis of toxoplasmosis gondii infection, CD4 count less than 100 cells/mm*3 -AND- Toxoplasma IgG positive -AND- failure, intolerance or contraindication to trimethoprim-sulfamethoxazole. For secondary prophylaxis of toxoplasmosis gondii infection, CD4 count less than 200 cells/mm*3. For secondary prophylaxis of cystoisosporiasis with CD4 count less than 200 cells/mm*3 or acute cystoisosporiasis infection: failure, intolerance or contraindication to trimethoprim-sulfamethoxazole. For primary prophylaxis of Pneumocystis jirovecii pneumonia: diagnosis of HIV -AND- CD4 count less than 200 cells/mm*3 -AND- failure, intolerance or contraindication to trimethoprim-sulfamethoxazole.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Daurismo

Products Affected

- **DAURISMO ORAL TABLET 100 MG, 25 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of newly diagnosed Acute Myeloid Leukemia -AND- Used in combination with cytarabine -AND- At least one comorbidity that preclude use of intensive induction chemotherapy defined as one of the following: 1) Age greater than or equal to 75 2) Severe cardiac or pulmonary comorbidity 3) Reduced renal function 4) Hepatic impairment 5.) Physician attests patient is not a candidate for intensive induction therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Deferasirox

Products Affected

- *deferasirox oral tablet, dispersible*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For chronic iron overload due to blood transfusions, transfusion history of greater than or equal to 100 mL/kg of packed red blood cells (i.e. at least 20 units of packed red blood cells for a 40 kg person or more in individuals weighing more than 40 kg) -And- history of serum ferritin consistently greater than 1,000 mcg/L or liver iron concentration (LIC) greater than or equal to 7 iron per gram of liver dry weight (mg Fe/g dw). For Chronic Iron Overload in Non-Transfusion-Dependent Thalassemia (NTDT) Syndrome, LIC of at least 5 mg Fe/g dw -AND- serum ferritin greater than 300 mcg/L.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization of chronic iron overload due to blood transfusion, continued requirement for regular blood transfusions -AND- serum ferritin level greater than or equal to 500mcg/L or LIC greater than or equal to 3 mg Fe/g dw. For reauthorization of chronic iron overload in NTDT syndrome, LIC greater than or equal to 3 mg Fe/g dw.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

Diacomit

Products Affected

- **DIACOMIT ORAL CAPSULE 250 MG, 500 MG**
- **DIACOMIT ORAL POWDER IN PACKET 250 MG, 500 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Dravets syndrome - AND- Used in combination with clobazam
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation supporting reduction in seizure frequency
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Dihydroergotamine

Products Affected

- *dihydroergotamine nasal*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of acute migraine headaches with or without aura -AND- requires non-oral route of administration -AND- therapeutic failure or intolerance to generic sumatriptan nasal spray.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Drizalma

Products Affected

- **DRIZALMA SPRINKLE ORAL**
  CAPSULE, DELAYED REL SPRINKLE
  20 MG, 30 MG, 40 MG, 60 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- inability to swallow tablets/capsules. For fibromyalgia, members must also have widespread bilateral pain above and below the waist for greater than 3 months duration -AND- At least 1 fibromyalgia-related symptom (e.g., cognitive impairment, fatigue, sleep disturbance, neurologic symptoms, exercise intolerance).
Age Restrictions	Deny if less than 18 years of age in the treatment of fibromyalgia, major depressive disorder, diabetic peripheral neuropathy and chronic musculoskeletal pain -OR- if less than 7 years of age in generalized anxiety disorder
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Dupixent

Products Affected

- **DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML**
- **DUPIXENT SYRINGE**
- **SUBCUTANEOUS SYRINGE 200 MG/1.14 ML, 300 MG/2 ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Mod/Sev atopic dermatitis (AD): failure/intolerance to 1 topical corticosteroid (TCS) or, if 2+ yrs, topical calcineurin inhibitor (e.g. tacrolimus, etc) OR, if sev AD, topical tx are precluded d/t body surface area involvement or severely damaged skin. TCS in combo w/Dupixent for mod/sev AD is permitted & allows coverage. Mod/sev asthma: hx of 2+ exacerbations req oral/inj corticosteroids in past 12mos or 1+ exacerbation req hospitalization in past 12mos AND blood eosinophils of at least 150cells/uL or current daily/alternate-day oral corticosteroid (OCS) AND inadequate control despite regular med/high-dose inhaled corticosteroids (ICS) & 1 or more add'l asthma controller (e.g. LABA, leukotriene receptor antagonist [LTRA], theophylline) +/- OCS, unless intolerant or contraindicated (c/i) to all AND will continue med/high dose ICS & 1 or more add'l asthma controller +/- OCS. Chronic rhinosinusitis w/ nasal polyposis (CRSwNP): failure, intolerance, or c/i to intranasal corticosteroid. Eosinophilic esophagitis: esophageal eosinophils of 15eos/hpf or higher on esophageal biopsy AND clinical esophageal dysfxn symptoms. Prurigo nodularis. COPD: blood eosinophils of at least 300cells/uL or current daily/alternate-day OCS AND inadequate control despite 3+ mos of regular LAMA, LABA, & ICS tx, unless intolerant or c/i to all. Chronic Spontaneous Urticaria: failure, intolerance, or c/i to 1 2nd-gen H1 antihistamine at max rec dose (e.g. cetirizine, etc). Bullous pemphigoid: failure, intolerance, or c/i on high/super high potency TCS or OCS. Allergic fungal rhinosinusitis: hx of sinonasal surgery AND diagnosis confirmed by at least 2 of the following: Type 1 hypersensitivity to fungus (history, in vitro IgE, or skin testing), positive fungal stain from surgical sinus contents, presence of eosinophilic mucin w/o sinus tissue invasion, presence of CRSwNP, or characteristic CT signs
Age Restrictions	
Prescriber Restrictions	

PA Criteria	Criteria Details
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For atopic dermatitis reauthorization, attestation of positive clinical response to therapy. For asthma reauthorization, attestation of one of the following is required (1-4): 1) decreased rescue medication or oral corticosteroid use, 2) decreased frequency of severe asthma exacerbations, 3) increased pulmonary function from baseline (e.g. FEV1), or 4) reduction in reported asthma related symptoms. For CRSwNP reauthorization, attestation of decrease in nasal polyp score or reduction in nasal congestion/obstruction severity score. For EoE reauthorization, attestation of histological remission (less than 15 eos/hpf) on esophageal biopsy or reduced severity or frequency of clinical symptoms of esophageal dysfunction. For prurigo nodularis reauthorization, attestation of reduction in itch or number of nodules or lesions from baseline. For COPD reauthorization, attestation of one of the following is required (1-4): 1) reduction in COPD symptoms, 2) improvement in exercise tolerance, 3) delayed disease progression, or 4) reduction in the number of COPD exacerbations. For CSU reauthorization, improved CSU symptoms. For BP reauthorization, 1 of the following is required (1-4): 1) attestation of disease control, 2) reduction in number of relapses, 3) improvement in BP symptoms, or 4) reduction in oral corticosteroid use. For allergic fungal rhinosinusitis reauthorization, attestation of decrease in nasal polyp score or reduction in nasal congestion/obstruction severity score.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Duvyzat

Products Affected

- **DUVYZAT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Duchenne muscular dystrophy with pathogenic mutation in the dystrophin gene.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

EGFR Tyrosine Kinase Inhibitors

Products Affected

- *erlotinib*
- **GILOTRIF**

PA Criteria	Criteria Details
Exclusion Criteria	Afatinib products: tumors with resistant EGFR mutations. Erlotinib products: use in NSCLC tumors with mutations other than those in FDA-approved indications. Use in combination with platinum based chemotherapy.
Required Medical Information	For afatinib, documentation of metastatic non-small cell lung cancer (NSCLC) -AND- one of the following, as detected by an FDA-approved test (1-3): 1) disease harbors EGFR exon 19 deletions 2) disease harbors EGFR exon 21 (L858R) substitution mutation 3) disease harbors non-resistant EGFR mutation (i.e., S768I, L861Q, G719X) -OR- documentation of squamous metastatic NSCLC and member has experienced progression on platinum-based chemotherapy. For erlotinib, documentation of metastatic NSCLC -AND- one of the following, as detected by an FDA-approved test (1-2): 1) disease harbors EGFR exon 19 deletions 2) disease harbors EGFR exon 21 (L858R) substitution mutations -OR- documentation of locally advanced, unresectable or metastatic pancreatic cancer -AND- all of the following (1-2): 1) using erlotinib as first-line therapy 2) using in combination with gemcitabine.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Emgality

Products Affected

- **EMGALITY PEN**
- **EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML, 300 MG/3 ML (100 MG/ML X 3)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For Episodic Migraine, defined as 4-14 migraine days per month OR Chronic Migraine, defined as 15 or more headaches per month, the following criteria will apply (1-2). 1) Documentation of average monthly migraine days. 2) Attestation that headaches are not caused by medication rebound or overutilization (e.g. not taking triptans exceeding more than 18 doses per month) or lifestyle factors (e.g. sleep patterns, caffeine use). For episodic cluster headaches, characterized by severe or very severe unilateral orbital, supraorbital, and/or temporal pain lasting 15 to 180 minutes when left untreated -AND- Attack frequency of at least one attack every other day during the cluster period.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For reauthorization of episodic migraine prevention, attestation of reduction in migraine frequency is required. For reauthorization of cluster headache, attestation of reduction in the number of mean weekly cluster headaches from baseline is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Ensacove

Products Affected

- **ENSACOVE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For locally advanced or metastatic non-small cell lung cancer (NSCLC) -AND- Disease is ALK-positive, as detected by an FDA-approved test -AND- Not previously received an ALK inhibitor.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Entresto Sprinkle

Products Affected

- **ENTRESTO SPRINKLE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of symptomatic heart failure with left ventricular systolic dysfunction -AND- weight less than 40kg, or weight greater than or equal to 40kg and less than 50kg and one of the following (1 or 2): 1) therapeutic failure or intolerance to Entresto (sacubitril/valsartan) tablets, or 2) inability to swallow tablets.
Age Restrictions	Deny if greater than 17 years old
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, all of the following are required (1-3): 1) attestation of positive clinical response to therapy, 2) member is younger than 18 years of age, 3) weight less than 40kg, or weight greater than or equal to 40kg and less than 50kg and one of the following (4 or 5): 5) intolerance to Entresto (sacubitril/valsartan) tablets, or 5) inability to swallow tablets.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Eohilia

Products Affected

- **EOHILIA**

PA Criteria	Criteria Details
Exclusion Criteria	Treatment duration greater than 12 weeks
Required Medical Information	Diagnosis of eosinophilic esophagitis -AND- esophageal eosinophil count greater than or equal to 15 eos/hpf on esophageal biopsy -AND- clinical symptoms of esophageal dysfunction (e.g., dysphagia, food impaction, gastroesophageal reflux)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 weeks
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Epclusa

Products Affected

- *sofosbuvir-velpatasvir*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guidance. For Brand Epclusa, the member has a contraindication to or is otherwise not a candidate for one of the following regimens recommended by the AASLD/IDSA guidelines containing the following agents: sofosbuvir/velpatasvir (i.e. Epclusa authorized generic), Mavyret.
Age Restrictions	Deny if less than 3 years of age
Prescriber Restrictions	
Coverage Duration	Criteria/duration applied consistent with current AASLD-IDSA guidance
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Epidiolex

Products Affected

- **EPIDIOLEX**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Lennox-Gastaut, Dravet syndromes or Tuberous Sclerosis Complex. For Lennox-Gastaut, trial and failure or intolerance of at least two standard of care treatments (e.g. lamotrigine, clobazam). For Lennox-Gastaut and Dravet syndromes, treatment is in combination with other conventional agents.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Eprontia

Products Affected

- *topiramate oral solution*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- inability to swallow pills or food. For migraine, therapeutic failure, intolerance, or contraindication to two generic preventive migraine therapies. For partial onset seizures, primary generalized tonic-clonic seizures, or adjunctive treatment of Lennox-Gastaut Syndrome, therapeutic failure, contraindication, or intolerance to two generic anti-epileptic drugs.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ergotamine

Products Affected

- *ergotamine-caffeine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of use to abort a vascular headache -AND- therapeutic failure, intolerance, or contraindication to a generic triptan -OR- documentation of use to prevent a vascular headache -AND- therapeutic failure, intolerance, or contraindication to generic prophylactic migraine medication (e.g., topiramate, propanolol, timolol).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Erivedge

Products Affected

- **ERIVEDGE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- if disease is locally advanced all of the following: 1) disease has recurred following surgery, or is not a candidate for surgery, 2) is not a candidate for radiation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Erleada

Products Affected

- **ERLEADA ORAL TABLET 240 MG, 60 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- the member meets one of the following (1 or 2) 1. Documentation of use in combination with a GnRH analog -OR- 2. The member has had a bilateral orchiectomy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Escitalopram Capsule

Products Affected

- *escitalopram oxalate oral capsule*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of major depressive disorder or generalized anxiety -AND- Therapy has been initiated with escitalopram 10mg or member has been receiving and is experiencing unfavorable tolerability to escitalopram 20mg -AND- Intolerance to generic escitalopram tablets -AND- Therapeutic failure, intolerance or contraindication to at least one other antidepressant (e.g., SSRI, TCA, MAOI).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Etanercept

Products Affected

- **ENBREL MINI**
- **ENBREL SUBCUTANEOUS SOLUTION**
- **ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5), 50 MG/ML (1 ML)**
- **ENBREL SURECLICK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). For polyarticular juvenile idiopathic arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy.
Age Restrictions	Deny if less than 18 years of age for Rheumatoid Arthritis and Ankylosing Spondylitis or less than 2 years of age for Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis or Less than 4 years of age for Plaque Psoriasis
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	Therapeutic failure or intolerance to 1 of the following preferred adalimumab products is required, when being utilized for the same medically accepted indication and age: Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606. For plaque psoriasis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen.
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Exxua

Products Affected

- **EXXUA ORAL TABLET EXTENDED RELEASE 24 HR**
- **EXXUA ORAL TABLET, EXT REL 24HR DOSE PACK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of major depressive disorder (MDD) -AND- Therapeutic failure or intolerance to generic bupropion hydrochloride tablets -AND- Therapeutic failure, intolerance or contraindication to one other generic antidepressant (e.g. SNRI, SSRI).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Fabhalta

Products Affected

- **FABHALTA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For paroxysmal nocturnal hemoglobinuria (PNH), meets one of the following (1 or 2): 1) PNH mutant clones confirmed by flow cytometry, or 2) glycosylphosphatidylinositol-anchored proteins (GPI-AP)-deficient polymorphonuclear cells (PMNs) confirmed by flow cytometry -AND- meets one of the following (3-6): 3) anemia secondary to PNH (e.g. hemoglobin less than 10.5 g/dL with symptoms of anemia), 4) elevated lactate dehydrogenase (LDH) greater than or equal to 1.5 times the upper limit of normal, 5) history of a thromboembolic event, or 6) clinical findings of systemic complications (e.g. fatigue, hemoglobinuria, abdominal pain, dyspnea, dysphagia, erectile dysfunction, history of blood cell transfusion due to PNH) -AND- will not be used in combination with another complement inhibitor for PNH (e.g. Soliris (eculizumab), Ultomiris (ravulizumab), Empaveli (pegcetacoplan)) unless initially cross-titrating. For diagnosis of primary immunoglobulin A nephrology (IgAN) confirmed by biopsy, member is at risk for rapid disease progression evidenced by one of the following (7 or 8): 7) Urine protein-to-creatinine ratio (UPCR) greater than or equal to 1.5 g/g or 8) Proteinuria greater than or equal to 1 g/day -AND- has experienced therapeutic failure, contraindication, or intolerance to a maximally tolerated dose of one of the following (a or b): a) Angiotensin converting enzyme (ACE) inhibitor, b) Angiotensin receptor blocker (ARB) -AND- experienced therapeutic failure, contraindication, or intolerance to one of the following (c or d): c) Filspari (sparsentan) or d) Tarpeyo (budesonide). For Complement 3 Glomerulopathy (C3G) confirmed by biopsy, meets all of the following (13-14): 13) UPCR greater than or equal to 1.0 g/g, 14) currently therapy of the member should be on the maximally tolerated dose of one of the following (e or f): e) ACE-inhibitor, f) ARB.
Age Restrictions	

PA Criteria	Criteria Details
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization of PNH, attestation of positive clinical response defined as one of the following (1-3): 1) hemoglobin stabilization or increase from baseline, 2) decrease in transfusions from baseline, or 3) decrease in LDH levels from baseline or reduction of hemolysis -AND- will not be used in combination with another complement inhibitor for PNH (e.g. Soliris (eculizumab), Ultomiris (ravulizumab), Empaveli (pegcetacoplan)). For reauthorization of IgAN, reduction in urine protein-to-creatinine ratio (UPCR) or proteinuria from baseline. For reauthorization of C3G, reduction in UPCR from baseline.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Fanapt

Products Affected

- **FANAPT**
- **FANAPT TITRATION PACK A**
- **FANAPT TITRATION PACK B**
- **FANAPT TITRATION PACK C**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis - AND - trial and failure of one of the following: olanzapine, quetiapine, or risperidone.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Fasenra

Products Affected

- **FASENRA PEN**
- **FASENRA SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 30 MG/ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of severe asthma and all of the following (1-4): 1) history of at least 2 asthma exacerbations requiring oral or injectable corticosteroid treatment in past 12 mos or at least 1 asthma exacerbation requiring hospitalization in past 12 mos 2) blood eosinophils greater than or equal to 150cells/uL within the past 6 weeks or greater than or equal to 300cells/uL within the past 12 mos in without other potential causes of eosinophilia (e.g. hypereosinophilic syndromes, neoplastic disease, known suspected parasitic infection) 3) inadequate symptom control despite regular treatment with medium or high dose inhaled corticosteroid (ICS) and at least 1 add'l asthma controller medication (e.g. long-acting beta2-agonist [LABA], leukotriene receptor antagonist [LTRA], theophylline), with or without oral corticosteroids (OCS), unless intolerant or contraindicated to all 4) will continue treatment with medium or high dose ICS and at least 1 add'l asthma controller medication, with or without OCS -OR- Documentation of eosinophilic granulomatosis with polyangiitis (EGPA) and all of the following (5-6): 5) history of relapsing or refractory disease 6) will be receiving standard of care while on Fasenra therapy with glucocorticoid treatment (e.g. prednisone or prednisolone), with or without immunosuppressive therapy (e.g. cyclosporine, leflunomide, azathioprine). Documentation of Hypereosinophilic syndrome (HES) and all of the following (7-8): 7) no identifiable non-hematologic secondary cause, 8) Treatment with HES therapy (chronic or episodic OCS, immunosuppressive or cytotoxic therapy) for at least 4wks, unless therapeutic failure, intolerant, or contraindicated to all.
Age Restrictions	
Prescriber Restrictions	

PA Criteria	Criteria Details
Coverage Duration	12 months
Other Criteria	For induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For severe asthma reauthorization, attestation of one of the following is required (1-4): 1) decreased rescue medication or oral corticosteroid use, 2) decreased frequency of severe asthma exacerbation, 3) increased pulmonary function from baseline (e.g. FEV1), or 4) reduction in reported asthma related symptoms. For EPGA reauthorization, attestation of one of the following is required (5-8): 5) reduction in the frequency and/or severity of relapses, 6) reduction or discontinuation of doses of corticosteroids and/or immunosuppressant, 7) disease remission, or 8) reduction in severity or frequency of EGPA-related symptoms. For HES reauthorization, 1 of the following is required (9-11): 9) reduction in frequency of HES flares, 10) maintenance or reduction in background HES therapy requirements, 11) reduction in or stabilization of eosinophil-mediated organ damage (e.g., cardiac, pulmonary, gastrointestinal, or neurological manifestations).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Fecal Microbiota Products

Products Affected

- **VOWST**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of a recent diagnosis of Clostridioides difficile infection (CDI) confirmed by a positive stool test -AND- Classified as recurrent (e.g., at least 2 CDI episodes) -AND- Will be used for prophylaxis and not treatment of recurrent CDI -AND- Attestation that antibiotic treatment for the most recent recurrent CDI is complete or will be completed.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 month
Other Criteria	For reauthorization, attestation of recurrent CDI episodes after administration of the initial fecal microbiota product -AND- Will be used for prophylaxis and not treatment of recurrent CDI -AND- Attestation that antibiotic treatment for the most recent recurrent CDI is complete or will be completed.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Fetzima

Products Affected

- **FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK 20 MG (2)- 40 MG (26)**
- **FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 20 MG, 40 MG, 80 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of major depressive disorder and trial and failure of two other generic antidepressants.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Filsuvez

Products Affected

- **FILSUVEZ**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of dystrophic epidermolysis bullosa (DEB) or junctional epidermolysis bullosa (JEB) -AND- at least one open wound.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of improvement in targeted wound(s) -AND- member requires additional courses of treatment.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Fintepla

Products Affected

- **FINTEPLA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Dravet syndrome or Lennox-Gastaut syndrome. For Lennox-Gastaut syndrome, therapeutic failure, contraindication, or intolerance to at least 2 standard of care treatments (e.g. lamotrigine, clobazam).
Age Restrictions	Deny if less than 2 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Firazyr

Products Affected

- *icatibant*
- **SAJAZIR**

PA Criteria	Criteria Details
Exclusion Criteria	Member should not be on two acute therapies simultaneously and acute therapy should not be used as prophylactic therapy
Required Medical Information	For the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) due to deficiency of C1INH (type I & II) with the following (1-3): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. For the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) with normal C1INH (type III) with the following (4-7): 4) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 5) Documentation of family history of HAE, FXII mutation, angiopoietin-1 mutation, plasminogen mutation, kininogen-1 mutation, myoferlin mutation, or heparin sulfate-glucosamine 3-O-sulfotransferas 6 mutation. 6) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 7) Medications known to cause angioedema have been evaluated and discontinued.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Firmagon

Products Affected

- **FIRMAGON KIT W DILUENT SYRINGE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of advanced prostate cancer.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Forteo

Products Affected

- *teriparatide subcutaneous pen injector 20 mcg/dose (560mcg/2.24ml)*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- at high risk for fracture, meeting one of the following (1. thru 4.) 1) History of previous hip or vertebral fracture. 2) T-score less than or equal to -2.5. 3) T-score between -1.0 and -2.5 -AND- meets FRAX calculation (A. or B.) A) 10-year risk of major osteoporotic fracture is greater than or equal to 20 percent or B) 10-year risk of hip fracture is greater than or equal to 3 percent. 4) Age 40 years or older with T-score between -1.0 and -2.5 -AND- History of glucocorticoid use for at least 3 months at a dose of 5mg per day or more of prednisone (or equivalent).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 months
Other Criteria	Documentation of trial/failure or intolerance to at least one oral bisphosphonate or all are contraindicated. Coverage of human parathyroid hormone related peptide analogs beyond 24 months will not be approved. A cumulative lifetime approval of teriparatide will be limited to a coverage duration of 24 months in the absence of provider attestation that the member remains at or has returned to having a high risk for fracture
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Fotivda

Products Affected

- **FOTIVDA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- member has received at least two prior systemic therapies.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Fruzaqla

Products Affected

- **FRUZAQLA ORAL CAPSULE 1 MG, 5 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- member has received previous threatment with a fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy -AND- member has received previous treatment with an anti-VEGF therapy -AND- one of the following, if member is RAS wild-type (1-2): 1) member has received previous therapy with an anti-EGFR therapy 2) prescriber attests that treatment with an anti-EGFR therapy would not be medically appropriate.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Gattex

Products Affected

- **GATTEX 30-VIAL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of short bowel syndrome (SBS) having less than 200 cm of functional small bowel -AND- Dependence on parenteral/intravenous nutrition -AND- weight of at least 10 kg.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of increase in weight from baseline or decrease in intravenous parenteral nutrition requirements from baseline -AND- 1 of the following (1-2): 1) continued dependence on parenteral nutrition/intravenous nutritional support, 2) not receiving parenteral nutrition/intravenous support and experienced therapeutic failure upon trial of discontinuation of parenteral nutrition/intravenous support.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Gavreto

Products Affected

- **GAVRETO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For metastatic non-small cell lung cancer, disease is RET fusion-positive as detected by an FDA approved test. For advanced or metastatic thyroid cancer, all of the following (1-2): 1) disease is RET fusion-positive 2) if radioactive iodine is appropriate, the member is radioactive iodine-refractory.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Gilenya

Products Affected

- *fingolimod*

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other disease modifying agents such as teriflunomide, interferons, Copaxone, Tysabri
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Glatiramer

Products Affected

- **COPAXONE SUBCUTANEOUS SYRINGE 20 MG/ML, 40 MG/ML**
- *glatiramer subcutaneous syringe 20 mg/ml, 40 mg/ml*
- **GLATOPA SUBCUTANEOUS SYRINGE 20 MG/ML, 40 MG/ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Gleevec

Products Affected

- *imatinib oral tablet 100 mg, 400 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Ph+ chronic myeloid leukemia -AND- one of the following: 1) member is newly diagnosed in chronic phase 2) member is in blast crisis, the accelerated phase or the chronic phase after failure of interferon-alpha therapy. Documentation of Ph+ acute lymphocytic leukemia -AND- one of the following: 1) for adults, member has relapsed or refractory disease 2) for pediatric patients, member is newly diagnosed and will be using imatinib in combination with a chemotherapy regimen. Documentation of adult agressive systemic mastocytosis -AND- one of the following: 1) documentation that the member does not have D816V c-KIT status 2) member's c-KIT status is unknown. For gastrointestinal stromal tumors (GIST) one of the following: 1) member has diagnosis of KIT (CD117)-positive unresectable and/or metastatic malignant GIST 2) imatinib will be used as adjuvent treatment following resection of KIT (CD117)-positive GIST. Documentation of unresectable, recurrent or metastatic dermatofibrosarcoma protuberans. Documentation of Hypereosinophilic Syndrome/Chronic Eosinophilic Leukemia. Documentation of myeloproliferative disease -AND- disease is associated with PDGFR gene rearrangements. Documentation of myelodysplastic syndrome -AND- disease is associated with PDGFR gene rearrangements.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Gleostine

Products Affected

- *lomustine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of primary or metastatic brain tumor(s) -AND- member has previously received surgical and/or radiotherapeutic procedure(s). Documentation of Hodgkin's lymphoma -AND- all of the following (1-2): 1) using lomustine in combination with other chemotherapies 2) member has experienced disease progression with initial chemotherapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

GLP1

Products Affected

- *liraglutide*
- **MOUNJARO**
- **OZEMPIC SUBCUTANEOUS**
- **TRULICITY**

PA Criteria	Criteria Details
Exclusion Criteria	Obesity or use for weight loss
Required Medical Information	Documentation of diabetes mellitus type 2
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Gomekli

Products Affected

- **GOMEKLI ORAL CAPSULE 1 MG, 2 MG**
- **GOMEKLI ORAL TABLET FOR SUSPENSION**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of neurofibromatosis type 1 (NF1) -AND- presence of symptomatic plexiform neurofibromas (PN) not amenable to complete resection.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Growth Hormone

Products Affected

- **NORDITROPIN FLEXPRO SUBCUTANEOUS PEN INJECTOR 10 MG/1.5 ML (6.7 MG/ML), 15 MG/1.5 ML (10 MG/ML), 5 MG/1.5 ML (3.3 MG/ML)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis, growth chart, member has open epiphyses, growth velocity, response to stimulation test, when applicable to meet standard diagnostic criteria. Additionally for growth failure due to chronic kidney disease, glomerular filtration rate is less than 89ml/min per 1.73m*2. For HIV wasting and cachexia, Concurrent use of antiretroviral therapy -AND- weight loss from baseline of at least 10% in the past 12 months or at least 5% in the past 6 months. For short bowel syndrome, receiving management for short bowel syndrome, including specialized nutritional support -AND- less than 200 cm of functional small bowel.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of growth velocity and member has open epiphyses, as applicable to meet standard continuation of therapy guidelines. For reauthorization of HIV wasting and cachexia, attestation of increase in weight from start of therapy. For reauthorization of short bowel syndrome, continued dependence on parenteral nutrition/intravenous nutritional support -AND- attestation of increase in weight from baseline or decrease in intravenous parenteral nutrition requirements from baseline.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

Hepcludex

Products Affected

- **HEPCLUDEX**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of chronic hepatitis delta virus (HDV) and all of the following (1-3): 1) diagnosis supported by detectable serum HDV RNA and positive serum anti-HDV antibodies, 2) attestation that HDV infection is classified as chronic, 3) liver status of no cirrhosis or compensated cirrhosis, 4) attestation that the chronic HBV infection will be managed as clinically appropriate per the FDA-approved labeling.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, all of the following are required (1-3): 1) liver status of no cirrhosis or compensated cirrhosis, 2) attestation that the chronic HBV infection continues to be managed as clinically appropriate per the FDA-approved labeling, 3) attestation that response to treatment warrants continued therapy.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Hernexeos

Products Affected

- **HERNEXEOS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For non-squamous non-small cell lung cancer (NSCLC), all of the following (1-2): 1) disease is unresectable or metastatic, 2) disease harbors HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

High-risk meds

Products Affected

- *amitriptyline*
- *benztropine oral*
- *clomipramine*
- *cyproheptadine oral tablet*
- *doxepin oral capsule*
- *doxepin oral concentrate*
- *doxepin oral tablet*
- *hydroxyzine hcl oral tablet*
- *imipramine hcl*
- *promethazine oral tablet*
- *trimipramine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For all medications subject to this PA group, the following information (1 through 3) is required: 1. Documentation of diagnosis 2. Explanation of risk-benefit profile favoring use of the high-risk medication 3. Attestation of an intent to monitor and address treatment-related adverse events. For target tricyclic antidepressants (TCAs), in addition to criteria 1 through 3 above, trial and failure or documentation of intolerance or contraindication to at least 2 non-high risk alternative drugs for the same indication, if available, is required (e.g. SSRIs and SNRIs). If using a TCA for a medically-accepted indication not shared by the safer alternatives listed, then no trial of alternatives is required.
Age Restrictions	Automatic approval if less than 65 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Doxepin doses less than or equal to 6 mg per day will receive automatic approval.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

High-risk meds phenobarbital

Products Affected

- *phenobarbital*

PA Criteria	Criteria Details
Exclusion Criteria	Coverage is not provided for use in sedation/insomnia
Required Medical Information	For use in seizures the following are required: 1. Explanation of risk-benefit profile favoring use of the high-risk medication 2. Attestation of an intent to monitor and address treatment-related adverse events. 3. For new starts, the trial and failure or documentation of intolerance or contraindication to at least 2 non-high risk alternative drugs used for seizures (e.g. carbamazepine, lamotrigine) is required.
Age Restrictions	Automatic approval if less than 65 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	Seizure disorders
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Hyrnuo

Products Affected

- **HYRNUO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For non-squamous non-small cell lung cancer (NSCLC), all of the following (1-2): 1) disease is locally advanced or metastatic, 2) disease harbors HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-approved test.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ibrance

Products Affected

- **IBRANCE ORAL CAPSULE 125 MG**
- **IBRANCE ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of HR-positive, HER2-negative advanced or metastatic breast cancer -AND- meets one of the following (1. or 2.): 1) documentation of use with an aromatase inhibitor as initial endocrine-based therapy -OR- 2) documentation of use with fulvestrant in patients with disease progression following endocrine therapy. Documentation of endocrine-resistant, locally advanced or metastatic breast cancer -AND- all of the following (3-6): 3) disease is HR-positive, HER2-negative 4) disease is PIK3CA-mutated, as detected by an FDA-authorized test 5) the member is using in combination with inavolisib and fulvestrant 6) the member has experienced recurrence on or after completing adjuvant endocrine therapy. Documentation of locally advanced or metastatic breast cancer -AND- all of the following (7-9): 7) disease is HR-positive, HER2-positive, 8) will be used following induction treatment, 9) will be used in combination with trastuzumab (with or without pertuzumab) and endocrine therapy as maintenance treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Ibtrozi

Products Affected

- **IBTROZI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ROS1-positive.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Iclusig

Products Affected

- **ICLUSIG**

PA Criteria	Criteria Details
Exclusion Criteria	Treatment of newly-diagnosed chronic phase CML
Required Medical Information	Documentation of T3151+ chronic myeloid leukemia (CML) -OR- documentation of chronic phase CML and member has experienced resistance or intolerance to at least two prior kinase inhibitors -OR- documentation of accelerated phase or blast phase CML and no other kinase inhibitor is indicated -OR- member is using Iclusig as monotherapy and meets one of the following (1-2): 1) documentation of T3151+ acute lymphoblastic leukemia (ALL) 2) documentation of Ph+ ALL and no other tyrosine kinase inhibitor therapy is indicated -OR- member has newly diagnosed Ph+ ALL and is using Iclusig in combination with chemotherapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Idhifa

Products Affected

- **IDHIFA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA approved test
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

IG

Products Affected

- **GAMMAGARD LIQUID**
- **GAMMAGARD LIQUID ERC**
- **GAMMAGARD S-D (IGA**
- **PRIVIGEN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For select diagnoses the following apply 1) For Myasthenia Gravis Syndrome, documentation that the patient is refractory to at least one other standard therapy (e.g., cholinesterase inhibitors, corticosteroids, azathioprine) given in therapeutic doses over at least 3 months OR is intolerant/contraindication to those standard therapies. 2) For Multiple Sclerosis, patient is refractory to at least one other standard therapy (e.g., interferons) given in therapeutic doses over at least 3 months OR is intolerant/contraindication to those standard therapies. 3) For B-cell CLL, associated with recurrent bacterial infections OR with Associated Hypogammaglobulinemia defined as IgG level less than 600mg/dL or evidence of a specific antibody deficiency. 4) For Bone Marrow Transplantation, the member is 20 years of age or older and within the first 100 days after transplantation. 5) For Dermatomyositis/Polymyositis, trial and failure, intolerance, or contraindication to at least one standard first line therapy (i.e. corticosteroids or immunosuppressants). 6) For Pediatric HIV, the patient is less than 13 y.o. who have entry CD4 lymphocyte count greater than or equal to 200/mcl and IgG less than 400mg/dL OR recurrent bacterial infections. 7) For Guillain-Barre syndrome, impaired function by objective assessment and/or objective findings on physical exam at the time of initial therapy and IVIG therapy must be initiated within 2 weeks of symptom onset. 8) For Autoimmune Mucocutaneous Blistering Diseases (e.g. Stevens-Johnson Syndrome), trial and failure, intolerance, or contraindication to at least one conventional therapy (e.g. corticosteroids) or the patient has rapidly progressive disease in which a clinical response could not be affected quickly enough using conventional agents.
Age Restrictions	
Prescriber Restrictions	

PA Criteria	Criteria Details
Coverage Duration	12 months
Other Criteria	Covered under Part B when administered in the home to a member with a diagnosis of primary immunodeficiency disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	Myasthenia Gravis syndrome, Multiple Sclerosis, Polymyositis, Bone Marrow Transplant, Pediatric HIV, Guillain-Barre syndrome, Autoimmune Mucocutaneous Blistering Diseases
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Imbruvica

Products Affected

- **IMBRUVICA ORAL CAPSULE 140 MG, 70 MG**
- **IMBRUVICA ORAL SUSPENSION**
- **IMBRUVICA ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For chronic graft versus host disease, previous treatment with at least 1 prior systemic therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For suspension, inability to swallow oral tablets or oral capsules is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Imkeldi

Products Affected

- **IMKELDI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Ph+ chronic myeloid leukemia -AND- one of the following: 1) member is newly diagnosed in chronic phase 2) member is in blast crisis, the accelerated phase or the chronic phase after failure of interferon-alpha therapy. Documentation of Ph+ acute lymphocytic leukemia -AND- one of the following: 1) for adults, member has relapsed or refractory disease 2) for pediatric patients, member is newly diagnosed and will be using imatinib in combination with a chemotherapy regimen. Documentation of adult agressive systemic mastocytosis -AND- one of the following: 1) documentation that the member does not have D816V c-KIT status 2) member's c-KIT status is unknown. For gastrointestinal stromal tumors (GIST) one of the following: 1) member has diagnosis of KIT (CD117)-positive unresectable and/or metastatic malignant GIST 2) imatinib will be used as adjuvent treatment following resection of KIT (CD117)-positive GIST. Documentation of unresectable, recurrent or metastatic dermatofibrosarcoma protuberans. Documentation of Hypereosinophilic Syndrome/Chronic Eosinophilic Leukemia. Documentation of myeloproliferative disease -AND- disease is associated with PDGFR gene rearrangements. Documentation of myelodysplastic syndrome -AND- disease is associated with PDGFR gene rearrangements.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Documentation of an inability to swallow oral tablets is required.
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Increlex

Products Affected

- **INCRELEX**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of severe primary IGF-1 deficiency and all of the following: 1) Normal or elevated response (greater than 10 ng/ml) to two (2) of the following standard growth hormone stimulation tests: arginine, clonidine, glucagon, insulin, levodopa, propranolol. 2) Serum IGF-1 concentration that is less than or equal to three (3) standard deviations below the normal value based on laboratory reference range. 3) Height less than or equal to three (3) standard deviations below normal (at or below the third percentile for gender and age). 4) Member has open epiphyses. -OR- Documentation of diagnosis of growth hormone deficiency caused by gene deletion and all of the following: 1) Growth velocity at least 2 standard deviations below the age-appropriate mean or height at least 2.25 standard deviations below the age-appropriate mean. 2) Subnormal response (less than 10 ng/mL) to two (2) of the following standard growth hormone stimulation tests: arginine, clonidine, glucagon, insulin, levodopa, propranolol. 3) Development of neutralizing antibodies to growth hormone product(s). 4) Member has open epiphyses
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For pediatric patients, reauthorization requires open epiphyses.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

Ingrezza

Products Affected

- **INGREZZA INITIATION PK(TARDIV)**
- **INGREZZA ORAL CAPSULE 40 MG, 60 MG, 80 MG**
- **INGREZZA SPRINKLE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of tardive dyskinesia -OR- documentation of chorea associated with Huntington's disease.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Inluriyo

Products Affected

- **INLURIYO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following (1-3): 1) disease is ER-positive, HER2-negative, 2) disease harbors an ESR1 mutation, as detected by an FDA-approved test, 3) member has experienced disease progression following at least one line of endocrine therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Inlyta

Products Affected

- **INLYTA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of advanced renal cell carcinoma -AND- one of the following (1-2): 1) if using axitinib as first line therapy, member is using axitinib in combination with avelumab or pembrolizumab 2) if using axitinib as a single-agent, member has been treated with at least one prior systemic therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Inqovi

Products Affected

- **INQOVI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For myelodysplastic syndrome, one of the following is required (1-2): 1) French American-British MDS subtypes of refractory anemia, refractory anemia with ringed sideroblasts or refractory anemia with excess blasts, 2) International Prognostic Scoring System group of intermediate-1, intermediate-2 or high-risk. For newly-diagnosed acute myeloid leukemia, use in combination with venetoclax -AND- one of the following is required (3-4): 3) age greater than or equal to 75 years of age, 2) 1 or more comorbidity that precludes the use of intensive induction chemotherapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Inrebic

Products Affected

- **INREBIC**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of intermediate-2 or high-risk myelofibrosis per an accepted risk stratification tool for myelofibrosis (e.g., International Prognostic Scoring System [IPSS]) -AND- If a new start, baseline platelet count of greater than or equal to 50x10*9/L
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Baseline platelet count to be provided.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Insulin Supplies

Products Affected

- **ALCOHOL PADS**
- **GAUZE PAD TOPICAL BANDAGE 2 X 2 "**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation the product is being used for the delivery of insulin into the body.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Interferon Alfa

Products Affected

- **PEGASYS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Interferon Beta

Products Affected

- **AVONEX INTRAMUSCULAR PEN INJECTOR KIT**
- **AVONEX INTRAMUSCULAR SYRINGE KIT**
- **BETASERON SUBCUTANEOUS KIT**
- **PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML**
- **PLEGRIDY SUBCUTANEOUS**

SYRINGE 125 MCG/0.5 ML

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

IPF Agents

Products Affected

- *nintedanib*
- *pirfenidone oral capsule*
- *pirfenidone oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of idiopathic pulmonary fibrosis -AND- baseline forced vital capacity (FVC) of at least 50% and a percent predicted diffusing capacity of the lungs of carbon monoxide (DLCO) of at least 30%. For nintedanib only, documentation of systemic sclerosis-associated interstitial lung disease -AND- baseline forced vital capacity (FVC) of at least 40% and a percent predicted diffusing capacity of the lungs of carbon monoxide (DLCO) of at least 30% -AND- documentation of a chest computed tomography (CT) scan demonstrating greater than or equal to 10% pulmonary fibrosis. For nintedanib only, documentation of chronic fibrosing interstitial lung disease with progressive phenotype -AND- chest computing tomography (CT) scan demonstrating greater than 10% fibrosing disease -AND- baseline forced vital capacity (FVC) of at least 45% and a percent predicted diffusing capacity of the lungs of carbon monoxide (DLCO) of at least 30% -AND- disease progression in previous 24 months shown by one of the following : 1. Relative decline in FVC greater than or equal to 10% predicted 2. Relative decline in FVC greater than or equal to 5% but less than 10% predicted and either worsening of respiratory symptoms or increased extent of fibrotic changes on CT 3. Worsening of respiratory symptoms and increasing extent of fibrotic changes on CT
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Iressa

Products Affected

- *gefitinib*

PA Criteria	Criteria Details
Exclusion Criteria	Use in tumors with EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.
Required Medical Information	Documentation of diagnosis -AND- the following: 1) EGFR exon 19 deletion mutations or exon 21 (L858R) mutations as detected by an FDA-approved test
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Itovebi

Products Affected

- **ITOVEBI ORAL TABLET 3 MG, 9 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of endocrine-resistant, locally advanced or metastatic breast cancer -AND- all of the following (1-4): 1) disease is HR-positive, HER2-negative 2) disease is PIK3CA-mutated, as detected by an FDA-approved test 3) the member is using in combination with palbociclib and fulvestrant 4) the member has experienced recurrence on or after completing adjuvant endocrine therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Itraconazole

Products Affected

- *itraconazole oral capsule*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. If using for diagnosis of onychomycosis, confirmation through positive laboratory testing (e.g. KOH preparation, fungal culture, or nail biopsy) is required.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Onychomycosis: 3 months. All other indications: 3 months initial, 12 months reauth
Other Criteria	Documentation of trial/failure or intolerance of amphotericin b must be provided for approval in patients with aspergillosis.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ivermectin Oral

Products Affected

- *ivermectin oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of strongyloidiasis of the intestinal tract (non-disseminated disease) or onchocerciasis -AND- Member weighs greater than or equal to 15kg.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Iwilfin

Products Affected

- **IWILFIN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of high-risk neuroblastoma (HRNB) -AND- partial response to anti-glycolipid disialoganglioside (GD2) immunotherapy (e.g., dinutuximab, naxitamab).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Jakafi

Products Affected

- **JAKAFI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of intermediate or high-risk myelofibrosis per an accepted risk stratification tool for myelofibrosis (e.g., International Prognostic Scoring System [IPSS]) and if a new start, baseline platelet count of greater than or equal to 50x10*9/L -OR- documentation of polycythemia vera and inadequate response or intolerance to hydroxyurea -OR- Documentation of steroid refractory acute graft-versus-host disease and prior therapy with at least one systemic corticosteroid -OR- Documentation of chronic graft-versus-host disease with prior failure of at least one systemic therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Baseline platelet count to be provided.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Jascayd

Products Affected

- **JASCAYD**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of idiopathic pulmonary fibrosis -AND- baseline forced vital capacity (FVC) of at least 45% -AND- a percent predicted diffusing capacity of the lungs of carbon monoxide (DLCO) of at least 25% -AND- 1 of the following (1-3): 1) Concomitant use of a stable dose of Esbriet (pirfenidone) or Ofev (nintedanib). For concomitant Esbriet (pirfenidone) therapy, Jascayd dose will remain 18 mg orally twice daily. 2) Receiving Jascayd as monotherapy and intolerance to Esbriet (pirfenidone) and Ofev (nintedanib), 3) Receiving Jascayd as monotherapy and contraindication to Esbriet (pirfenidone) and Ofev (nintedanib). Diagnosis of progressive pulmonary fibrosis (PPF) -AND- documentation of a chest computed tomography (CT) scan demonstrating at least 10% pulmonary fibrosis -AND- a baseline FVC of at least 45% -AND- a percent predicted DLCO of at least 25% -AND- at least 2 of the following (4-6): 4) Worsening of respiratory symptoms 5) Physiological evidence of disease progression defined as 1 of the following (a or b): a) Decline in FVC of at least 5% (relative from baseline). b) Decline in percent predicted DLCO of at least 10% (relative from baseline). 6) Radiological evidence of disease progression defined as increased extent of fibrotic changes on imaging (e.g., chest computed tomography scan) -AND- One of the following (7-9): 7) Concomitant use of a stable dose of Ofev (nintedanib), 8) Treatment naive to antifibrotic treatment, or 9) Previously discontinued Ofev (nintedanib) with no plans to initiate or resume background PPF treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Jaypirca

Products Affected

- **JAYPIRCA ORAL TABLET 100 MG, 50 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For relapsed or refractory mantle cell lymphoma, member has received at least two (2) previous lines of systemic therapy, at least one (1) of which was a BTK inhibitor. For relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, member has previously been treated with a covalent BTK inhibitor.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Jideytro

Products Affected

- **JIDEYTRO ORAL TABLET 100 MG, 25 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ROS1-positive and member has received a prior ROS1 kinase inhibitor.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Joenja

Products Affected

- **JOENJA ORAL TABLET 70 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of activated phosphoinositide 3-kinase delta syndrome (APDS) with genetic confirmation of variant in PIK3CD or PIK3R1 gene.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Jynarque

Products Affected

- *tolvaptan (polycys kidney dis) oral tablet*
- *tolvaptan (polycys kidney dis) oral tablets, sequential*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of rapidly progressing autosomal dominant polycystic kidney disease defined by one of the following: 1.) Historical decline in eGFR greater than or equal to 3mL/min/1.73 m*2 within a 12 month period, or 2.) Mayo imaging classification of 1C, 1D, or 1E.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, prescriber attestation of slowed decline of kidney function
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Kalydeco

Products Affected

- **KALYDECO ORAL GRANULES IN PACKET 13.4 MG, 25 MG, 5.8 MG, 50 MG, 75 MG**
- **KALYDECO ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cystic fibrosis (CF) in patients who have one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR gene) that is responsive to ivacaftor based on clinical and or in vitro assay (e.g. G551D, G1244E, G1349D)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Kerendia

Products Affected

- **KERENDIA**

PA Criteria	Criteria Details
Exclusion Criteria	eGFR less than 25 mL/min/1.73 m*2, serum potassium greater than 5.5 mEq/L
Required Medical Information	Documentation of type 2 diabetes mellitus with chronic kidney disease (T2DM+CKD) or heart failure (HF) with left ventricular ejection fraction (LVEF) of greater than or equal to 40% -AND- one of the following (1. 2. or 3.): 1) concomitant use of a sodium-glucose Cotransporter-2 (SGLT2) inhibitor 2) therapeutic failure to at least one SGLT2 inhibitor or 3) contraindication or intolerance to at least one SGLT2 inhibitor.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation that signs or symptoms of hyperkalemia are not present.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Kesimpta

Products Affected

- **KESIMPTA PEN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Kineret

Products Affected

- **KINERET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For Deficiency of Interleukin-1 Receptor Antagonist (DIRA), therapeutic failure or intolerance to at least one (1) corticosteroid, or all corticosteroids are contraindicated.
Age Restrictions	Deny if less than 18 years of age for Rheumatoid Arthritis
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	For rheumatoid arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Rinvoq and Xeljanz/Xeljanz XR. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Kisqali

Products Affected

- **KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1), 400 MG/DAY (200 MG X 2), 600 MG/DAY (200 MG X 3)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- disease is classified as HR-positive, HER2-negative -AND- one of the following (1-3): 1) member is using ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy 2) member is using ribociclib in combination with fulvestrant and member is using fulvestrant as initial endocrine-based therapy or member has experienced disease progression on endocrine therapy. 3) disease is classified as stage II or stage III early breast cancer at high risk of recurrence, ribociclib is being used in combination with an aromatase inhibitor as adjuvant treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Komzifti

Products Affected

- **KOMZIFTI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For relapsed or refractory acute myeloid leukemia, the member has a susceptible NPM1 mutation -AND- the member has no satisfactory alternative treatment options.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Korlym

Products Affected

- *mifepristone oral tablet 300 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of endogenous Cushing's syndrome -AND- Patient is not a candidate for surgery or where surgery has failed -AND- one of the following (1 or 2): 1) Diagnosis of diabetes, 2) Glucose intolerance
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Koselugo

Products Affected

- **KOSELUGO ORAL CAPSULE 10 MG, 25 MG**
- **KOSELUGO ORAL CAPSULE, SPRINKLE 5 MG, 7.5 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- for neurofibromatosis type 1 (NF1), documentation of symptomatic, inoperable plexiform neurofibromas (PN)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For Koselugo granules, 1 of the following is required (1-2): 1) inability to swallow oral capsules, 2) body surface area of less than 0.55 m*2
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Krazati

Products Affected

- **KRAZATI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of non-small cell lung cancer -AND- disease is KRAS G12C-mutated as determined by an FDA approved test -AND- member has received at least one prior systemic therapy -AND- using as a single agent.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Kuvan

Products Affected

- **JAVYGTOR**
- *sapropterin*
- **ZELVYSIA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documented diagnosis of PKU -AND- documented baseline Phe level greater than 6 mg/dL -AND- clinical documentation of current weight -AND- sapropterin dihydrochloride dose does not exceed 20 mg/kg/day
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, initial therapy has resulted in decrease in phenylalanine levels from baseline or current phenylalanine levels within the range of 120-360 micromol/L -AND- clinical documentation of current weight is required -AND- sapropterin dihydrochloride dose does not exceed 20 mg/kg/day.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Kygevvi

Products Affected

- **KYGEVVI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of Thymidine Kinase 2 Deficiency (TK2d) -AND- Pathogenic mutation in TK2 gene, as confirmed by genetic testing -AND- symptom onset on or before 12 years of age
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Latuda

Products Affected

- *lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg, 80 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. If medication is being used for bipolar 1 disorder, documentation of trial and failure or intolerance to one other formulary medication indicated in bipolar 1 disorder (e.g. quetiapine)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lazcluze

Products Affected

- **LAZCLUZE ORAL TABLET 240 MG, 80 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of non-small cell lung cancer (NSCLC) -AND- all of the following (1-4): 1) disease harbors EGFR exon 19 deletions or EGFR exon 21 (L858R) substitution mutation, as detected by an FDA-approved test 2) disease is locally advanced or metastatic, 3) member is treatment naive for advanced disease, 4) using in combination with amivantinib.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Lenvima

Products Affected

- **LENVIMA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of differentiated thyroid cancer -AND- meets all of the following (1-3): 1) disease is locally recurrent or metastatic 2) disease is progressive 3) disease is radioactive iodine refractory. Documentation of advanced renal cell carcinoma -AND- one of the following (4-5): 4) member is using lenvatinib in combination with pembrolizumab and is using lenvatinib and pembrolizumab as first-line treatment 5) member is using lenvatinib in combination with everolimus and has experienced therapeutic failure or intolerance to one prior anti-angiogenic therapy. Documentation of unresectable hepatocellular carcinoma -AND- member is using lenvatinib as first-line treatment. Documentation of endometrial cancer -AND- meets all of the following (6-10): 6) member is using lenvatinib in combination with pembrolizumab 7) disease is advanced 8) disease is not classified as microsatellite instability-high or disease is classified as mismatch repair proficient as determined by an FDA-approved test 9) member has experienced disease progression following prior systemic therapy 10) member is not a candidate for curative surgery or radiation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Leukine

Products Affected

- **LEUKINE INJECTION RECON SOLN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis: following induction chemotherapy in patients who are 55 years or older with acute myelogenous leukemia (AML) -OR- mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis and autologous transplantation -OR- acceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantation -OR- acceleration of myeloid reconstitution following allogeneic BMT -OR- treatment of delayed neutrophil recovery or graft failure after autologous or allogeneic BMT -OR- following acute exposure to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Lidoderm

Products Affected

- *lidocaine topical adhesive patch,medicated 5 %*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of postherpetic neuralgia (PHN) or diabetic peripheral neuropathy (DPN) -AND- One of the following (1-3): 1) trial and failure of 1 other agent used to treat diagnosis (e.g. gabapentin for PHN, duloxetine for DPN), 2) inability to swallow oral medication, 3) unable to take an oral medication due to potential adverse events (e.g. sedation).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	Diabetic peripheral neuropathy
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lifyorli

Products Affected

- **LIFYORLI ORAL CAPSULE 125 MG/DAY(100 MG X1-25MG X1), 125 MG/DAY(100 MG X1-25MG X3), 125 MG/DAY(100 MG X1-25MG X9), 150 MG/DAY(100 MG X1-25MG X2), 150 MG/DAY(100 MG X1-25MG X3), 150 MG/DAY(100 MG X1-25MG X9)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For epithelial ovarian, fallopian tube, or primary peritoneal cancer, all of the following (1-3): 1) disease is platinum-resistant, 2) member has received 1-3 prior systemic treatment regimens, at least 1 of which included bevacizumab, 3) using in combination with nab-paclitaxel.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Litfulo

Products Affected

- **LITFULO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For severe alopecia areata, therapeutic failure/intolerance to an intralesional corticosteroid or high potency topical corticosteroid, or contraindication to all.
Age Restrictions	Deny if less than 12 years of age
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Livtencity

Products Affected

- **LIVTENCITY**

PA Criteria	Criteria Details
Exclusion Criteria	Diagnosis of CMV prophylaxis.
Required Medical Information	Documentation of refractory cytomegalovirus infection or disease as evidenced by antigenemia or polymerase chain reaction (PCR) test -AND- all of the following (1-3): 1) member weighs at least 35 kg, 2) member is a recipient of hematopoietic stem cell transplant -OR- solid organ transplant. 3) member has experienced therapeutic failure to one of the following: ganciclovir, valganciclovir, cidofovir, or foscarnet.
Age Restrictions	Deny if less than 12 years of age
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	For reauthorization, attestation of a previous reduction in CMV DNA level -AND- documentation of one of the following (1-3): 1) new onset symptomatic CMV infection, 2) virologic relapse with treatment-emergent maribavir resistance or 3) continued antiviral treatment is required to achieve virologic clearance.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Loargys

Products Affected

- **LOARGYS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of Arginase 1 Deficiency (ARG1-D) -AND- Used in conjunction with dietary protein restriction -AND- Diagnosis is confirmed by 1 of the following (1-3): 1) genetic testing, 2) newborn screening, or 3) elevated arginine levels in plasma.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lokelma

Products Affected

- **LOKELMA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of hyperkalemia as defined by serum potassium level between 5.1 and 7.4 mmol/L on at least two (2) screenings -AND- Modification of medications to reduce serum potassium levels were not successful, when applicable
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of reduction in serum potassium levels following Lokelma administration and continued treatment for hyperkalemia is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Lonsurf

Products Affected

- **LONSURF**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of metastatic colorectal cancer as a single agent or in combination with bevacizumab in patients who have previously been treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and if RAS wild-type, an anti-EGFR therapy -OR- documentation of metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lorbrena

Products Affected

- **LORBRENA ORAL TABLET 100 MG, 25 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of ALK-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Lotronex

Products Affected

- *alosetron oral tablet 0.5 mg, 1 mg*

PA Criteria	Criteria Details
Exclusion Criteria	For irritable bowel syndrome (IBS): Exclude if male gender
Required Medical Information	Documentation of chronic severe diarrhea-predominant IBS -AND- trial and failure or intolerance to one anti-diarrheal (e.g. loperamide), anti-spasmodic, or tricyclic antidepressant, or contraindication to all
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 weeks initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation that symptoms of IBS continue to persist AND positive clinical response.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lumakras

Products Affected

- **LUMAKRAS ORAL TABLET 120 MG, 240 MG, 320 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of locally advanced or metastatic non-small cell lung cancer -AND- disease is KRAS G12C-mutated as determined by an FDA approved test -AND- member has received at least one prior systemic therapy -AND- using as a single agent. Documentation of metastatic colorectal cancer -AND- disease is KRAS G12C-mutated as determined by an FDA approved test -AND- using in combination with panitumumab -AND- prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lybalvi

Products Affected

- **LYBALVI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of schizophrenia or bipolar I disorder -AND- One of the following (1 or 2): 1) Therapeutic failure, intolerance or contraindication to generic risperidone and generic quetiapine, 2) Currently stable and responding to olanzapine but experiencing weight gain from the medication. If using for maintenance monotherapy treatment of bipolar 1 disorder, only criterion 2 is required.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lynparza

Products Affected

- **LYNPARZA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, all of the following (1-2): 1) in complete or partial response to first-line platinum-based chemotherapy 2) diagnosis of deleterious or suspected deleterious BRCA mutated disease or disease is associated with homologous recombination deficiency (HRD) positive status with a deleterious or suspected deleterious BRCA mutation or genomic instability and will be using in combination with bevacizumab. For recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, all of the following (1-2): 1) deleterious or suspected deleterious germline or somatic BRCA mutation 2) in complete or partial response to platinum-based chemotherapy. For deleterious or suspected deleterious gBRCAm, HER2-negative breast cancer, 1 of the following (1-2): 1) classified as high-risk, early breast cancer and has been treated with neoadjuvant or adjuvant chemotherapy 2) has been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting and if hormone receptor (HR)-positive, has been previously treated with or considered inappropriate for treatment with endocrine therapy. For metastatic pancreatic adenocarcinoma, all of the following (1-2): 1) a deleterious or suspected deleterious gBRCA mutation 2) did not progress on at least 16 weeks of a first-line platinum-based chemotherapy regimen. For deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutation metastatic castration-resistant prostate cancer, all of the following (1-2): 1) progressed following prior treatment with enzalutamide or abiraterone 2) concurrently receiving a gonadotropin-releasing hormone (GnRH) analog or has had a bilateral orchiectomy. For deleterious or suspected deleterious BRCA mutation metastatic castration-resistant prostate cancer, using in combination with all of the following (1-2): 1) abiraterone 2) prednisone or prednisolone.
Age Restrictions	

PA Criteria	Criteria Details
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Lyrica

Products Affected

- *pregabalin oral capsule 100 mg, 150 mg, 200 mg, 225 mg, 25 mg, 300 mg, 50 mg, 75 mg*
- *pregabalin oral solution*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. When using pregabalin products concomitantly with an opiate agonist, attestation of an intent to monitor and address concomitant drug-drug interaction adverse events for opiate potentiators.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Lytgobi

Products Affected

- **LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG X 5)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following (1-2): 1) disease harbors FGFR2 fusions or other rearrangements 2) member has experienced therapeutic failure or intolerance to at least one prior therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Mavyret

Products Affected

- **MAVYRET ORAL PELLETS IN PACKET**
- **MAVYRET ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guidance
Age Restrictions	Deny if less than 3 years of age
Prescriber Restrictions	
Coverage Duration	Criteria/duration applied consistent with current AASLD-IDSA guidance
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Megace

Products Affected

- *megestrol oral suspension 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml)*
- *megestrol oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Mekinist

Products Affected

- **MEKINIST ORAL RECON SOLN**
- **MEKINIST ORAL TABLET 0.5 MG, 2 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For trametinib monotherapy, documentation of unresectable or metastatic melanoma -AND- meets all of the following (1-2): 1) member has a BRAF V600E or V600K mutation 2) member is BRAF inhibitor treatment naive. For use in combination with dabrafenib, documentation of unresectable or metastatic melanoma or melanoma with lymph node(s) involvement following complete resection and member is using trametinib and dabrafenib as adjuvant therapy -AND- member has a BRAF V600E or V600K mutation. For use in combination with dabrafenib, documentation of metastatic non-small cell lung cancer, locally advanced or metastatic anaplastic thyroid cancer, or low-grade glioma -AND- member has a BRAF V600E mutation, as detected by an FDA approved test when FDA indicated. For use in combination with dabrafenib, documentation of unresectable or metastatic solid tumors -AND- all of the following (1-3): 1) BRAF V600E mutation 2) disease has progressed following prior treatment 3) member has no satisfactory alternative treatment options.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For Mekinist powder for oral solution, attestation of inability to swallow Mekinist (trametinib) tablets is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Mektovi

Products Affected

- **MEKTOVI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For unresectable or metastatic melanoma, all of the following (1-2): 1) BRAF V600E or V600K mutation status, as detected by an FDA-authorized test 2) using in combination with encorafenib. For metastatic non-small cell lung cancer, all of the following (1-2): 1) BRAF V600E mutation status, as detected by an FDA-authorized test 2) using in combination with encorafenib.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Metyrosine

Products Affected

- *metyrosine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of pheochromocytoma defined by 1 of the following (1 or 2): 1) Elevated metanephrines in plasma or urine, or 2) Tumor evidence from CT scan or MRI -AND- Documentation of 1 of the following (3., 4., or 5.): 3) Planned resection surgery, 4) Resection surgery is contraindicated, or 5) malignant pheochromocytoma. -AND- therapeutic failure, contraindication, or intolerance to a selective alpha-blocker (e.g., doxazosin, prazosin, terazosin).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Modeyso

Products Affected

- **MODEYSO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of diffuse midline glioma -AND- disease harbors an H3 K27M mutation -AND- member has experienced progressive disease following prior therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Mulpleta

Products Affected

- **MULPLETA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of thrombocytopenia and chronic liver disease - AND- beneficiary is scheduled to undergo a procedure -AND- trial and failure or intolerance to Doptelet
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 month
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Myasthenia Gravis

Products Affected

- **ZILBRYSQ SUBCUTANEOUS SYRINGE 16.6 MG/0.416 ML, 23 MG/0.574 ML, 32.4 MG/0.81 ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of generalized myasthenia gravis (gMG) -AND- Anti-acetylcholine receptor (AChR) antibody-positive -AND- Therapeutic failure, contraindication, or intolerance to generic pyridostigmine.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of gMG signs/symptoms improvement (e.g., speech, swallowing, mobility, and/or respiratory function) -OR- decreased gMG exacerbations.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Namzaric

Products Affected

- *memantine-donepezil*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis and intolerance to generic memantine and generic donepezil
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Nayzilam

Products Affected

- **NAYZILAM**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of seizure clusters or acute repetitive seizures -AND- the member is currently receiving antiepileptic maintenance therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Nemluvio

Products Affected

- **NEMLUVIO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of prurigo nodularis -OR- Documentation of moderate to severe atopic dermatitis and one of the following (1-3): 1) trial and failure or intolerance to at least one topical corticosteroid or one topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus), 2) severe atopic dermatitis and the member is incapable of applying topical therapies due to the extent of body surface area involvement, or 3) severe atopic dermatitis and topical therapies are contraindicated due to severely damaged skin.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For prurigo nodularis, must follow recommended dosing guidelines based upon weight. For atopic dermatitis, must follow recommended dosing based on FDA approved dosing guidelines. For induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For prurigo nodularis reauthorization, attestation of reduction in itch or number of nodules or lesions from baseline.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Nerlynx

Products Affected

- **NERLYNX**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of early-stage, HER2-positive breast cancer -AND- meets all of the following: 1)member has received adjuvant trastuzumab-based therapy 2) member is using neratinib as a single agent. Documentation of advanced HER-2 positive, or metastatic HER2-positive breast cancer and meets all of the following 1) using neratinib in combination with capecitabine 2) member has received two or more prior anti-HER2 based regimens in the metastatic setting.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Nexavar

Products Affected

- *sorafenib*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For locally recurrent or metastatic, progressive, differentiated thyroid carcinoma, refractory to radioactive iodine treatment
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Nexletol

Products Affected

- **NEXLETOL**
- **NEXLIZET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	1.HeFH supported by 1 of the following (a-d): a) causal mutation of FH by genetic testing, b) untreated LDL-C at least 190mg/dL w/physical signs of FH (e.g. xanthomas, xanthelasma), c) untreated LDL-C at least 160mg/dL before 20 yrs old w/physical signs of FH, d) diagnosis based on WHO criteria/Dutch Lipid Clinical Network criteria w/score over 8 points, definite on Simon Broome register, or definite on the Make Early Diagnosis to Prevent Early Deaths tool AND LDL-C at least 70mg/dL or non-HDL-C at least 100mg/dL or less than 50% decrease in baseline LDL-C, or if very high risk, LDL-C at least 55mg/dL or non-HDL-C at least 85mg/dL -AND- Attestation of combination use with other LDL-C lowering therapies or concomitant LDL-C lowering therapy is not possible. 2.ASCVD or attestation of high risk for CVD -AND- Therapeutic failure/intolerance/contraindication to ezetimibe. 3. Primary Hyperlipidemia/Hypercholesterolemia (w/o ASCVD or HeFH) AND LDL-C at least 70mg/dL or non-HDL-C at least 100mg/dL or less than 50% decrease in baseline LDL-C -AND- Attestation of combination use with other LDL-C lowering therapies or concomitant LDL-C lowering therapy is not possible. -AND- Therapeutic failure/intolerance/contraindication to ezetimibe.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization

PA Criteria	Criteria Details
Other Criteria	For reauthorization of ASCVD or High ASCVD Risk, attestation of need for continued therapy is required. For reauthorization associated with all other diagnoses, documentation showing an LDL-C reduction from baseline -AND- attestation of continued use in combination with other LDL-C lowering therapies or concomitant LDL-C lowering therapy is not possible. Therapeutic failure to a max tolerated statin or documented statin intolerance is required. Statin intolerance defined as follows: statin related rhabdomyolysis or skeletal muscle symptoms while receiving at least 2 separate trials of different statin which resolved upon discontinuation of statin or documentation of one of the following during any course of statin therapy: 1. CK increase to 10x upper limit of normal 2. LFTs increase to 3x upper limit of normal 3. Hospitalization due to severe statin-related AEs such as rhabdomyolysis.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ninlaro

Products Affected

- **NINLARO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of multiple myeloma -AND- previous treatment with at least 1 prior therapy -AND- used in combination with lenalidomide and dexamethasone
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Nitisinone

Products Affected

- *nitisinone*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of hereditary tyrosinemia type 1 (HT-1) confirmed by biochemical or genetic testing -AND- dietary restriction of tyrosine and phenylalanine.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Northera

Products Affected

- *droxidopa oral capsule 100 mg, 200 mg, 300 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of neurogenic orthostatic hypotension caused by primary autonomic failure (e.g., Parkinson's disease, multiple system atrophy, or pure autonomic failure), dopamine beta-hydroxylase deficiency or non-diabetic autonomic neuropathy -AND- Documentation of inadequate response, intolerance or contraindication to preferred generic alternative midodrine.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	For reauthorization, attestation of increase from baseline of systolic or diastolic blood pressure upon standing -OR- attestation of decrease from baseline of neurogenic orthostatic hypotension symptoms upon standing (e.g., dizziness, feeling faint, etc.).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Nubeqa

Products Affected

- **NUBEQA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of non-metastatic castration-resistant prostate cancer or metastatic castration-sensitive prostate cancer -AND- one of the following (1-2): 1) using in combination with a GnRH analog 2) member has had a bilateral orchiectomy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Nuedexta

Products Affected

- *dextromethorphan-quinidine*
- **NUEDEXTA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation supporting improvement in symptoms is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Nuplazid

Products Affected

- **NUPLAZID**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of hallucinations and delusions associated with Parkinson's disease psychosis
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Nurtec

Products Affected

- **NURTEC ODT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For Episodic Migraine Prevention, defined as 4-14 migraine days per month, the following criteria will apply (1-2). 1) Documentation of average monthly migraine days. 2) Attestation that headaches are not caused by medication rebound or overutilization (e.g. not taking triptans exceeding more than 18 doses per month) or lifestyle factors (e.g. sleep patterns, caffeine use). For acute treatment of migraine with or without aura, trial and failure of one generic triptan or all triptans are contraindicated.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization of episodic migraine prevention, attestation of reduction in migraine frequency. For reauthorization of acute treatment of migraine, attestation of reduction in migraine symptoms.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Nuvigil

Products Affected

- *armodafinil*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of shift work sleep disorder (SWSD) substantiated by excessive sleepiness or insomnia that is temporarily associated with a recurring work schedule that overlaps the usual time for sleep -AND- Symptoms are accompanied by a reduction of total sleep time -AND- Symptoms experienced for at least 3 months -AND- Sleep log or actigraphy monitoring for at least 14 days including both work and free days -AND- Sleep disturbance is not better explained by another current sleep disorder, medical or neurological disorder, mental disorder, medication use, or substance use disorder. Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) -AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than or equal to 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than or equal to 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. Diagnosis of obstructive sleep apnea/hypopnea syndrome (OSAHS) documented by objective polysomnography or home sleep apnea test as established in accordance with ICSD or DSM V criteria acceptable for all indications
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	For reauthorization, provider attestation of improvement in daytime sleepiness is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Octreotide

Products Affected

- *octreotide acetate injection solution*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For acromegaly, high pretreatment insulin-like growth factor-1 (IGF-1) based on laboratory reference range -AND- therapeutic failure or cannot be treated with surgical resection, pituitary irradiation or bromocriptine mesylate.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization of acromegaly, decreased or normalized IGF-1 from baseline
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Odomzo

Products Affected

- **ODOMZO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy or for use in patients who are not candidates for surgery or radiation therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ogsiveo

Products Affected

- **OGSIVEO ORAL TABLET 100 MG, 150 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of progressing desmoid tumor(s) requiring systemic therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ojemda

Products Affected

- **OJEMDA ORAL SUSPENSION FOR RECONSTITUTION**
- **OJEMDA ORAL TABLET 400 MG/WEEK (100 MG X 4), 500 MG/WEEK (100 MG X 5), 600 MG/WEEK (100 MG X 6)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of relapsed or refractory pediatric low-grade glioma -AND- one of the following (1-2): 1) BRAF fusion or rearrangement, or 2) BRAF V600K mutation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Ojjaara

Products Affected

- **OJJAARA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of intermediate or high-risk myelofibrosis -AND- attestation of anemia.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Onfi

Products Affected

- *clobazam oral suspension*
- *clobazam oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of seizures due to Lennox-Gastaut Syndrome -AND- documentation of adjunctive therapy -AND- therapeutic failure or intolerance of a previous antiepileptic therapy
Age Restrictions	Deny if less than 2 years old
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Onureg

Products Affected

- **ONUREG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of acute myeloid leukemia that has achieved first complete remission or complete remission with incomplete blood count recovery following intensive induction chemotherapy -AND- Inability to complete intensive curative therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Opipza

Products Affected

- **OPIPZA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- 1 of the following (1-2): 1) intolerance to generic aripiprazole tablets, 2) inability to swallow oral tablets. If medication is being used for major depressive disorder, documentation of adjunctive therapy and therapeutic failure, contraindication or intolerance to one other generic antidepressant in addition to the antidepressant currently being used for the treatment of MDD (e.g. SSRI, SNRI, NDRIs, TCA, MAOI).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Orencia

Products Affected

- **ORENCIA CLICKJECT**
- **ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For polyarticular juvenile idiopathic arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage.
Age Restrictions	Deny if less than 18 years of age for Rheumatoid Arthritis or less than 2 years of age for Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis
Prescriber Restrictions	
Coverage Duration	Plan Year

PA Criteria	Criteria Details
Other Criteria	For rheumatoid arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Rinvoq and Xeljanz/Xeljanz XR. For psoriatic arthritis, patients over 18 years of age must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Cosentyx, Otezla/Otezla XR, Skyrizi SC, Rinvoq, and Xeljanz/Xeljanz XR. For polyarticular juvenile idiopathic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Rinvoq/Rinvoq LQ, and Xeljanx/Xeljanz solution. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606. Preferred ustekinumab products include Steqema with NDC starting with 72606 and Yesintek with NDC starting with 83257.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Orgovyx

Products Affected

- **ORGOVYX**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of advanced prostate cancer
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens per indication.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Orkambi

Products Affected

- **ORKAMBI ORAL GRANULES IN PACKET**
- **ORKAMBI ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cystic fibrosis and homozygous F508del mutation
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Orserdu

Products Affected

- **ORSERDU ORAL TABLET 345 MG, 86 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following (1-4): 1) member is male or a postmenopausal female 2) disease is ER-positive, HER2-negative 3) disease harbors an ESR1 mutation, as detected by an FDA-approved test 4) member has experienced disease progression on or after an endocrine based regimen.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Otezla

Products Affected

- **OTEZLA**
- **OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)- 20 MG (51), 10 MG (4)-20 MG (4)-30 MG (47)**
- **OTEZLA XR**
- **OTEZLA XR INITIATION**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For plaque psoriasis, all of the following (1-2): 1) member is greater than or equal to 18 years of age with mild-to-severe disease -OR- if the member is greater than or equal to 6 years of age and less than 18 years, weight is greater than or equal to 20 kg for Otezla or 50 kg for Otelza XR, and member has moderate-to-severe disease -AND- 2) inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For oral ulcers associated with Behcet's Disease, inadequate response or intolerance to one systemic therapy for prevention of recurrent oral ulcers. For psoriatic arthritis, if the member is greater than or equal to 6 years of age and less than 18 years and weight is greater than or equal to 20 kg for Otezla or 50 kg for Otelza XR.
Age Restrictions	Deny if less than 6 years of age for plaque psoriasis or psoriatic arthritis. Deny if less than 18 years of age for Behcet's Disease.
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Ozempic Oral

Products Affected

- **OZEMPIC ORAL**

PA Criteria	Criteria Details
Exclusion Criteria	Obesity or use for weight loss
Required Medical Information	Documentation of diabetes mellitus type 2
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Panretin

Products Affected

- **PANRETIN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cutaneous lesions in patients with AIDS-related Kaposi Sarcoma (KS) who are not receiving systemic therapy for KS.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Pemazyre

Products Affected

- **PEMAZYRE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of unresectable locally advanced cholangiocarcinoma or metastatic cholangiocarcinoma -AND- all of the following (1-2): 1) disease harbors FGFR2 fusion or other rearrangement as detected by an FDA-approved test 2) member has experienced therapeutic failure or intolerance to at least on prior therapy. Documentation of relapsed or refractory myeloid/lymphoid neoplasms -AND- disease harbors an FGFR1 rearrangement.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Pheburane

Products Affected

- **PHEBURANE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- intolerence to generic sodium phenylbutyrate.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Piqray

Products Affected

- **PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1), 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following: 1) HR-positive, HER2-negative tumor status, 2) PIK3CA mutation positive as detected by an FDA-approved test, 3) disease progression on or after an endocrine-based regimen, 4) Concomitant therapy with fulvestrant
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Pomalyst

Products Affected

- *pomalidomide*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of multiple myeloma, and combination use with dexamethasone, and previous trial of at least 2 therapies including lenalidomide and a proteasome inhibitor, and disease progression on or within 60 days of completion of the last therapy -OR- Documentation of AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV negative
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Posaconazole Tablet

Products Affected

- *posaconazole oral tablet,delayed release (dr/ec)*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For aspergillus or candida infection prophylaxis, high risk of developing invasive Aspergillosis or Candidiasis infection due to being severely immunocompromised (e.g., hematopoietic stem cell transplant recipients with graft versus host disease, those with hematologic malignancies with prolonged neutropenia from chemotherapy) -AND- weight greater than 40 kg. For invasive aspergillosis infection, trial/failure or contraindication to voriconazole.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Preferred Adalimumab

Products Affected

- **HADLIMA**
- **HADLIMA PUSHTOUCH**
- **HADLIMA(CF)**
- **HADLIMA(CF) PUSHTOUCH**
- **SIMLANDI(CF) AUTOINJECTOR**
- **SIMLANDI(CF) SUBCUTANEOUS SYRINGE KIT 20 MG/0.2 ML, 40 MG/0.4 ML**
- **YUFLYMA(CF) AI CROHN'S-UC-HS**
- **YUFLYMA(CF) AUTOINJECTOR**
- **YUFLYMA(CF) SUBCUTANEOUS SYRINGE KIT 40 MG/0.4 ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For ankylosing spondylitis, inadequate response or intolerance to at least one nonsteroidal anti-inflammatory drug (NSAID). For moderate to severe polyarticular juvenile idiopathic arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For uveitis, inadequate response or intolerance to 1 immunosuppressant or corticosteroid, or all are contraindicated.
Age Restrictions	Deny if less than 18 years of age for Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, and Ankylosing Spondylitis or less than 12 years of age for Hidradenitis Suppurative or Less than 6 years of age for Crohn's disease or Less than 5 years of age for Ulcerative Colitis or less than 2 years of age for Polyarticular Juvenile Idiopathic Arthritis and Uveitis
Prescriber Restrictions	
Coverage Duration	Plan Year

PA Criteria	Criteria Details
Other Criteria	For plaque psoriasis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For rheumatoid arthritis therapy without concomitant methotrexate, doses above plan quantity limit will be approved aligned with recommended weekly dosing regimen. For pediatric ulcerative colitis and hidradenitis suppurativa, doses above plan quantity limit will be approved to align with recommended dosing regimen. Induction therapy or treatment regimens for other indications are aligned with plan quantity limit on Humira starter kit. These criteria are applicable to Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Preferred Ustekinumab

Products Affected

- **STEQEYMA SUBCUTANEOUS SOLUTION**
- **STEQEYMA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML**
- **YESINTEK SUBCUTANEOUS SOLUTION**
- **YESINTEK SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- documentation of member weight and prescribed dose. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For Crohn's Disease or Ulcerative Colitis, attestation of receiving or currently undergoing a single induction dose of IV ustekinumab within 2 months of initiating therapy with ustekinumab SC.
Age Restrictions	Deny if less than 18 years of age for Ulcerative Colitis. Deny if less than 6 years of age for Plaque Psoriasis and Psoriatic Arthritis. Deny if less then 2 years of age for Crohn's Disease.
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	Must follow recommended dosing guidelines based upon weight. Induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For pediatric Crohn's disease, doses above plan quantity limit will be approved to align with recommended dosing regimen.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Prenatal Vitamins

Products Affected

- **PRENATAL VITAMIN PLUS LOW IRON**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of nutritional supplementation required in a female of child-bearing potential during pre-conception, pregnancy, or lactation
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Prescription Drug Combo

Products Affected

- *acetaminophen-codeine oral solution 120-12 mg/5 ml*
- *acetaminophen-codeine oral tablet*
- *alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg*
- *buprenorphine*
- *clonazepam oral tablet 0.5 mg, 1 mg, 2 mg*
- *clonazepam oral tablet,disintegrating 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg*
- *clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg*
- **DIAZEPAM INTENSOL**
- *diazepam oral solution 5 mg/5 ml (1 mg/ml)*
- *diazepam oral tablet*
- *fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr*
- *hydrocodone-acetaminophen oral tablet 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg*
- *hydromorphone oral liquid*
- *hydromorphone oral tablet 2 mg, 4 mg, 8 mg*
- **LORAZEPAM INTENSOL**
- *lorazepam oral tablet 0.5 mg, 1 mg, 2 mg*
- *methadone oral solution 10 mg/5 ml, 5 mg/5 ml*
- *methadone oral tablet 10 mg, 5 mg*
- *morphine concentrate oral solution*
- *morphine oral solution 10 mg/5 ml (2 mg/ml), 20 mg/5 ml (4 mg/ml)*
- *morphine oral tablet*
- *morphine oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg*
- *oxycodone oral capsule*
- *oxycodone oral concentrate*
- *oxycodone oral tablet 10 mg, 15 mg, 20 mg, 30 mg, 5 mg*
- *oxycodone-acetaminophen oral tablet 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg*
- *tramadol oral tablet 50 mg*
- *tramadol-acetaminophen*
- *zaleplon oral capsule 10 mg, 5 mg*
- *zolpidem oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	

PA Criteria	Criteria Details
Required Medical Information	For concomitant use of opiate agonist and substance abuse therapy, documentation of acute pain condition (eg, acute traumatic injury) in which treatment with other agents would cause insufficient pain control or treatment for terminal illness related pain. For concomitant use of an opiate agonist, benzodiazepine, and centrally acting skeletal muscle relaxant, trial/failure of at least 2 other skeletal muscle relaxants (eg, methocarbamol, metaxalone), understanding these skeletal muscle relaxants are high-risk medications in geriatric patients, attestations that non-opiate (eg, NSAIDs) and non-benzodiazepine therapies (eg, SSRI, SNRI) have been considered, and attestation of intent to monitor & address concomitant drug-drug interaction adverse events. For concomitant use of opiate agonist and other opiate potentiators (eg, gabapentinoids, sedative-hypnotics), attestation of intent to monitor & address concomitant drug-drug interaction adverse events. For long acting opioid medications, the following apply (1-3): 1)Severe pain requiring daily, around-the-clock, long-term opioid treatment. 2)Not opioid naive. 3)Attestations that non-opiate alternative therapies have been explored (eg, NSAIDs), controlled substance history was reviewed in the state Prescription Drug Monitoring Program (PDMP), counseling on potential adverse effects of opioid analgesics, including risk of misuse, abuse, addiction.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Opiate tx for pain+subs. abuse, approve opiate x 1mo. All other combos and dx approve x 12mo.
Other Criteria	Opiate agonists will receive automatic approval if no recent claims for a substance abuse therapy (e.g. buprenorphine-naloxone) OR a benzodiazepine with a centrally acting skeletal muscle relaxant (e.g., carisoprodol) OR a gabapentinoid OR a sedative-hypnotic. Benzodiazepines (e.g. triazolam, alprazolam) will receive automatic approval if no recent claims for an opiate agonist with a centrally acting skeletal muscle relaxant (e.g. carisoprodol). Sedative-hypnotics (e.g. zolpidem) will receive automatic approval if no recent claims for an opiate agonist.
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Prevymis Oral Pellets

Products Affected

- **PREVYMIS ORAL PELLETS IN PACKET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis.
Age Restrictions	Deny if less than 6 months of age with HSCT. Deny if less than 12 years of age with kidney transplant.
Prescriber Restrictions	
Coverage Duration	7 months
Other Criteria	One of the following is required (1-2): 1) inability to swallow tablets, 2) unable to use Prevymis (letermovir) tablets due to body weight dosing limitations.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Prolia

Products Affected

- **ENOBY**
- **JUBBONTI**
- **PROLIA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -And- For osteoporosis at high risk for fracture, meeting one of the following (1. thru 4.) 1) History of previous fracture. 2) T-score less than or equal to -2.5. 3) T-score between -1.0 and -2.5 (i.e. osteopenia) -AND- meets FRAX calculation (A. or B.) A) 10-year risk of major osteoporotic fracture is greater than or equal to 20 percent or B) 10-year risk of hip fracture is greater than or equal to 3 percent. 4) Age 40 years or older with T-score between -1.0 and -2.5 -AND- History of glucocorticoid use for at least 3 months at a dose of 5mg per day or more of prednisone (or equivalent).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	For osteoporosis and osteopenia, documentation of trial/failure or intolerance to at least one oral bisphosphonate or all are contraindicated -OR- very high risk for a fracture, defined by one of the following: fracture within past 12 months, fracture while on osteoporosis therapy, history of multiple fractures, fractures while on drugs causing skeletal harm, fall risk, history of injurious falls, T-score less than -3, FRAX 10 year major osteo fracture risk of greater than 30%, or FRAX 10 year hip fracture risk of greater than 4.5%. Covered under Part B for patients eligible for home health services when provider certifies that patient sustained bone fracture related to post-menopausal osteoporosis and is unable to learn the skills needed to self-administer the drug or is otherwise physically or mentally incapable of administering the drug or family/caregivers are unable or unwilling to administer the drug.

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Provigil

Products Affected

- *modafinil*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of shift work sleep disorder (SWSD) substantiated by excessive sleepiness or insomnia that is temporarily associated with a recurring work schedule that overlaps the usual time for sleep -AND- Symptoms are accompanied by a reduction of total sleep time -AND- Symptoms experienced for at least 3 months -AND- Sleep log or actigraphy monitoring for at least 14 days including both work and free days -AND- Sleep disturbance is not better explained by another current sleep disorder, medical or neurological disorder, mental disorder, medication use, or substance use disorder. Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) -AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than or equal to 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than or equal to 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. Diagnosis of obstructive sleep apnea/hypopnea syndrome (OSAHS) documented by objective polysomnography or home sleep apnea test as established in accordance with ICSD or DSM V criteria acceptable for all indications. Diagnosis of fatigue associated with Multiple Sclerosis (MS)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	For reauthorization, provider attestation of improvement in daytime sleepiness is required.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	Fatigue associated with Multiple Sclerosis (MS)
Part B Prerequisite	No
Prerequisite Therapy Required	No

Pulmonary Arterial Hypertension

Products Affected

- **ADEMPAS**
- *ambrisentan*
- *macitentan*
- **OPSUMIT**
- **OPSYNVI**
- *sildenafil (pulm.hypertension) oral tablet*
- *tadalafil (pulm. hypertension)*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of pulmonary arterial hypertension, substantiated by results from right heart catheterization (RHC), defined as a mean pulmonary arterial pressure (mPAP) of greater than 20 mmHg at rest, with a pulmonary capillary wedge pressure (PWP) of less than or equal to 15 mmHg, and a PVR greater than or equal to 3 Wood units -AND- WHO Group. For sildenafil in pediatric individuals, an exception to RHC will be allowed when the risk of RHC outweighs the benefit -AND- prescriber attests alternative studies have been completed (i.e. CT, MRI or specified test ruling out other causes of pulmonary hypertension). For Adempas, additional diagnosis of CTEPH as documented by right heart catheterization and V/Q scan substantiating mPAP greater than 20 mmHg at rest and PWP less than or equal to 15 mmHg and documented presence of occlusive thrombi within the pulmonary arteries will be approved.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

Pulmozyme

Products Affected

- **PULMOZYME**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of cystic fibrosis -AND- Used in conjunction with standard therapies for management of cystic fibrosis to improve pulmonary function.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Inhalation solutions covered under Part B when administered in the home setting using a covered nebulizer (i.e. DME). For reauthorization, attestation of increase in FEV1 or decrease in number of hospitalizations or pulmonary exacerbations.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Qinlock

Products Affected

- **QINLOCK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of advanced gastrointestinal stromal tumor -AND- Prior treatment with imatinib and 2 other kinase inhibitors.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Quinine

Products Affected

- *quinine sulfate*

PA Criteria	Criteria Details
Exclusion Criteria	Treatment or prevention of leg cramps
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	10 days
Other Criteria	Doses for duration greater than 10 days will not be approved
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Qulipta

Products Affected

- **QULIPTA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of Episodic Migraine, defined as 4-14 migraine days per month OR Chronic Migraine, defined as 15 or more headaches per month, of which 8 or more are migraine days. The following criteria will apply (1-2). 1) Documentation of average monthly migraine days. 2) Attestation that headaches are not caused by medication rebound (e.g. not taking triptans exceeding more than 18 doses per month) or lifestyle factors (e.g. sleep patterns, caffeine use).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of reduction in migraine frequency
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ravicti

Products Affected

- *glycerol phenylbutyrate*

PA Criteria	Criteria Details
Exclusion Criteria	Urea cycle disorders due to N-acetylglutamate synthetase deficiency, Treatment of acute hyperammonemia in urea cycle disorders
Required Medical Information	Documentation of chronic management of a urea cycle disorders (UCDs)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Repatha

Products Affected

- **REPATHA SURECLICK**
- **REPATHA SYRINGE**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with another PCSK9 inhibitor or siRNA directed to PCSK9.
Required Medical Information	1.HoFH supported by 1 of the following (a-d): a) bi-allelic causal mutations of FH by genetic testing, b) LDL-C over 560mg/dL, c) LDL-C over 400mg/dL w/aortic valve disease or xanthomata at less than 20 yrs old, d) LDL-C over 400mg/dL and 1 or both parents w/clinically diagnosed FH, positive genetic testing for a known LDL-C-raising gene (e.g., LDLR, ApoB, PCSK9) defect, or autosomal-recessive FH AND current LDL-C over 115mg/dL (if 17yrs or younger) or over 70mg/dL (18yrs or older) or over 55mg/dL w/ASCVD or major ASCVD risk factors (18yrs or older). 2.HeFH supported by 1 of the following (a-d): a) causal mutation of FH by genetic testing, b) untreated LDL-C at least 190mg/dL or untreated LDL-C at least 160mg/dL before 20 yrs old, c) physical signs of FH (e.g. xanthomas, xanthelasma), d) diagnosis based on WHO criteria/Dutch Lipid Clinical Network criteria w/score over 8 points, definite on Simon Broome register, or definite on the Make Early Diagnosis to Prevent Early Deaths tool AND LDL-C at least 70mg/dL or non-HDL-C at least 100mg/dL or less than 50% decrease in baseline LDL-C, or if very high risk, LDL-C at least 55mg/dL or non-HDL-C at least 85mg/dL. 3.Hypercholesterolemia w/ASCVD or attestation of major CV risk AND LDL-C at least 55mg/dL or non-HDL-C at least 85mg/dL or Lp(a) at least 125nmol/L or, if ASCVD, less than 50% decrease in baseline LDL-C. 4.Primary Hyperlipidemia/Hypercholesterolemia (w/o ASCVD, HeFH, or HoFH) AND LDL-C at least 70mg/dL or non-HDL-C at least 100mg/dL or less than 50% decrease in baseline LDL-C.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization

PA Criteria	Criteria Details
Other Criteria	For reauthorization associated with Major Cardiovascular Risk, attestation of need for continued Repatha therapy is required. For reauthorization associated with all other diagnoses, documentation showing an LDL-C reduction on Repatha therapy from baseline must be provided. Therapeutic failure to a max tolerated statin or documented statin intolerance is required. Statin intolerance defined as follows: statin related rhabdomyolysis or skeletal muscle symptoms while receiving at least 2 separate trials of different statins which resolved upon discontinuation of statin or attestation of one of the following during any course of statin therapy: 1. CK increase to 10x upper limit of normal 2. LFTs increase to 3x upper limit of normal 3. Hospitalization due to severe statin-related AEs such as rhabdomyolysis.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Retevmo

Products Affected

- **RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of locally advanced or metastatic non-small cell lung cancer -AND- disease is classified as RET gene fusion as detected by an FDA approved test. Documentation of advanced or metastatic medullary thyroid cancer -AND- disease is classified as RET mutation as detected by an FDA approved test. Documentation of advanced or metastatic thyroid cancer -AND- all of the following (1-2): 1) disease is classified as RET gene fusion as detected by an FDA approved test 2) if radioactive iodine is appropriate for the member, the member is radioactive iodine-refractory. Documentation of locally advanced or metastatic solid tumor(s) -AND- disease harbors a RET gene fusion, as detected by an FDA-approved test -AND- one of the following (1-2): 1) the member has no satisfactory alternative treatments 2) the member's tumors have progressed following prior systemic treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Revlimid

Products Affected

- *lenalidomide*

PA Criteria	Criteria Details
Exclusion Criteria	Documentation of chronic lymphocytic leukemia outside of a controlled clinical trial
Required Medical Information	Diagnosis of multiple myeloma in combination with dexamethasone -OR- diagnosis of multiple myeloma, as maintenance following autologous hematopoietic stem cell transplant (auto-HSCT) -OR- diagnosis of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities -OR- diagnosis of mantle cell lymphoma (MCL) in which disease has relapsed or progressed after two prior therapies, one of which included bortezomib -OR- diagnosis of follicular lymphoma in combination with a rituximab product after previous treatment -OR- diagnosis of marginal zone lymphoma in combination with a rituximab product after previous treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Revuforj

Products Affected

- **REVUFORJ ORAL TABLET 110 MG, 160 MG, 25 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For relapsed or refractory acute leukemia, member has a lysine methyltransferase 2A gene (KMT2A) translocation, as determined by an FDA-authorized test. For relapsed or refractory acute myeloid leukemia, the member has a susceptible NPM1 mutation -AND- the member has no satisfactory alternative treatment options.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Rexulti

Products Affected

- **REXULTI ORAL TABLET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For major depressive disorder, documentation of adjunctive therapy and therapeutic failure, contraindication or intolerance to one other generic antidepressant in addition to the antidepressant currently being used for the treatment of MDD (e.g. SSRI, SNRI, NDRIs, TCA, MAOI). For schizophrenia, therapeutic failure, intolerance, or contraindication to one other generic atypical antipsychotic (e.g. quetiapine).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Rezdiffra

Products Affected

- **REZDIFFRA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in conjunction with diet and exercise. Liver biopsy (within the past 3 years) or noninvasive tests (NITs) (performed within the past 6 months) indicating stage F2 or F3 fibrosis -AND- attestation of 1 cardiometabolic risk factor (e.g. obesity, hyperglycemia, hypertriglyceridemia, hyperlipidemia, hypertension) -AND- attestation that member does not have evidence of cirrhosis, hepatic decompensation, or hepatocellular carcinoma -AND- attestation that member's alcohol consumption is not defined as excess alcohol use (greater than 20g/day in females or greater than 30g/day in males)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of continued use in conjunction with diet and exercise -AND- member has experienced improvement or stabilization of fibrosis as demonstrated by NIT -AND- member has not progressed to stage F4 fibrosis -AND- attestation that member does not have evidence of cirrhosis, hepatic decompensation, or hepatocellular carcinoma -AND- attestation that member's alcohol consumption is not defined as excess alcohol use (greater than 20g/day in females or greater than 30g/day in males)
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	No

Rezlidhia

Products Affected

- **REZLIDHIA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA approved test
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Rinvoq

Products Affected

- **RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG, 45 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe active rheumatoid arthritis, an inadequate response or intolerance to at least one non-biologic DMARD (e.g., leflunomide, methotrexate) or all non-biologic DMARDs are contraindicated. For moderate to severe refractory atopic dermatitis whose disease is not adequately controlled with other systemic drug products, documentation of one of the following (1 or 2): 1) trial & failure, or intolerance to at least one topical corticosteroid -OR- topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus) 2) The member has severe atopic dermatitis and is incapable of applying topical therapies due to the extent of body surface area involvement or topical therapies are contraindicated due to severely damaged skin. For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). For Non-radiographic Axial Spondyloarthritis, trial & failure or intolerance to two nonsteroidal anti-inflammatory drugs (NSAIDs) or contraindication to all. For polyarticular juvenile idiopathic arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) or all non-biologic DMARDs are contraindicated or requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Plan Year

PA Criteria	Criteria Details
Other Criteria	For diagnoses in which tumor necrosis factor (TNF) blockers are also indicated (e.g., Rheumatoid Arthritis, Psoriatic Arthritis), the member has experienced therapeutic failure or intolerance to at least 1 TNF blocker. For ulcerative colitis or Crohns disease, the member has experienced therapeutic failure or intolerance to at least 1 systemic therapy if TNF blockers are not advisable.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Rinvoq LQ

Products Affected

- **RINVOQ LQ**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For polyarticular juvenile idiopathic arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) or all non-biologic DMARDs are contraindicated or requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage.
Age Restrictions	For PsA, deny if 18 years of age or older
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	The member has experienced therapeutic failure or intolerance to at least 1 tumor necrosis factor (TNF) blocker.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Rivfloza

Products Affected

- **RIVFLOZA SUBCUTANEOUS SOLUTION**
- **RIVFLOZA SUBCUTANEOUS SYRINGE 128 MG/0.8 ML, 160 MG/ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of all of the following (1-4): 1) diagnosis of primary hyperoxaluria type 1 (PH1) confirmed by one of the following (a or b): a) Genetic testing (i.e., AGXT gene mutation), b) Liver biopsy (i.e., absence or significantly reduced AGT activity), 2) relatively preserved kidney function (e.g., eGFR greater than or equal to 30 mL/min/1.73 m2), 3) at least two elevated urinary oxalate levels greater than 1.5 times the upper reference limit, and 4) The member has not received a liver transplant.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, continued preserved kidney function (e.g., eGFR greater than or equal to 30 mL/min/1.73 m2) -AND- reduction in urinary oxalate levels from baseline -AND- has not received a liver transplant.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Romvimza

Products Affected

- **ROMVIMZA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of symptomatic tenosynovial giant cell tumor -AND- attestation that surgical resection may cause one of the following (1-2): 1) worsening functional limitation, 2) severe morbidity
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Rozlytrek

Products Affected

- **ROZLYTREK ORAL CAPSULE 100 MG, 200 MG**
- **ROZLYTREK ORAL PELLETS IN PACKET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For metastatic non-small cell lung cancer, the tumor status is ROS1-positive. For solid tumors with NTRK gene fusion without a known acquired resistance mutation, the tumors are metastatic or surgical resection is likely to result in severe morbidity - AND- There are no satisfactory alternative treatments or the tumors have progressed following treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Rubraca

Products Affected

- **RUBRACA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, all of the following (1-2): 1) Disease harbors a deleterious BRCA mutation (germline or somatic) 2) member is in complete or partial response to platinum-based chemotherapy. For metastatic castration-resistant prostate cancer, all of the following (1-3): 1) disease harbors a deleterious BRCA mutation (germline and/or somatic) 2) member has been treated with androgen receptor-directed therapy 3) member is concurrently receiving a gonadotropin-releasing hormone (GnRH) analog or member has had a bilateral orchiectomy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Rydapt

Products Affected

- **RYDAPT**

PA Criteria	Criteria Details
Exclusion Criteria	Use as single agent induction therapy for AML
Required Medical Information	Documentation of diagnosis. For a new diagnosis of acute myeloid leukemia, member is using in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy regimens and member is FLT3 mutation positive as detected by an FDA-approved test.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Sabril

Products Affected

- *vigabatrin*
- **VIGADRONE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of refractory complex partial seizures -AND- documentation of adjunctive therapy -AND- therapeutic failure or intolerance to at least two alternative treatments (e.g. carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, tiagabine) -OR- documentation of use as monotherapy in treatment of infantile spasms
Age Restrictions	Deny if less than 2 years of age in treatment of refractory complex partial seizures -OR- if less than 1 month old and greater than 2 years of age in treatment of infantile spasms
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Samsca

Products Affected

- *tolvaptan*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of symptomatic hypervolemic or euvolemic hyponatremia evidenced by (1. or 2.): 1.) Serum Na less than 125 mEq/L -OR- 2.) Serum NA less than 135mEq/L with symptoms (e.g. nausea, malaise, lethargy, headache, seizures)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 month
Other Criteria	Doses must be initiated in the hospital setting to closely monitor serum sodium. Treatment should be limited to 30 days to minimize risk of liver injury. For reauthorization, treatment is for a new episode of a clinically significant euvolemic or hypervolemic hyponatremia -AND- on of the following (1. or 2.) 1.) Serum Na less than 125 mEq/L -OR- 2.) Serum NA less than 135mEq/L with symptoms (e.g. nausea, malaise, lethargy, headache, seizures)
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Saphris

Products Affected

- *asenapine maleate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis - AND - trial and failure of one of the following: olanzapine, quetiapine, or risperidone.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Scemblix

Products Affected

- **SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- one of the following (1-3): 1) the member is newly-diagnosed, 2) member has been previously treated for Ph+ CML in chronic phase, 3) disease is positive for the T3151 mutation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Secuado

Products Affected

- **SECUADO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- intolerance to generic asenapine sublingual tablets -AND- trial/failure or intolerance to 1 of the following or all are contraindicated (1-3): 1) olanzapine, 2) quetiapine, 3) risperidone.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Siliq

Products Affected

- **SILIQ**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	For psoriasis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For psoriasis, patients must have therapeutic failure or intolerance to 2 preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Cosentyx, Otezla/Otezla XR, and Skyrizi SC. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606. Preferred ustekinumab products include Steqema with NDC starting with 72606 and Yesintek with NDC starting with 83257.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

Sirturo

Products Affected

- **SIRTURO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. Criteria will be applied consistent with the current ATS/CDC/ERS/IDSA Clinical Practice Guideline for the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of disease improvement -AND- member requires additional antimicrobial therapy.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Skyclarys

Products Affected

- **SKYCLARYS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Friedreichs ataxia confirmed by genetic testing (i.e., FXN gene mutation).
Age Restrictions	Deny if less than 16 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Skyrizi

Products Affected

- **SKYRIZI SUBCUTANEOUS PEN INJECTOR**
- **SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML, 55 MG/0.37 ML**
- **SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML), 360 MG/2.4 ML (150 MG/ML)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For Crohns disease, attestation of receiving or currently undergoing IV administration of Skyrizi within 3 months of initiating therapy with Skyrizi SC. For moderate to severe ulcerative colitis, attestation of receiving or currently undergoing IV administration of Skyrizi within 3 months of initiating therapy with Skyrizi SC.
Age Restrictions	Deny if less than 18 years of age for Crohn's disease and ulcerative colitis. Deny if less than 6 years of age for plaque psoriasis and psoriatic arthritis.
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	For induction therapy, doses above plan quantity limit will be approved when aligned with recommended induction therapy dosing regimen.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Sohonos

Products Affected

- **SOHONOS ORAL CAPSULE 1 MG, 1.5 MG, 10 MG, 5 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	Deny if female and less than 8 years of age -OR- if male and less than 10 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of reduction in volume of new heterotopic ossification from baseline.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Solaraze

Products Affected

- *diclofenac sodium topical gel 3 %*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- trial and failure, intolerance, or contraindication to one of the following (1 or 2): 1) topical fluorouracil solution or fluorouracil 5% cream 2) topical imiquimod 5% cream
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	For reauthorization, attestation of 30 day washout period since optimal therapeutic effect may not be evident until 30 days following cessation of therapy AND attestation of previous response to diclofenac sodium 3% topical gel therapy
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Somavert

Products Affected

- **SOMAVERT**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For acromegaly, high pretreatment insulin-like growth factor-1 (IGF-1) based on laboratory reference range -AND- inadequate or partial response to surgery or radiotherapy or not a candidate for surgery or radiotherapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization of acromegaly, decreased or normalized IGF-1 from baseline
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Sprycel

Products Affected

- *dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For adults with Ph+ chronic myeloid leukemia, the member is newly diagnosed in the chronic phase -OR- the member is in chronic, accelerated, or myeloid or lymphoid blast phase and has resistance or intolerance to prior therapy including imatinib. For adults with Ph+ acute lymphocytic leukemia, member has had resistance or intolerance to prior therapy. For pediatric patients with Ph+ CML, the member is in the chronic phase. For pediatric patients with Ph+ acute lymphoblastic leukemia, the member is newly diagnosed and will be using in combination with chemotherapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Steroidogenesis Inhibitors

Products Affected

- **SIGNIFOR**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- patient is not a candidate for pituitary surgery or surgery has not been curative
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of decrease in urinary free cortisol levels from baseline
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Stivarga

Products Affected

- **STIVARGA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of metastatic colorectal cancer and trial of a fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy, AND an anti-VEGF therapy AND if RAS wild-type, an anti-EGFR therapy -OR- documentation of locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) after treatment with both imatinib and sunitinib -OR- documentation of hepatocellular cancer AND previous treatment with sorafenib
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Sutent

Products Affected

- *sunitinib malate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For gastrointestinal stromal tumor (GIST), the member has experienced therapeutic failure, intolerance, or contraindication to imatinib. For a high risk of recurrent renal cell carcinoma, member has had a nephrectomy and sunitinib is to be used as adjuvant treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Sympazan

Products Affected

- **SYMPAZAN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of seizures due to Lennox-Gastaut Syndrome -AND- documentation of adjunctive therapy -AND- therapeutic failure or intolerance of a previous antiepileptic therapy -AND- unable to tolerate generic clobazam
Age Restrictions	Deny if less than 2 years old
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Synarel

Products Affected

- **SYNAREL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For central precocious puberty (CPP), advancement of bone age is beyond chronological age -AND- Basal luteinizing hormone (LH) level greater than 0.2-0.3IU/L or leuprolide-stimulating LH level greater than 3.3-5 IU/L. For female with endometriosis, attestation of not pregnant if of childbearing age -AND- Therapeutic failure, contraindication or intolerance to 2 of the following standard of care treatments: NSAIDs, combination hormonal contraceptive, progestin (i.e. medroxyprogesterone injection), GnRH agonist (i.e. Leuprolide) or danazol
Age Restrictions	Deny if greater than 8 years of age for females or greater than 9 years of age for males unless there is medical necessity for treatment of central precocious puberty. Deny if less than 18 years of age for endometriosis.
Prescriber Restrictions	
Coverage Duration	Endometriosis: 6 months, CPP: 6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization for CPP, attestation of pubertal development slowing from baseline.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tabrecta

Products Affected

- **TABRECTA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of metastatic non-small cell lung cancer with MET exon 14 skipping mutation as detected by an FDA approved test.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tafinlar

Products Affected

- **TAFINLAR ORAL CAPSULE**
- **TAFINLAR ORAL TABLET FOR SUSPENSION**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For dabrafenib monotherapy, documentation of unresectable or metastatic melanoma -AND- documentation of a BRAF V600E mutation. For use in combination with trametinib, documentation of unresectable or metastatic melanoma or melanoma with lymph node(s) involvement following complete resection and member is using trametinib and dabrafenib as adjuvant therapy -AND- member has a BRAF V600E or V600K mutation. For use in combination with trametinib, documentation of metastatic non-small cell lung cancer, locally advanced or metastatic anaplastic thyroid cancer, or low-grade glioma -AND- member has a BRAF V600E mutation, as detected by an FDA-approved test when FDA indicated. For use in combination with trametinib, documentation of unresectable or metastatic solid tumors -AND- all of the following (1-3): 1) BRAF V600E mutation 2) disease has progressed following prior treatment 3) member has no satisfactory alternative treatment options.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For Tafinlar tablets for oral suspension, attestation of inability to swallow Tafinlar (dabrafenib) capsules is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

Tagrisso

Products Affected

- **TAGRISSO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of non-small cell lung cancer (NSCLC) and one of the following (1-5): 1) Adjuvant therapy after tumor resection -AND- disease harbors EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test 2) Locally advanced disease -AND- using as first-line therapy -AND- disease harbors EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test -AND- used in combination with pemetrexed and platinum-based chemotherapy, 3) Metastatic disease -AND- using as first-line therapy -AND- disease harbors EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test -AND- used with or without combination therapy of pemetrexed and platinum-based chemotherapy, 4) Metastatic disease -AND- disease harbors EGFR T790M mutations, as detected by an FDA-approved test -AND- has progressed on or after EGFR TKI therapy, 5) Locally advanced, unresectable (stage III) disease -AND- disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy -AND- disease harbors EGFR exon 19 deletions or EGFR exon 21 L858R mutations, as detected by an FDA-approved test.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Talzenna

Products Affected

- **TALZENNA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of deleterious or suspected deleterious gBRCAm, HER2-negative locally advanced or metastatic breast cancer as a single agent - OR- Documentation of HRR gene-mutated metastatic castration-resistant prostate cancer in combination with enzalutamide
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Targretin

Products Affected

- *bexarotene oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Targretin Gel

Products Affected

- *bexarotene topical*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cutaneous lesions associated with one (1) of the following stages of cutaneous T-cell lymphoma (CTCL) (1. or 2.): 1) Stage IA or 2) Stage IB - AND- the member has experience therapeutic failure, contraindication, or intolerance to at least one other therapy for CTCL.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tascenso ODT

Products Affected

- **TASCENSO ODT**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other disease modifying agents such as teriflunomide, interferons, Copaxone, Tysabri
Required Medical Information	Documentation of a relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) -AND- Inability to swallow capsules
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tasigna

Products Affected

- *nilotinib hcl*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For adult patients with Ph+ chronic myeloid leukemia (CML), member's CML is in the chronic or accelerated phase and the member is no longer responding to or is intolerant to imatinib -OR- member is newly diagnosed in the chronic phase. For pediatric patients, one of the following (1-2): 1) member has chronic phase or accelerated phase Ph+ CML and is is resistant or intolerant to prior tyrosine kinase inhibitor therapy 2) member is newly diagnosed with Ph+ CML in the chronic phase.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tasimelteon

Products Affected

- *tasimelteon*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documented diagnosis of Non-24 Sleep-Wake disorder in patient that is totally blind -AND- evidenced by all the following (1 through 4): 1) history of insomnia, excessive daytime sleepiness, or both alternating with asymptomatic episodes 2) symptoms persistent for at least 3 months 3) daily sleep logs for at least 1 month demonstrating a sleep/wake pattern that delays each day 4) sleep disturbances are not better explained by another current disorder or medication/substance use
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of increased total nighttime sleep or decreased daytime nap duration for Non-24 Sleep-Wake disorder
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tazorac

Products Affected

- *tazarotene topical cream*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of 1 of the following (A or B). A) Documentation of plaque psoriasis -AND- trial and failure or intolerance to at least one topical corticosteroid (e.g. fluocinonide, mometasone, triamcinolone, betamethasone). B) Documentation of acne vulgaris -AND- trial and failure or intolerance of at least two topical acne medications (e.g. adapalene, clindamycin, sulfacetamide, erythromycin) one of which must be generic topical tretinoin
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tecfidera

Products Affected

- *dimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg, 120 mg (14)- 240 mg (46), 240 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other disease modifying agents such as interferons, Copaxone, Tysabri, Aubagio, Gilenya
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tepmetko

Products Affected

- **TEPMETKO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of metastatic non-small cell lung cancer with a MET exon 14 skipping alteration
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Testosterone (androgens)

Products Affected

- *testosterone cypionate*
- *testosterone enanthate*
- *testosterone transdermal gel in metered-dose pump 20.25 mg/1.25 gram (1.62 %)*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of primary or secondary hypogonadism in males -OR- documentation of chronic steroid treatment in men. In all previously noted indications, members must also have documented low total testosterone level below the normal range for the laboratory -OR- a total testosterone level near the lower limit of the normal range with a low free testosterone level which is less than normal based upon the laboratory reference range -OR- the member is not producing any testosterone. Additional approvable indications include female patients with metastatic breast cancer (testosterone enanthate only), primary or secondary hypogonadism in males with testicular failure due to double orchidectomy, and delayed puberty in males (testosterone enanthate only).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off Label Uses	Gender Dysphoria, Gender Identity Disorder
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tezspire

Products Affected

- **TEZSPIRE SUBCUTANEOUS PEN INJECTOR**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of severe asthma AND all of the following (1-3): 1) one of the following (a. or b.): a) history of at least two asthma exacerbations requiring oral or injectable corticosteroid treatment in the past 12 months, b) history of at least one asthma exacerbation requiring hospitalization in the past 12 months, 2) inadequate symptom control despite regular treatment with medium or high dose inhaled corticosteroid (ICS) and at least one additional asthma controller medication (e.g. long-acting beta2-agonist [LABA], leukotriene receptor antagonist [LTRA], theophylline) with or without oral corticosteroids (OCS), 3) member will continue treatment with medium or high dose ICS and at least one additional asthma controller medication, with or without OCS. Diagnosis of chronic rhinosinusitis with nasal polyposis (CRwNP) and therapeutic failure, contraindication, or intolerance to 1 generic intra-nasal corticosteroid.
Age Restrictions	Deny if less than 12 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For asthma, therapeutic failure, intolerance, or contraindication to 1 of the following: Cinqair, Dupixent, Fasenra, Nucala, or Xolair. For CRwNP, therapeutic failure, intolerance, or contraindication to 1 of the following: Dupixent, Nucala, or Xolair. For asthma reauthorization, attestation of 1 of the following (1-4): 1) decreased rescue medication or oral corticosteroid use, 2) decreased frequency of severe asthma exacerbations, 3) increased pulmonary function from baseline (e.g. FEV1), or 4) reduction in reported asthma related symptoms. For CRwNP reauthorization, 1 of the following (5-6): 5) decrease in nasal polyp score, or 6) reduction in nasal congestion/obstruction severity score.

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Thalomid

Products Affected

- **THALOMID ORAL CAPSULE 100 MG, 50 MG**

PA Criteria	Criteria Details
Exclusion Criteria	Use as monotherapy for ENL treatment in the presence of moderate to severe neuritis
Required Medical Information	Documentation of multiple myeloma in combination with dexamethasone -OR- documentation for use in the treatment of cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) -OR- documentation of therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Thrombopoiesis Stimulating Agents

Products Affected

- *eltrombopag olamine oral powder in packet 12.5 mg, 25 mg*
- *eltrombopag olamine oral tablet 12.5 mg, 25 mg, 50 mg, 75 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of persistent or chronic immune idiopathic thrombocytopenia purpura and trial and failure of corticosteroid or immunoglobulin therapy or splenectomy -OR- documentation of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy -OR- severe aplastic anemia who have had an insufficient response to immunosuppressive therapy -OR- documentation of first line treatment for severe aplastic anemia and used in combination with at least two immunosuppressive therapies.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Platelet count to be provided
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tibsovo

Products Affected

- **TIBSOVO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- disease is IDH1 mutation positive as detected by an FDA-approved test. For newly-diagnosed acute myeloid leukemia, member is using as monotherapy or in combination with azacitidine -AND- member meets one of the following (1-5): 1) age is greater than or equal to 75 years of age 2) severe cardiac or pulmonary comorbidity 3) reduced renal function 4) hepatic impairment 5) or prescriber attestation that member is not a candidate for intensive induction therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tocilizumab

Products Affected

- **ACTEMRA ACTPEN**
- **ACTEMRA SUBCUTANEOUS**

PA Criteria	Criteria Details
Exclusion Criteria	Part A covered for Covid-19 in hospitalized patients
Required Medical Information	Documentation of diagnosis. For rheumatoid arthritis, patients must have an inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide). For polyarticular juvenile idiopathic arthritis, patients must have an inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For systemic sclerosis-associated interstitial lung disease (SSc-ILD), patients must have therapeutic failure or intolerance to one immunosuppressant (e.g., mycophenolate mofetil, corticosteroids, cyclophosphamide). Documentation of systemic juvenile idiopathic arthritis.
Age Restrictions	Deny if less than 18 years of age for systemic sclerosis-associated interstitial lung disease (SSc-ILD), Rheumatoid Arthritis, and Giant Cell Arteritis or less than 2 years of age for Polyarticular Juvenile Idiopathic Arthritis and Systemic Juvenile Idiopathic Arthritis
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	For rheumatoid arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Rinvoq and Xeljanz/Xeljanz XR. For polyarticular juvenile idiopathic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, Rinvoq/Rinvoq LQ, and Xeljanz/Xeljanz solution. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606.

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Topical Lidocaine

Products Affected

- *lidocaine hcl mucous membrane solution 4 % (40 mg/ml)*
- *lidocaine topical ointment*
- *lidocaine-prilocaine topical cream*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tretinoin

Products Affected

- *tretinoin topical cream*
- *tretinoin topical gel 0.01 %, 0.025 %*

PA Criteria	Criteria Details
Exclusion Criteria	Cosmetic use
Required Medical Information	Documentation of acne vulgaris -AND- trial and failure or intolerance of at least two generic topical non-retinoid acne medications (e.g. clindamycin-benzoyl peroxide)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Trikafta

Products Affected

- **TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL**
- **TRIKAFTA ORAL TABLETS, SEQUENTIAL**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cystic fibrosis (CF) in patients who have at least one F508del mutation or another mutation in the cystic fibrosis transmembrane conductance regulator (CFTR gene) that is responsive to elexacaftor/tezacaftor/ivacaftor based on in vitro assay (e.g. E56K, R117C, A455E)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Trintellix

Products Affected

- **TRINTELLIX**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of major depressive disorder -AND- Therapeutic failure, intolerance or contraindication to one generic antidepressant (e.g. SSRI, TCA, MAOI).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Truqap

Products Affected

- **TRUQAP**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For locally advanced or metastatic breast cancer, all of the following (1-3): 1) HR mutation status, HER2 mutation status, and PIK3CA/AKT1/PTEN status as detected by an FDA-authorized test 2) concomitant therapy with fulvestrant 3) disease progression on at least one endocrine-based regimen in the metastatic setting -OR- recurrence on or within 12 months of completing adjuvant therapy. For metastatic prostate cancer, all of of the following (5-8): 5) disease is androgen pathway modulation-naive or -sensitive 6) disease is PTEN-deficient, as detected by an FDA-authorized test, 7) will be used in combination with abiraterone and prednisone, 8) concurrently receiving a gonadotropin-releasing hormone analog or has had bilateral orchiectomy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tukysa

Products Affected

- **TUKYSA ORAL TABLET 150 MG, 50 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For advanced unresectable HER2-positive breast cancer or metastatic HER2-positive breast cancer, member will be using in combination with trastuzumab and capecitabine -AND- member has received one or more prior anti-HER2 based regimens in the metastatic setting. For RAS wild-type HER2-positive unresectable or metastatic colorectal cancer, member will be using in combination with trastuzumab -AND- member has experienced disease progression following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Turalio

Products Affected

- **TURALIO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of symptomatic tenosynovial giant cell tumor associated with severe morbidity and functional limitations -AND- patient is not amenable to improvement with surgery or not a candidate for surgery
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Tykerb

Products Affected

- *lapatinib*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For advanced HER2-positive, or metastatic HER2-positive breast cancer, the member has received prior therapy with an anthracycline, a taxane, and trastuzumab -AND- will be using in combination with capecitabine. For HR+, metastatic breast cancer, the member is post-menopausal -AND- the member's cancer over expresses the HER2 receptor -AND- the member will be using lapatinib in combination with letrozole.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Tymlos

Products Affected

- **TYMLOS**

PA Criteria	Criteria Details
Exclusion Criteria	Treatment duration greater than 24 months.
Required Medical Information	Documentation of diagnosis -AND- at high risk for fracture, meeting one of the following (1. thru 3.) 1) History of previous hip or vertebral fracture. 2) T-score less than or equal to -2.5. 3) T-score between -1.0 and -2.5 -AND- meets FRAX calculation (A. or B.) A) 10-year risk of major osteoporotic fracture is greater than or equal to 20 percent or B) 10-year risk of hip fracture is greater than or equal to 3 percent.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 months
Other Criteria	Documentation of trial/failure or intolerance to at least one oral bisphosphonate or all are contraindicated. Additional documentation of trial/failure, intolerance or contraindication to preferred parathyroid hormone analog teriparatide. Coverage of human parathyroid hormone related peptide analogs beyond 24 months will not be approved. A cumulative lifetime approval of Tymlos will be limited to a coverage duration of 24 months.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ubrelvy

Products Affected

- **UBRELVY ORAL TABLET 100 MG, 50 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of acute treatment of migraine with or without aura -AND- trial and failure of one generic triptan or all triptans are contraindicated
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	Patients must have therapeutic failure, intolerance, or contraindication to Nurtec ODT. For reauthorization, attestation of reduction in migraine symptoms.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Uptravi

Products Affected

- **UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG** **PACK**
- **UPTRAVI ORAL TABLETS,DOSE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of pulmonary arterial hypertension, substantiated by results from right heart catheterization (RHC), defined as a mean pulmonary arterial pressure (mPAP) of greater than 20 mmHg at rest, with a pulmonary capillary wedge pressure (PWP) of less than or equal to 15 mmHg, and a PVR greater than or equal to 3 Wood units -AND- WHO Group.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Trial and failure of Opsumit is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ustekinumab

Products Affected

- **STELARA SUBCUTANEOUS SOLUTION**
- **STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML**
- *ustekinumab subcutaneous solution*
- *ustekinumab subcutaneous syringe 45 mg/0.5 ml, 90 mg/ml*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- documentation of member weight and prescribed dose. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For Crohn's Disease or Ulcerative Colitis, attestation of receiving or currently undergoing a single induction dose of IV ustekinumab within 2 months of initiating therapy with ustekinumab SC.
Age Restrictions	Deny if less than 18 years of age for Ulcerative Colitis. Deny if less than 6 years of age for Plaque Psoriasis and Psoriatic Arthritis. Deny if less then 2 years of age for Crohn's Disease.
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	For ustekinumab products except Steqeyma and Yesintek, intolerance to both preferred ustekinumab products is required: Steqeyma with NDC starting with 72606 and Yesintek with NDC starting with 83257. Must follow recommended dosing guidelines based upon weight. Subcutaneous induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For pediatric Crohn's disease, doses above plan quantity limit will be approved to align with recommended dosing regimen.
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Valchlor

Products Affected

- **VALCHLOR**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of Stage IA or IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received at least one prior skin-directed therapy (e.g. topical corticosteroids, topical chemotherapy, local radiation and topical retinoids).
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Valtoco

Products Affected

- **VALTOCO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of seizure clusters or acute repetitive seizures -AND- the member is currently receiving antiepileptic maintenance therapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Vanflyta

Products Affected

- **VANFLYTA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- disease is FLT3-ITD-positive as detected by an FDA-approved test -AND- one of the following (1-3): 1) member is receiving induction therapy and is using Vanflyta in combination with standard cytarabine and anthracycline induction therapy 2) member is receiving consolidation therapy and is using Vanflyta in combination with standard cytarabine consolidation therapy 3) member is receiving maintenance therapy and is using Vanflyta as monotherapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Venclexta

Products Affected

- **VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG**
- **VENCLEXTA STARTING PACK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For newly-diagnosed AML, member is using in combination with azacitidine, decitabine, or cytarabine -AND- age greater than or equal to 75 years or presence of at least one comorbidity that precludes use of intensive induction chemotherapy (i.e. severe cardiac or pulmonary comorbidity, reduced renal function, hepatic impairment, or physician attestation) is required.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Verquvo

Products Affected

- **VERQUVO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of heart failure (NYHA Class II to IV) -AND- Left ventricular ejection fraction less than 45% -AND- Hospitalization for heart failure or received outpatient IV diuretics for heart failure -AND- Used in combination with a angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker or Entresto -AND- Used in combination with bisoprolol, carvedilol IR/ER or metoprolol succinate ER.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Verzenio

Products Affected

- **VERZENIO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- disease is classified as HR-positive, HER2-negative. For early breast cancer that is at high risk of recurrence and is node-positive, all of the following (1-2): 1) used in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) 2) used as adjuvant treatment. For advanced or metastatic breast cancer, used as initial endocrine-based therapy and used in combination with an aromatase inhibitor -OR- used after documented disease progression following endocrine therapy and used in combination with fulvestrant -OR- used after documented disease progression and used following endocrine therapy and prior chemotherapy in the metastatic setting and will be used as monotherapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Viibryd

Products Affected

- *vilazodone*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of major depressive disorder -AND- Therapeutic failure, intolerance or contraindication to one generic antidepressant (e.g. SSRI, TCA, MAOI).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Vijoice

Products Affected

- **VIJOICE ORAL GRANULES IN MG PACKET**
- **VIJOICE ORAL TABLET 125 MG, 250 MG/DAY (200 MG X1-50 MG X1), 50**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of severe manifestations of PIK3CA Related Overgrowth Spectrum (PROS)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Vitrakvi

Products Affected

- **VITRAKVI ORAL CAPSULE 100 MG, 25 MG**
- **VITRAKVI ORAL SOLUTION**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation -AND- Tumors are metastatic or surgical resection is likely to result in severe morbidity -AND- There are no satisfactory alternative treatments or tumors have progressed following treatment.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Vivjoa

Products Affected

- **VIVJOA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of recurrent vulvovaginal candidiasis defined as at least 3 episodes of vulvovaginal candidiasis in less than one year -AND Documentation the member is NOT of reproductive potential defined as postmenopausal or another reason for permanent infertility (e.g., tubal ligation, hysterectomy, salpingo-oophorectomy) -AND- the member has experienced therapeutic failure, contraindication, or intolerance to a six-month maintenance course of oral fluconazole.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	14 weeks
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Vonjo

Products Affected

- **VONJO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of intermediate or high-risk myelofibrosis -AND- attestation of a platelet count of less than 50 x 10*9/L.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Voranigo

Products Affected

- **VORANIGO ORAL TABLET 10 MG, 40 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following (1-3): 1) grade 2 astrocytoma or grade 2 oligodendroglioma, 2) disease harbors a susceptible isocitrate dehydrogenase (IDH)-1 or IDH-2 mutation, as detected by an FDA-approved test, 3) will be used following surgery including biopsy, sub-total resection, or gross total resection.
Age Restrictions	Deny if less than 12 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Voriconazole

Products Affected

- *voriconazole intravenous recon soln*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- attestation that the beneficiary cannot take oral voriconazole
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	3 months
Other Criteria	For reauthorization, attestation of continued indicators of active disease (e.g. histopathology, positive cultures) is required
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Vosevi

Products Affected

- **VOSEVI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guidance - AND- the member has a contraindication to or is otherwise not a candidate for one of the following regimens recommended by the AASLD/IDSA guidelines containing the following agents: sofosbuvir/velpatasvir (i.e. Epclusa authorized generic), Mavyret.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Criteria/duration applied consistent with current AASLD-IDSA guidance
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Votrient

Products Affected

- *pazopanib oral tablet 200 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Documentation of adipocytic soft tissue sarcoma or gastrointestinal stromal tumor
Required Medical Information	Documentation of diagnosis. For advanced soft-tissue sarcoma, trial/failure of at least one prior chemotherapy regimen.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Vraylar

Products Affected

- **VRAYLAR**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	For a diagnosis of schizophrenia and bipolar I disorder, therapeutic failure, intolerance, or contraindication to one other generic atypical antipsychotic (e.g. quetiapine). For major depressive disorder, documentation of adjunctive therapy and therapeutic failure, contraindication or intolerance to one other generic antidepressant in addition to the antidepressant currently being used for the treatment of MDD (e.g. SSRI, SNRI, NDRIs, TCA, MAOI).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Vumerity

Products Affected

- **VUMERITY**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other disease modifying agents such as interferons, Copaxone, Tysabri, Aubagio, Gilenya
Required Medical Information	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) -AND- Therapeutic failure or intolerance to generic dimethyl fumarate
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	5 years
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Welireg

Products Affected

- **WELIREG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For von Hippel Lindau (VHL) syndrome, one of the following diagnoses not requiring immediate surgery (1, 2, or 3): 1) Renal cell carcinoma (RCC) 2) CNS hemangioblastoma 3) Pancreatic neuroendocrine tumor. For advanced RCC with a clear cell component, all of the following are required (4-6): 4) prior treatment with a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI), 5) prior treatment with a programmed death receptor-1 (PD-1) or a programmed death-ligand (PD-L1) inhibitor, 6) will be used as monotherapy. For RCC with a clear cell component, all of the following are required (7-8): 7) at intermediate-high or high risk of recurrence following nephrectomy -OR- has undergone nephrectomy and resection of metastatic lesions, 8) will be used as adjuvant treatment in combination with pembrolizumab or pembrolizumab berahyaluronidase alfa-pmph.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

Winrevair

Products Affected

- **WINREVAIR**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of pulmonary arterial hypertension, substantiated by results from right heart catheterization (RHC), defined as a mean pulmonary arterial pressure (mPAP) of greater than 20 mmHg at rest, with a pulmonary capillary wedge pressure (PWP) of less than or equal to 15 mmHg, and a PVR greater than or equal to 3 Wood units -AND- WHO Group -AND- Concomitant use of at least one of the following (1-4): 1) generic endothelin-1 receptor antagonist, 2) phosphodiesterase type 5 inhibitor, 3) soluble guanylate cyclase stimulator, 4) generic prostacyclin agent -AND- Background therapy with PAH-specific therapies will be continued while being treated with Winrevair.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Xalkori

Products Affected

- **XALKORI ORAL CAPSULE**
- **XALKORI ORAL PELLET 150 MG, 20 MG, 50 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For metastatic non-small cell lung cancer (NSCLC), disease is ALK-positive as detected by an FDA-approved test or ROS1-positive as detected by an FDA-approved test. For relapsed or refractory anaplastic large cell lymphoma (ALCL), disease is ALK-positive. For unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT), disease is ALK-positive.
Age Restrictions	Deny if less than 1 year of age or greater than 21 years of age for ALCL.
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For crizotinib oral pellets and NSCLC, inability to swallow capsules is required. For crizotinib oral pellets and ALCL / IMT, inability to swallow oral capsules -OR- body surface area less than 1.34 m2 is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Xcopri

Products Affected

- **XCOPRI**
- **XCOPRI MAINTENANCE PACK**
- **XCOPRI TITRATION PACK**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of partial-onset seizures -AND- Therapeutic failure, intolerance or contraindication to 1 other anti-epileptic drug (e.g. carbamazepine, levetiracetam)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xdemvy

Products Affected

- **XDEMVY**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis confirmed by identification of Demodex infection via microscopic examination of pulled eyelashes -OR- identification of collarettes via slit-lamp evaluation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 weeks
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Xeljanz

Products Affected

- *tofacitinib oral tablet*
- *tofacitinib oral tablet extended release 24 hr*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe active rheumatoid arthritis, an inadequate response or intolerance to at least one non-biologic DMARD (e.g., leflunomide, methotrexate). For immediate release formulation for polyarticular juvenile idiopathic arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For ankylosing spondylitis, inadequate response or intolerance to at least one nonsteroidal anti-inflammatory drug (NSAID).
Age Restrictions	Deny if less than 18 years of age for rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis. For extended release, deny if less than 18 years of age for psoriatic arthritis. For immediate release, deny if less than 2 years of age for polyarticular juvenile idiopathic arthritis and psoriatic arthritis.
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	The member has experienced inadequate response or intolerance to at least 1 tumor necrosis factor (TNF) blocker. Doses greater than 10 mg per day (immediate release) and 11 mg per day (extended release) will not be approved for rheumatoid arthritis and psoriatic arthritis. Doses greater than 20mg per day (immediate release) and 22 mg per day (extended release) will not be approved for ulcerative colitis.
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xeljanz Solution

Products Affected

- *tofacitinib oral solution*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. Documentation of polyarticular juvenile idiopathic arthritis -AND- Inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) or requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage.
Age Restrictions	Deny if less than 2 years of age for polyarticular juvenile idiopathic arthritis and psoriatic arthritis.
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	The member has experienced therapeutic failure or intolerance to at least 1 tumor necrosis factor (TNF) blocker.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xenazine

Products Affected

- *tetrabenazine oral tablet 12.5 mg, 25 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- attestation that the beneficiary is not actively suicidal
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	In patients with comorbid depression, attestation of adequate treatment for depression is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Xermelo

Products Affected

- **XERMELO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of carcinoid syndrome diarrhea AND used in combination with a somatostatin analog AND trial and failure of somatostatin analog monotherapy
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	3 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of reduction in average number of daily bowel movements -AND- the member will continue to use in combination with a somatostatin analog.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xgeva

Products Affected

- **WYOST**
- **XGEVA**
- **XTRENBO**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For hypercalcemia of malignancy, refractory to bisphosphonates. For giant cell tumor of bone, unresectable or surgical resection is likely to result in severe morbidity -AND- one of the following (1. or 2.)- 1.) the member is 18 years old or older -OR- 2.) the member is a skeletally mature adolescent (e.g. has at least one mature long bone)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Plan Year
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xifaxan

Products Affected

- **XIFAXAN ORAL TABLET 550 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of 1 or 2. 1) Diagnosis of hepatic encephalopathy AND trial/failure, intolerance, or contraindication to lactulose. 2) Diagnosis of Irritable Bowel Syndrome with Diarrhea (IBS-D) AND trial/failure, intolerance to one of the following medications for IBS-D or documentation of contraindication to all: antidiarrheal (e.g., loperamide), antispasmodic (e.g., dicyclomine, hyoscyamine), tricyclic antidepressant (e.g., amitriptyline, nortriptyline).
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Hepatic encephalopathy: 1 year. IBS-D: 14 days.
Other Criteria	No more than three courses of rifaximin for the treatment of IBS-D will be approved per lifetime.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xolair

Products Affected

- **XOLAIR**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of the following (1-2): 1) Chronic Spontaneous Urticaria, 2) trial/failure or intolerance of a second-generation non-sedating H1 antihistamine at the maximum recommended doses (e.g. cetirizine, fexofenadine, loratadine, desloratadine, levocetirizine). -OR- Documentation of the following (3-9): 3) moderate to severe persistent asthma, 4) a positive skin test or in vitro reactivity to a perennial aeroallergen, 5) Baseline IgE titer greater than or equal to 30 IU/mL, 6) documented pretreatment FEV1 less than 80% predicted in adults or less than 90% predicted in children and adolescents or FEV1 reversibility of at least 12% and 200mL after albuterol administration, 7) history of at least 2 asthma exacerbations requiring oral or injectable corticosteroid treatment in past 12mos or at least 1 asthma exacerbation requiring hospitalization in past 12mos, 8) inadequate symptom control despite regular treatment w/ medium- or high-dose inhaled corticosteroids (ICS) and at least 1 add'l asthma controller medication (e.g. long-acting beta2-agonist [LABA], leukotriene receptor antagonist [LTRA], theophylline) w/ or w/o OCS, unless intolerant or contraindicated to all, 9) will continue treatment with a medium- or high-dose ICS and at least 1 add'l asthma controller medication w/ or w/o OCS -OR- Documentation of the following (10-11): 10) chronic rhinosinusitis with nasal polyps (CRSwNP), 11) will use concomitantly with nasal corticosteroid maintenance treatment, -OR- Documentation of the following (12-17): 12) IgE mediated food allergy, 13) diagnosis confirmed by skin prick test or food-specific antibodies, 14) previous allergic reaction to food, 15) using for the reduction of allergic reactions (type 1), including anaphylaxis, 16) will be used in conjunction with food allergen avoidance, 17) member has a documented prescription for epinephrine.
Age Restrictions	
Prescriber Restrictions	

PA Criteria	Criteria Details
Coverage Duration	12 months
Other Criteria	For asthma reauthorization, attestation of one of the following is required (1-4): 1) decreased rescue medication or oral corticosteroid use, 2) decreased frequency of asthma exacerbations, 3) increased pulmonary function from baseline (e.g. FEV1), or 4) reduction in reported asthma related symptoms. For CSU reauthorization, improved CSU symptoms. For CRSwNP reauthorization, attestation of decrease in nasal polyp score or reduction in nasal congestion/obstruction severity score. For IgE-mediated food allergy reauthorization, member requires continuation of therapy and will continue food allergen avoidance.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xolremdi

Products Affected

- **XOLREMDI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of WHIM syndrome (warts, hypogammaglobulinemia, infections, myelokathexis).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of reduction in incidence of infections is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Xospata

Products Affected

- **XOSPATA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- member is FLT3 mutation-positive.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Xpovio

Products Affected

- **XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40 MG/WEEK (10 MG X 4), 40MG TWICE WEEK (40 MG X 2), 60 MG/WEEK (60 MG X 1), 60MG TWICE WEEK (120 MG/WEEK), 80 MG/WEEK (40 MG X 2), 80 MG/WEEK (80 MG X 1), 80MG TWICE WEEK (160 MG/WEEK)**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of use in combination with dexamethasone for relapse or refractory multiple myeloma with failure, intolerance or contraindication to 5 therapies (e.g. bortezomib, carfilzomib, lenalidomide, pomalidomide and daratumumab) -OR- Documentation of use in combination with both bortezomib and dexamethasone for multiple myeloma after receiving 1 prior multiple myeloma therapy -OR- Documentation of relapsing or refractory diffuse large B-cell lymphoma with failure, intolerance or contraindication to at least 2 lines of systemic therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Xtandi

Products Affected

- **XTANDI ORAL CAPSULE**
- **XTANDI ORAL TABLET 40 MG, 80 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For castration-resistant prostate cancer and metastatic castration sensitive-prostate cancer, the member is using in combination with a GnRH analog or the member has had a bilateral orchiectomy. For non-metastatic castration-sensitive prostate cancer, the member has biochemical recurrence at high risk for metastasis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Xyrem

Products Affected

- *sodium oxybate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) - AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. If the member has a diagnosis of cataplexy provision of baseline number of cataplexy episodes is required.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	If 18 years or older and no diagnosis of cataplexy, trial and failure, intolerance, or contraindication to generic modafinil -AND- a generic CNS stimulant indicated for use in narcolepsy (e.g. methylphenidate, amphetamine salts) is required. For reauthorization, attestation supporting improvement in symptoms of narcolepsy and cataplexy (if applicable) is required.
Indications	All FDA-approved Indications.
Off Label Uses	

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Yonsa

Products Affected

- **YONSA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- using in combination with methylprednisolone.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Yorvipath

Products Affected

- **YORVIPATH SUBCUTANEOUS PEN INJECTOR 168 MCG/0.56 ML, 294 MCG/0.98 ML, 420 MCG/1.4 ML**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of hypoparathyroidism -AND- albumin-corrected serum calcium greater than or equal to 7.8 mg/dL -AND- trial and failure of an active form of vitamin D (e.g. calcitriol, alfacalcidol).
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For reauthorization, attestation of normalization or improvement in total serum calcium from baseline is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Zavesca

Products Affected

- *miglustat*
- **YARGESA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of mild to moderate type 1 Gaucher disease confirmed by the following (A. or B.) A. (1, 2, 3, 4, or, 5): 1)Hepatomegaly. 2)Splenomegaly. 3)Bone disease (i.e. osteonecrosis, osteopenia, secondary pathologic fractures, bone infarct). 4)Bone marrow complications as defined by anemia with hemoglobin less than or equal to 11.5 g/dL for females or 12.5 g/dL for males or thrombocytopenia with platelet count less than or equal to 120,000/mm*3 -OR- 5)Symptomatic disease (e.g. bone pain, exertional limitation, cachexia). -OR- B. Attestation of deficiency in glucocerebrosidase activity in peripheral leukocytes or genetic testing confirms mutant alleles.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Attestation enzyme replacement therapy (e.g. Cerezyme, Elelyso, or VPRIV) is not a therapeutic option
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Zavzpret

Products Affected

- **ZAVZPRET**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of acute migraine headaches with or without aura -AND- Therapeutic failure, contraindication or intolerance to one generic triptan -AND- Inability to swallow capsules/tablets
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization
Other Criteria	For reauthorization, attestation of reduction in migraine symptoms.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Zejula

Products Affected

- **ZEJULA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, member is in complete or partial response to first-line platinum-based therapy -AND- disease is associated with homologous recombination deficiency-positive status, defined by at least one of the following (1 or 2): 1) a deleterious or suspected deleterious BRCA mutation or 2) genomic instability. For recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, all of the following (1-2): 1) disease harbors a deleterious or suspected deleterious germline BRCA mutation 2) member is in a complete or partial response to platinum-based chemotherapy.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Zelboraf

Products Affected

- **ZELBORAF**

PA Criteria	Criteria Details
Exclusion Criteria	Wild-type BRAF melanoma
Required Medical Information	Documentation of diagnosis. For unresectable or metastatic melanoma, member has a BRAF V600E mutation. For Erdheim-Chester Disease, member has a BRAF V600 mutation.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Zelsuvmi

Products Affected

- **ZELSUVMI**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of molluscum contagiosum
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 weeks
Other Criteria	For reauthorization, attestation that the member has previously experienced complete or partial clearance of molluscum contagiosum lesions with Zelsuvmi -AND- additional course of therapy is required for recurrence of molluscum contagiosum
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Zenbexus

Products Affected

- **ZENBEXUS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of multiple myeloma -AND- combination use with daratumumab/hyaluronidase-fihj and dexamethasone -AND- received at least 1 prior line of therapy that included a proteasome inhibitor and an immunomodulatory agent.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Zeposia

Products Affected

- **ZEPOSIA**
- **ZEPOSIA STARTER KIT (28-DAY)**
- **ZEPOSIA STARTER PACK (7-DAY)**

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use of Zeposia and other disease modifying agents such as interferons, Copaxone, Tysabri.
Required Medical Information	Documentation of diagnosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Ulcerative Colitis: Plan Year, Multiple Sclerosis: 24 months
Other Criteria	For moderate to severe active ulcerative colitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products: a preferred adalimumab product, a preferred ustekinumab SC product, Skyrizi SC, Rinvoq, and Xeljanz/Xeljanz XR. Please Note: Preferred adalimumab products include Hadlima with NDC starting with 78206, Simlandi with NDC starting with 51759, and Yuflyma with NDC starting 72606. Preferred ustekinumab products include Steqema with NDC starting with 72606 and Yesintek with NDC starting with 83257.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Zokinvy

Products Affected

- **ZOKINVY**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- BSA of at least 0.39 m*2. For Hutchinson-Gilford Progeria Syndrome (HGPS), a mutation in the LMNA gene is required. For Processing-Deficient Progeroid Lamionpathy (PL), 1 of the following is required (1-3): 1) heterozygous LMNA mutation and progerin-like protein accumulation, 2) homozygous ZMPSTE24 mutations, or 3) compound heterozygous ZMPSTE24 mutations.
Age Restrictions	Deny if less than 12 months of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Zolinza

Products Affected

- **ZOLINZA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent, or recurrent disease on or following 2 systemic therapies. Systemic therapies include bexarotene, interferon alpha, extracorporeal photochemotherapy, PUVA, single agent or combination chemotherapies (e.g. cyclophosphamide, vinblastine, romidepsin)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Zonisade

Products Affected

- **ZONISADE**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of partial-onset seizures -AND- Documentation of adjunctive therapy -AND- Inability to swallow capsules -AND- Therapeutic failure/intolerance to 2 or contraindication to all of the following (1-6): 1) generic carbamazepine suspension/chewable tablet/extended-release capsule, 2) generic gabapentin capsules/solution, 3) generic lacosamide solution, 4) generic levetiracetam solution, 5) generic oxcarbazepine suspension, 6) generic pregabalin capsules/solution.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Zoryve 0.15 Cream

Products Affected

- **ZORYVE TOPICAL CREAM 0.15 %**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of all of the following (1-3). 1) Documentation of mild to moderate atopic dermatitis -AND- 2) therapeutic failure, contraindication or intolerance to one generic formulary topical corticosteroid -OR- documentation of facial or anogenital involvement -AND- 3) therapeutic failure, contraindication or intolerance to topical generic tacrolimus or topical generic pimecrolimus.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

Ztalmy

Products Affected

- **ZTALMY**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of seizures associated with CDKL5 deficiency confirmed by genetic testing.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Zurzuvae

Products Affected

- **ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis of postpartum depression -AND- attestation of symptom onset began during the third trimester of pregnancy or up to 4 weeks post-delivery -AND- less than or equal to 12 months postpartum.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	30 days
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Zykadia

Products Affected

- **ZYKADIA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- ALK mutations, as detected by an FDA approved test.
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Zytiga

Products Affected

- *abiraterone oral tablet 250 mg, 500 mg*
- **ABIRTEGA**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- using in combination with prednisone.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

Index of Drugs

abiraterone oral tablet 250 mg, 500 mg 375
ABIRTEGA 375
acetaminophen-codeine oral solution 120-12 mg/5 ml 234
acetaminophen-codeine oral tablet 234
acitretin 1
ACTEMRA ACTPEN 306
ACTEMRA SUBCUTANEOUS 306
ACTIMMUNE 2
ADEMPAS 242
AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 140 MG/ML, 70 MG/ML 6
AKEEGA 7
ALCOHOL PADS 132
ALECENSA 8
alosetron oral tablet 0.5 mg, 1 mg 174
alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg 234
ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG 10
ALUNBRIG ORAL TABLETS,DOSE PACK 10
ambrisentan 242
amitriptyline 112
ANZUPGO 13
ARIKAYCE 14
aripiprazole oral solution 16
aripiprazole oral tablet,disintegrating 16
armodafinil 205
asenapine maleate 269
ATTRUBY 15
AUGTYRO ORAL CAPSULE 160 MG, 40 MG 18
AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG 19
AUSTEDO XR 19
AUSTEDO XR TITRATION KT(WK1-4) ORAL TABLET, EXT REL 24HR DOSE PACK 12-18-24-30 MG 19
AUVELITY ORAL TABLET, IR AND ER, BIPHASIC 20
AVMAPKI-FAKZYNJA 21
AVONEX INTRAMUSCULAR PEN INJECTOR KIT 134
AVONEX INTRAMUSCULAR SYRINGE KIT 134
AYVAKIT 22
BAFIERTAM 23
BALVERSA 24
BENLYSTA SUBCUTANEOUS 26
benztropine oral 112
BESREMI 28
BESREMI PEN 28
BETASERON SUBCUTANEOUS KIT 134
bexarotene oral 292
bexarotene topical 293
BOSULIF ORAL CAPSULE 100 MG, 50 MG 29
BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG 29
bosutinib oral tablet 400 mg 30
BRAFTOVI 31
BRINSUPRI 33
BRUKINSA ORAL TABLET 34
buprenorphine 234
CABOMETYX 36
CALQUENCE (ACALABRUTINIB MAL) 37
CAPLYTA 38
CAPRELSA ORAL TABLET 100 MG, 300 MG 39
carglumic acid 40
CAYSTON 41
CERDELGA 42
CINRYZE 45
clobazam oral suspension 212
clobazam oral tablet 212
clomipramine 112
clonazepam oral tablet 0.5 mg, 1 mg, 2 mg 234
clonazepam oral tablet,disintegrating 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg 234
clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg 234
COBENFY 47
COBENFY STARTER PACK 47
COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1), 140 MG/DAY(80 MG X1-20 MG X3), 60 MG/DAY (20 MG X 3/DAY) 48

COPAXONE SUBCUTANEOUS SYRINGE 20 MG/ML, 40 MG/ML 102
COPIKTRA 49
COSENTYX (2 SYRINGES) 51
COSENTYX PEN (2 PENS) 51
COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML 51
COSENTYX UNOREADY PEN 51
COTELLIC 53
cyproheptadine oral tablet 112
CYSTARAN 54
dalfampridine 11
DANZITEN 55
dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg 280
DAURISMO ORAL TABLET 100 MG, 25 MG 57
deferasirox oral tablet, dispersible 58
dextromethorphan-quinidine 202
DIACOMIT ORAL CAPSULE 250 MG, 500 MG 60
DIACOMIT ORAL POWDER IN PACKET 250 MG, 500 MG 60
DIAZEPAM INTENSOL 234
diazepam oral solution 5 mg/5 ml (1 mg/ml) 234
diazepam oral tablet 234
diclofenac sodium topical gel 3 % 278
dihydroergotamine nasal 61
dimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg, 120 mg (14)- 240 mg (46), 240 mg 298
doxepin oral capsule 112
doxepin oral concentrate 112
doxepin oral tablet 112
DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 20 MG, 30 MG, 40 MG, 60 MG 62
droxidopa oral capsule 100 mg, 200 mg, 300 mg 200
DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML 63
DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 200 MG/1.14 ML, 300 MG/2 ML 63
DUVYZAT 65
eltrombopag olamine oral powder in packet 12.5 mg, 25 mg 304
eltrombopag olamine oral tablet 12.5 mg, 25 mg, 50 mg, 75 mg 304
EMGALITY PEN 68
EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML, 300 MG/3 ML (100 MG/ML X 3) 68
ENBREL MINI 80
ENBREL SUBCUTANEOUS SOLUTION 80
ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5), 50 MG/ML (1 ML) 80
ENBREL SURECLICK 80
ENOBY 238
ENSACOVE 70
ENTRESTO SPRINKLE 71
EOHILIA 72
EPIDIOLEX 74
ergotamine-caffeine 76
ERIVEDGE 77
ERLEADA ORAL TABLET 240 MG, 60 MG 78
erlotinib 66
escitalopram oxalate oral capsule 79
everolimus (antineoplastic) oral tablet 4
everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg 4
EXXUA ORAL TABLET EXTENDED RELEASE 24 HR 82
EXXUA ORAL TABLET, EXT REL 24HR DOSE PACK 82
FABHALTA 83
FANAPT 85
FANAPT TITRATION PACK A 85
FANAPT TITRATION PACK B 85
FANAPT TITRATION PACK C 85
FASENRA PEN 86
FASENRA SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 30 MG/ML 86

fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr 234
FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK 20 MG (2)- 40 MG (26) 89
FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 20 MG, 40 MG, 80 MG 89
FILSUVEZ 90
fingolimod 101
FINTEPLA 91
FIRMAGON KIT W DILUENT SYRINGE 94
FOTIVDA 97
FRUZAQLA ORAL CAPSULE 1 MG, 5 MG 98
GAMMAGARD LIQUID 120
GAMMAGARD LIQUID ERC 120
GAMMAGARD S-D (IGA < 1 MCG/ML) 120
GATTEX 30-VIAL 99
GAUZE PAD TOPICAL BANDAGE 2 X 2 " 132
GAVRETO 100
gefitinib 138
GILOTRIF 66
glatiramer subcutaneous syringe 20 mg/ml, 40 mg/ml 102
GLATOPA SUBCUTANEOUS SYRINGE 20 MG/ML, 40 MG/ML 102
glycerol phenylbutyrate 248
GOMEKLI ORAL CAPSULE 1 MG, 2 MG 107
GOMEKLI ORAL TABLET FOR SUSPENSION 107
guanfacine oral tablet extended release 24 hr 3
HADLIMA 229
HADLIMA PUSHTOUCH 229
HADLIMA(CF) 229
HADLIMA(CF) PUSHTOUCH 229
HEPCLUDEX 110
HERNEXEOS 111
hydrocodone-acetaminophen oral tablet 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg 234
hydromorphone oral liquid 234
hydromorphone oral tablet 2 mg, 4 mg, 8 mg 234
hydroxyzine hcl oral tablet 112
HYRNUO 114
IBRANCE ORAL CAPSULE 125 MG 115
IBRANCE ORAL TABLET 115
IBTROZI 117
icatibant 92
ICLUSIG 118
IDHIFA 119
imatinib oral tablet 100 mg, 400 mg 103
IMBRUVICA ORAL CAPSULE 140 MG, 70 MG 122
IMBRUVICA ORAL SUSPENSION 122
IMBRUVICA ORAL TABLET 122
imipramine hcl 112
IMKELDI 123
INCRELEX 125
INGREZZA INITIATION PK(TARDIV) 127
INGREZZA ORAL CAPSULE 40 MG, 60 MG, 80 MG 127
INGREZZA SPRINKLE 127
INLURIYO 128
INLYTA 129
INQOVI 130
INREBIC 131
ITOVEBI ORAL TABLET 3 MG, 9 MG 139
itraconazole oral capsule 140
ivabradine oral tablet 5 mg, 7.5 mg 50
ivermectin oral 141
IWILFIN 142
JAKAFI 143
JASCAYD 144
JAVYGTOR 159
JAYPIRCA ORAL TABLET 100 MG, 50 MG 146
JIDEYTRO ORAL TABLET 100 MG, 25 MG 147
JOENJA ORAL TABLET 70 MG 148
JUBBONTI 238

KALYDECO ORAL GRANULES IN PACKET 13.4 MG, 25 MG, 5.8 MG, 50 MG, 75 MG 150
KALYDECO ORAL TABLET 150
KERENDIA 151
KESIMPTA PEN 152
KINERET 153
KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1), 400 MG/DAY (200 MG X 2), 600 MG/DAY (200 MG X 3) 154
KOMZIFTI 155
KOSELUGO ORAL CAPSULE 10 MG, 25 MG 157
KOSELUGO ORAL CAPSULE, SPRINKLE 5 MG, 7.5 MG 157
KRAZATI 158
KYGEVVI 160
lapatinib 315
LAZCLUZE ORAL TABLET 240 MG, 80 MG 162
lenalidomide 253
LENVIMA 163
LEUKINE INJECTION RECON SOLN 165
lidocaine hcl mucous membrane solution 4 % (40 mg/ml) 308
lidocaine topical adhesive patch,medicated 5 % 166
lidocaine topical ointment 308
lidocaine-prilocaine topical cream 308
LIFYORLI ORAL CAPSULE 125 MG/DAY(100 MG X1-25MG X1), 125 MG/DAY(100 MG X1-25MG X3), 125 MG/DAY(100 MG X1-25MG X9), 150 MG/DAY(100 MG X1-25MG X2), 150 MG/DAY(100 MG X1-25MG X3), 150 MG/DAY(100 MG X1-25MG X9) 167
liraglutide 106
LITFULO 168
LIVTENCITY 169
LOARGYS 170
LOKELMA 171
lomustine 105
LONSURF 172
LORAZEPAM INTENSOL 234
lorazepam oral tablet 0.5 mg, 1 mg, 2 mg 234
LORBRENA ORAL TABLET 100 MG, 25 MG 173
LUMAKRAS ORAL TABLET 120 MG, 240 MG, 320 MG 175
lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg, 80 mg 161
LYBALVI 176
LYNPARZA 177
LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG X 5) 180
macitentan 242
MAVYRET ORAL PELLETS IN PACKET 181
MAVYRET ORAL TABLET 181
megestrol oral suspension 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml) 182
megestrol oral tablet 182
MEKINIST ORAL RECON SOLN 183
MEKINIST ORAL TABLET 0.5 MG, 2 MG 183
MEKTOVI 185
memantine-donepezil 190
methadone oral solution 10 mg/5 ml, 5 mg/5 ml 234
methadone oral tablet 10 mg, 5 mg 234
metyrosine 186
mifepristone oral tablet 300 mg 156
miglustat 361
modafinil 240
MODEYSO 187
morphine concentrate oral solution 234
morphine oral solution 10 mg/5 ml (2 mg/ml), 20 mg/5 ml (4 mg/ml) 234
morphine oral tablet 234
morphine oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg 234
MOUNJARO 106
MULPLETA 188
NAYZILAM 191
NEMLUVIO 192
NERLYNX 194
NEXLETOL 196
NEXLIZET 196
nilotinib hcl 295

NINLARO 198
nintedanib 136
nitisinone 199
NORDITROPIN FLEXPRO SUBCUTANEOUS PEN INJECTOR 10 MG/1.5 ML (6.7 MG/ML), 15 MG/1.5 ML (10 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) 108
NUBEQA 201
NUEDEXTA 202
NUPLAZID 203
NURTEC ODT 204
octreotide acetate injection solution 207
ODOMZO 208
OGSIVEO ORAL TABLET 100 MG, 150 MG 209
OJEMDA ORAL SUSPENSION FOR RECONSTITUTION 210
OJEMDA ORAL TABLET 400 MG/WEEK (100 MG X 4), 500 MG/WEEK (100 MG X 5), 600 MG/WEEK (100 MG X 6) 210
OJJAARA 211
ONUREG 213
OPIPZA 214
OPSUMIT 242
OPSYNVI 242
ORENCIA CLICKJECT 215
ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML 215
ORGOVYX 217
ORKAMBI ORAL GRANULES IN PACKET 218
ORKAMBI ORAL TABLET 218
ORSERDU ORAL TABLET 345 MG, 86 MG 219
OTEZLA 220
OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)- 20 MG (51), 10 MG (4)-20 MG (4)-30 MG (47) 220
OTEZLA XR 220
OTEZLA XR INITIATION 220
oxycodone oral capsule 234
oxycodone oral concentrate 234
oxycodone oral tablet 10 mg, 15 mg, 20 mg, 30 mg, 5 mg 234
oxycodone-acetaminophen oral tablet 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg 234
OZEMPIC ORAL 222
OZEMPIC SUBCUTANEOUS 106
PANRETIN 223
paroxetine hcl oral suspension 12
paroxetine hcl oral tablet 12
pazopanib oral tablet 200 mg 335
PEGASYS 133
PEMAZYRE 224
PHEBURANE 225
phenobarbital 113
PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1), 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2) 226
pirfenidone oral capsule 136
pirfenidone oral tablet 136
PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML 134
PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML 134
pomalidomide 227
posaconazole oral tablet,delayed release (dr/ec) 228
pregabalin oral capsule 100 mg, 150 mg, 200 mg, 225 mg, 25 mg, 300 mg, 50 mg, 75 mg 179
pregabalin oral solution 179
PRENATAL VITAMIN PLUS LOW IRON 233
PREVYMIS ORAL PELLETS IN PACKET 237
PRIVIGEN 120
PROLASTIN-C INTRAVENOUS SOLUTION 9
PROLIA 238
promethazine oral tablet 112
PULMOZYME 244
pyrimethamine 56
QINLOCK 245
quinine sulfate 246
QULIPTA 247

REPATHA SURECLICK 249
REPATHA SYRINGE 249
RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG 251
REVUFORJ ORAL TABLET 110 MG, 160 MG, 25 MG 254
REXULTI ORAL TABLET 255
REZDIFFRA 256
REZLIDHIA 258
RINVOQ LQ 261
RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG, 45 MG 259
RIVFLOZA SUBCUTANEOUS SOLUTION 262
RIVFLOZA SUBCUTANEOUS SYRINGE 128 MG/0.8 ML, 160 MG/ML 262
ROMVIMZA 263
ROZLYTREK ORAL CAPSULE 100 MG, 200 MG 264
ROZLYTREK ORAL PELLETS IN PACKET 264
RUBRACA 265
rufinamide 25
RYDAPT 266
SAJAZIR 92
sapropterin 159
SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG 270
SECUADO 271
SIGNIFOR 281
sildenafil (pulm.hypertension) oral tablet 242
SILIQ 272
SIMLANDI(CF) AUTOINJECTOR 229
SIMLANDI(CF) SUBCUTANEOUS SYRINGE KIT 20 MG/0.2 ML, 40 MG/0.4 ML 229
SIRTURO 274
SKYCLARYS 275
SKYRIZI SUBCUTANEOUS PEN INJECTOR 276
SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML, 55 MG/0.37 ML 276
SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML), 360 MG/2.4 ML (150 MG/ML) 276
sodium oxybate 357
sodium phenylbutyrate 35
sofosbuvir-velpatasvir 73
SOHONOS ORAL CAPSULE 1 MG, 1.5 MG, 10 MG, 5 MG 277
SOMAVERT 279
sorafenib 195
STELARA SUBCUTANEOUS SOLUTION 319
STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML 319
STEQEYMA SUBCUTANEOUS SOLUTION 231
STEQEYMA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML 231
STIVARGA 282
sunitinib malate 283
SYMPAZAN 284
SYNAREL 285
TABRECTA 286
tadalafil (pulm. hypertension) 242
tadalafil oral tablet 2.5 mg, 5 mg 44
TAFINLAR ORAL CAPSULE 287
TAFINLAR ORAL TABLET FOR SUSPENSION 287
TAGRISSO 289
TALZENNA 291
TASCENSO ODT 294
tasimelteon 296
tazarotene topical cream 297
TEPMETKO 299
teriflunomide 17
teriparatide subcutaneous pen injector 20 mcg/dose (560mcg/2.24ml) 95
testosterone cypionate 300
testosterone enanthate 300
testosterone transdermal gel in metered-dose pump 20.25 mg/1.25 gram (1.62 %) 300
tetrabenazine oral tablet 12.5 mg, 25 mg 347
TEZSPIRE SUBCUTANEOUS PEN INJECTOR 301

THALOMID ORAL CAPSULE 100 MG, 50 MG 303
TIBSOVO 305
TOBI PODHALER 43
tobramycin in 0.225 % nacl 43
tobramycin inhalation 43
tofacitinib oral solution 346
tofacitinib oral tablet 344
tofacitinib oral tablet extended release 24 hr 344
tolvaptan 268
tolvaptan (polycys kidney dis) oral tablet 149
tolvaptan (polycys kidney dis) oral tablets, sequential 149
topiramate oral solution 75
tramadol oral tablet 50 mg 234
tramadol-acetaminophen 234
tretinoin topical cream 309
tretinoin topical gel 0.01 %, 0.025 % 309
TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL 310
TRIKAFTA ORAL TABLETS, SEQUENTIAL 310
trimipramine 112
TRINTELLIX 311
TRULICITY 106
TRUQAP 312
TUKYSA ORAL TABLET 150 MG, 50 MG 313
TURALIO 314
TYMLOS 316
UBRELVY ORAL TABLET 100 MG, 50 MG 317
UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG 318
UPTRAVI ORAL TABLETS,DOSE PACK 318
ustekinumab subcutaneous solution 319
ustekinumab subcutaneous syringe 45 mg/0.5 ml, 90 mg/ml 319
VALCHLOR 321
VALTOCO 322
VANFLYTA 323
VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG 324
VENCLEXTA STARTING PACK 324
VERQUVO 325
VERZENIO 326
vigabatrin 267
VIGADRONE 267
VIJOICE ORAL GRANULES IN PACKET 328
VIJOICE ORAL TABLET 125 MG, 250 MG/DAY (200 MG X1-50 MG X1), 50 MG 328
vilazodone 327
VITRAKVI ORAL CAPSULE 100 MG, 25 MG 329
VITRAKVI ORAL SOLUTION 329
VIVJOA 330
VONJO 331
VORANIGO ORAL TABLET 10 MG, 40 MG 332
voriconazole intravenous recon soln 333
VOSEVI 334
VOWST 88
VRAYLAR 336
VUMERITY 337
WELIREG 338
WINREVAIR 340
WYOST 349
XALKORI ORAL CAPSULE 341
XALKORI ORAL PELLET 150 MG, 20 MG, 50 MG 341
XCOPRI 342
XCOPRI MAINTENANCE PACK 342
XCOPRI TITRATION PACK 342
XDEMVY 343
XERMELO 348
XGEVA 349
XIFAXAN ORAL TABLET 550 MG 350
XOLAIR 351
XOLREMDI 353
XOSPATA 354

XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40 MG/WEEK (10 MG X 4), 40MG TWICE WEEK (40 MG X 2), 60 MG/WEEK (60 MG X 1), 60MG TWICE WEEK (120 MG/WEEK), 80 MG/WEEK (40 MG X 2), 80 MG/WEEK (80 MG X 1), 80MG TWICE WEEK (160 MG/WEEK) 355
XTANDI ORAL CAPSULE 356
XTANDI ORAL TABLET 40 MG, 80 MG 356
XTRENBO 349
YARGESA 361
YESINTEK SUBCUTANEOUS SOLUTION 231
YESINTEK SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML .. 231
YONSA 359
YORVIPATH SUBCUTANEOUS PEN INJECTOR 168 MCG/0.56 ML, 294 MCG/0.98 ML, 420 MCG/1.4 ML 360
YUFLYMA(CF) AI CROHN'S-UC-HS . 229
YUFLYMA(CF) AUTOINJECTOR 229
YUFLYMA(CF) SUBCUTANEOUS SYRINGE KIT 40 MG/0.4 ML 229
YULITHIRA 4
zaleplon oral capsule 10 mg, 5 mg 234
ZAVZPRET 362
ZEJULA 363
ZELBORAF 364
ZELSUVMI 365
ZELVYSIA 159
ZENBEXUS 366
ZEPOSIA 367
ZEPOSIA STARTER KIT (28-DAY) 367
ZEPOSIA STARTER PACK (7-DAY) ... 367
ZILBRYSQ SUBCUTANEOUS SYRINGE 16.6 MG/0.416 ML, 23 MG/0.574 ML, 32.4 MG/0.81 ML 189
ZOKINVY 368
ZOLINZA 369
zolpidem oral tablet 234
ZONISADE 370
ZORYVE TOPICAL CREAM 0.15 % ... 371
ZTALMY 372
ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG 373
ZYKADIA 374

Sección: Terapia por pasos

Entresto Tablet

Products Affected

- **ENTRESTO 24 MG-26 MG TABLET**
- **ENTRESTO 49 MG-51 MG TABLET**
- **ENTRESTO 97 MG-103 MG TABLET**

Details

Criteria	Require a 1 month trial of generic sacubitril/valsartan tablets (Step 1 drug) in the last 90 days

Herpetic Keratitis

Products Affected

- **ZIRGAN 0.15 % EYE GEL**

Details

Criteria	Require a 1 month trial of generic trifluridine eye drops (Step 1 drug) in the last 90 days when utilized for the same medically accepted indication and age

Pulmonary Antiinflammatory

Products Affected

- *fluticasone propionate 100 mcg/actuation blister powder for inhalation*
- *fluticasone propionate 110 mcg/actuation hfa aerosol inhaler*
- *fluticasone propionate 220 mcg/actuation hfa aerosol inhaler*
- *fluticasone propionate 250 mcg/actuation blister powder for inhalation*
- *fluticasone propionate 44 mcg/actuation hfa aerosol inhaler*
- *fluticasone propionate 50 mcg/actuation blister powder for inhalation*

Details

Criteria	Require a 1 month trial of Qvar and Asmanex/Asmanex HFA (Step 1 drugs) in the last 180 days

Rho Kinase Inhibitors

Products Affected

- **RHOPRESSA 0.02 % EYE DROPS DROPS**
- **ROCKLATAN 0.02 %-0.005 % EYE**

Details

Criteria	Require a 1 month trial of one preferred glaucoma drug (Step 1 drug) in the last 120 days

Rytary

Products Affected

- **RYTARY 23.75 MG-95 MG CAPSULE,EXTENDED RELEASE**
- **RYTARY 36.25 MG-145 MG CAPSULE,EXTENDED RELEASE**
- **RYTARY 48.75 MG-195 MG CAPSULE,EXTENDED RELEASE**
- **RYTARY 61.25 MG-245 MG CAPSULE,EXTENDED RELEASE**

Details

Criteria	Require a trial of generic carbidopa/levodopa product (Step 1 drug) in the last 90 days

Index of Drugs

ENTRESTO 24 MG-26 MG TABLET..... 1
ENTRESTO 49 MG-51 MG TABLET..... 1
ENTRESTO 97 MG-103 MG TABLET..... 1
fluticasone propionate 100 mcg/actuation blister powder for inhalation..... 3
fluticasone propionate 110 mcg/actuation hfa aerosol inhaler..... 3
fluticasone propionate 220 mcg/actuation hfa aerosol inhaler..... 3
fluticasone propionate 250 mcg/actuation blister powder for inhalation..... 3
fluticasone propionate 44 mcg/actuation hfa aerosol inhaler..... 3
fluticasone propionate 50 mcg/actuation blister powder for inhalation..... 3
RHOPRESSA 0.02 % EYE DROPS..... 4
ROCKLATAN 0.02 %-0.005 % EYE DROPS..... 4
RYTARY 23.75 MG-95 MG CAPSULE,EXTENDED RELEASE..... 5
RYTARY 36.25 MG-145 MG CAPSULE,EXTENDED RELEASE..... 5
RYTARY 48.75 MG-195 MG CAPSULE,EXTENDED RELEASE..... 5
RYTARY 61.25 MG-245 MG CAPSULE,EXTENDED RELEASE..... 5
ZIRGAN 0.15 % EYE GEL..... 2